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13 Correlates of Patient Retention in HIV Care and Treatment Programs in
Nigeria
Chinenye Ugoji1 (presenting), Rukeme Ake-Uzoigwe1, 
Manzilat Ladele1, Christopher Akolo1, Gabou Mendy1, 
Patrick Dakum1, Dennis Onotu2, Okey Nwanyanwu2, 
Manhattan Charurat3, William Blattner3
1 Institute of Human Virology Nigeria, Abuja, NIGERIA
2 Centers for Disease Control, Nigeria, Abuja, NIGERIA
3 Institute of Human Virology, University of Maryland, Baltimore,
MD, USA
Background: Long-term retention is a crucial component of HIV care
because treatment success can only be measured among retained
patients. However, poor retention has continually challenged long-
term HIV management. Understanding of determinants of retention
will inform proactive retention strategies particularly in developing
countries where poorly-developed geographic mapping systems
have hampered patient tracking. We evaluated the correlates reten-
tion in a large HIV program in Nigeria.
Methods: In March 2011, we conducted a retrospective quality of
care evaluation for 5320 randomly selected HIV-positive adults aged
³15 years (64.2% female; median age: 35 years) enrolled in 37 treat-
ment facilities in our program. Eligible patients were enrolled 15
months prior to the evaluation or earlier. Retention was described as
having one or more clinic visits in the review year (2010). Patient-
related correlates of retention were determined using logistic
regression.
Results: 144 patients died/transferred in the review year. In total, 3231
(62.4%) of 5176 patients were retained (65.6% female; median age:
36.5 years). 75.8% of patients on ART, and 23.4% pre-ART patients
were retained. Correlates of retention were: Age 30-60 years
(OR=1.37,95% CI:1.22-1.57) versus <30years; Female gender
(OR=1.17,95%CI:1.05-1.32) vs males; Baseline CD4 cell count (100-350
cells/mm3 OR=1.25, 95% CI: 1.08-1.46 vs  <100cells/mm3); Baseline
WHO stage(WHO Stage 1-2:OR1.76, 95% CI:1.52-2.05) vs WHO stage
3-4; Being on ART(OR=10.3,95% CI:8.8-11.9) vs non-ART; Later year of
enrolment (2008-09 OR:1.21, 95% CI:1.08-1.34 vs 2005-07); Later year of
ART initiation 2008-09 (OR:1.73,95% CI:1.49-2.01 vs 2005-07); In a mul-
tivariate model, gender, age, ART Status, baseline CD4 counts and
WHO stage remained significant correlates of retention in our study.
Conclusions: 3 out of 4 pre-ART patients and 1-in-4 ART patients
were not retained in 37 HIV treatment facilities in Nigeria. Pre-ART
status, male gender, age <30, baseline CD4 counts <100 cells/ml and
baseline WHO stage³3 were the strongest predictors of poor reten-
tion. It is imperative that HIV programs proactively identify high-risk
patients and intensify retention efforts in their early stages of care.
14 A Quality Of Care ScoringMethodology For HIV Treatment
Programs In Nigeria
Chinenye Ugoji1 (presenting), Manzilat Ladele1, 
Rukeme Ake-Uzoigwe1, Gabou Mendy1, Mary-Ann Etiebet2, 
Patrick Dakum1, Dennis Onotu3, Okey Nwanyanwu3
1 Institute of Human Virology Nigeria, Abuja, NIGERIA
2 Institute of Human Virology, University of Maryland, Baltimore,
MD, USA
3 Centers for Disease Control, Nigeria, Abuja, NIGERIA
Introduction: Gains recorded in the scale-up of HIV treatment servic-
es in Nigeria must be accompanied by robust program quality and
good retention. Consequently, Quality Evaluation and improvement
activities are pivotal to program implementation at the Institute of
Human Virology Nigeria (IHVN). However, poor appreciation of eval-
uation reports by health care workers (HCW) hamper results utility
for improvement activities. In 2009, we developed a Quality Scoring
Methodology (QSM) that improved HCW appreciation and utilization
of evaluation reports. 
Description: IHVN’s retrospective quality of care evaluation assess-
es indicators on pre-defined service delivery benchmarks, abstract-
ed from patient medical records. Quality Scores are computed by
categorizing indicators into 5 service delivery domains-
Clinical/Laboratory/Documentation/Retention/Care and support
(including adherence assessments). Quintiles are created for each
indicator as the basis for assignment of scores for facilities and
domains. Scores range from 1-5; 1 and 5 representing the lowest and
highest performance respectively.  A domain quality score (DQS) is
an average of the quintile scores of its indicators. A facility’s overall
quality score (OQS) is the weighted average of the sum of the scores
for each domain.
Lessons Learned: OQS between facilities are compared using
graphs.  Facility-specific scores are represented by color-coded bars
with each color corresponding to a specific domain. A facility’s bar
height depicts its OQS relative to other similar facilities. Color codes
within each bar depicts contribution of each service domain to the
facility’s OQS. The QSM has been successfully used by HCWs to pri-
oritize and target implemented initiatives, track program quality and
identify training/mentoring needs. This methodology exposed the
contribution of poor retention to facilities’ OQS and has informed ini-
tiatives that improved retention rates.
Recommendations: Quality evaluations are crucial for successful
programs, but going one step further with the QSM increases utility
of evaluation reports and promotes implementation of QI initiatives
that strengthen HIV service delivery and health systems.
16 Improving HIV Counseling and TestingServices for Men who have Sex with
Men in Nigeria 
Kelechi Ugoh1 (presenting), Oliver Anene1
1 Initiative for Improved Male Health, Abuja, NIGERIA
Introduction: Despite HIV Prevention initiatives by stakeholders in
Nigeria, MSM are highly discriminated in Health settings. These
experiences limit their demand for HIV  (HTC), and consequently
force them to conceal their sexual orientation and health issues
which in turn increases the risk associated  with HIV .The objectives
of this analysis was to understand  MSM preference for HIV (HTC),
and to improve service delivery.
Methods: An analysis was conducted for a year in 6 councils of the
FCT. Two (2) mobile HTC models were used in this study (A and B).
Model A involved MSM trained HTC officers, while Model B, non-
MSM health personnel who were recruited to provide HTC in both
drop in center, and at outreaches. Outreaches were conducted at 3
months intervals with help from community mobilizers. Refreshment
was provided for clients during HTC as a means of motivation, and
clients were allowed to choose either Model A or B. Consent forms
during pre-test counseling and structured questionnaires were
administered after post-test counseling.
Results: 768 MSM, between the ages of 18-41 years, were counseled
and tested. 595 were counseled and tested by Model A and 173 by
Model B, respectively. These respondents gave the following rea-
sons for the overwhelming turn outs in Model A: 399 said they shared
the same sexual Orientation with Model officers, while 196 were
comfortable because there was no fear of stigma or discrimination.
In model B, MSM gave the following reasons: 138 said the HTC
seems more confidential and their HIV status was not going to be dis-
closed to other familiar MSM, while 35 responded that B officers
were qualified medical personnel who provided professional health
services.
Conclusions: Many MSM clients preferred model A to B. Thus, for
rapid breakthrough in HIV/AIDS prevention and Ols (opportunistic
infections) management, MSM should be trained and recruited  as
HTC officers. Also, stakeholders must continue to collaborate with
the Nigerian government to completely eliminate the discrimination
of MSM.
17 The Art of Adherence: Using BodyMapping Methodologies to Explore
HIV-Positive Women’s Relationships with
their Medications 
Treena Orchard1 (presenting), Tricia Smith2, Kate Salters3, 
Alexis Palmer3, Warren Michelow3, Arn Schilder3, Bob Hogg3
1 University of Western Ontario, London, ON, CANADA
2 Queen’s University, Kingston, ON, CANADA
3 BC Centre for Excellence in HIV/AIDS, Vancouver, BC, CANADA
Background: Optimal adherence to HAART (³ 95% of prescribed
mediation) is critical to maintaining health and preventing adverse
health outcomes like resistance to HIV medications, immune system
collapse, and death. Most medical research on adherence examines
the degree to which HIV-positive people follow prescribed medical
advice. Missing from this approach is an understanding of how med-
ical information about adherence is incorporated into the health
practices of people living with HIV/AIDS and the gendered nature of
such practices. In response to this, we conducted a qualitative study
with service providers and women and men with histories of poly-
substance drug use to explore how gender and ideas about the body
impact medication practices.
Methods: We completed semi-structured interviews with providers
and HIV-positive participants (n=25) and body mapping with six
women participants, a unique methodology that allowed participants
to communicate their experiences with HAART through art-based
practices. These activities, which are the focus of this paper, includ-
ed two workshops, follow-up interviews, and a community-based art
show.
Results: The women identified many factors that make it difficult to
take HAART consistently, including fatigue with complex medical
regimens, a desire to avoid daily reminders of their disease status,
and incomplete knowledge of their medications. However, they did
not focus exclusively on these struggles and placed equal impor-
tance on explaining, through symbols, words, and colors, how their
relationship with their medications has evolved within the context of
their on-going ‘journey’ of living with HIV.
Conclusions: Our body mapping data provide new and important
insights regarding the ideologies and practices that inform how HIV-
positive women approach taking HAART. Of particular importance
are the socio-emotional and physical impediments to taking their
medications consistently, along with the complex and often ambiva-
lent position these medications occupy within the unique and coura-
geous journeys these women travel as they live with HIV.
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26 Self-Reported Adherence toAntiretroviral Treatment and Its
Correlates among AIDS Patients in Hunan
Province of China
Xianhong Li1 (presenting), Jia Chen2, Yan Zhang3, Honghong Wang2
1 School of Nursing, Central South University, Changsha, Hunan,
CHINA
2 Central South University, Changsha, Hunan, CHINA
3 Hainan Medical College, Haikou, Hainan, CHINA
Background: Optimal adherence to antiretroviral treatment (ART) is
critical for suppressing drug-resistant, delaying the disease progres-
sion, reducing the death rate, and improving the quality of life among
AIDS patients. With the comprehensive adherence intervention from
the health care organizations, national and international research
foundations, how is the situation of adherence to ART in Hunan
Province is unclear nowadays.
Methods: A cross-sectional survey was conducted in two major
CARE sites of Hunan from July 2010 to Oct 2011 by face-to-face inter-
views. Adherence measures included direct questioning regarding
the number of doses taken in the 7 days prior to interview, the
Community Programs for Clinical Research on AIDS (CPCRA)
Adherence Self-Report questionnaire, and a 30-day visual analogue
scale (VAS).
Results: The mean age of the 418 subject was 38 years old (SD=9.7),
with 293 (70%) were male, 305 (73%) were from city, 244 (58.4%) were
educated form high school or lower, and 117 (28%) were active or for-
mer heroin users. The average ART time was 18 months (range: 1,73).
According to the 30-day-VAS, 72% (301/418) of subject maintained
more than 90% adherence, but during past 7 days, 90% (375/418)
reported more than 90% adherence and 78% (325/418) reported 100%
adherence. The three measures of self-reported adherence were
highly correlated. On multivariate analysis, heroin abuse (odds ratio
[OR] =1.7; 95%confidence interval[CI]=1.1, 2.7, p<0.05), less educated
(OR=1.3; 95%CI=1.0. 1.7; p<0.05) and lack of remind from family mem-
bers (OR=1.5; 95%CI=1.0. 2.4; p<0.05) were associated with 90% or
less adherence.
Conclusions: The adherence to ART among AIDS patients in Hunan
was improved compared to that of 5 years ago by the same measure-
ment. Strategies for future intervention should consider how to help
drug users or less-educated people (such as farmers) to maintain
optimal ART adherence, and family involved in Chinese culture might
be a choice.
29 Pediatric Resistance to AntiretroviralTherapy: The Role of the Caregiver
Bronwyne Coetzee1 (presenting), Ruth Bland2, Ashraf Kagee3
1 Stellenbosch University, Stellenbosch, SOUTH AFRICA
2 Africa Centre for Health and Population Studies, KwaZulu Natal,
SOUTH AFRICA
3 Stellenbosch University, Cape Town, SOUTH AFRICA
Background: The success of antiretroviral therapy (ART) in the treat-
ment of HIV relies predominantly on optimal adherence to daily med-
ication taken at prescribed times with appropriate nutrition. For chil-
dren under 5 years, caregivers are responsible for administration of
medication doses and reporting of doses to clinicians at monthly
clinic visits. Suboptimal adherence to treatment may cause compro-
mised immune suppression and drug resistance. Yet, various factors
limit optimal adherence. The aim of this study was to qualitatively
ascertain caregivers’, doctors’, nurses’, ARV counselors’, and tradi-
tional healers’ perspectives of the barriers and facilitators to care-
givers’ treatment administration practices (TAP’s). 
Methods: Doctors and nurses providing ART to children in rural KZN
participated in in-depth interviews. ART counselors, traditional heal-
ers and primary caregivers participated in focus groups. The focus
groups and interviews were conducted in isiZulu with the assistance
of an isiZulu speaking translator. Interviews and focus groups were
recorded and transcribed. Transcripts were translated into English
where necessary and back translated to ensure accurate interpreta-
tion. Analysis was conducted using Atlas.ti 7 a qualitative data man-
agement tool. 
Results: Barriers to caregivers’ administration practices as reported
by doctors, nurses, counselors and traditional healers were (1) poor
caregiver knowledge of TAP’s and (2) multiple persons administering
treatment. Many caregivers reported not receiving the compulsory
counseling sessions before their child was initiated on treatment and
were thus unable to understand the importance of accurate and
timely doses. Caregivers reported that poor palatability of treatment
was the main characteristic of the child that inhibited caregiver
administration practices. The main facilitator to TAP was the fre-
quent monitoring of caregiver knowledge of administration practices
by clinicians and counselors. 
Conclusions: Continual monitoring of the caregiver by clinicians and
counselors is necessary to ensure favorable treatment outcomes,
such as suppressed viral loads, in young children receiving ART. 
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30 Depressive Symptoms and Correlatesamong People Living with HIV in
Hunan, China
Honghong Wang1 (presenting), Jia Chen1, Caihong Zhang2,
Xianhong Li3, Kristopher Fennie4, Ann Williams5
1 Central South University, Changsha, Hunan, CHINA
2 Hainan Medical College, International School of Nursing, Haikou,
Hainan Province, CHINA
3 School of Nursing, Central South University, Changsha, Hunan,
CHINA
4 Florida International University, Miami, FL, USA
5 University of California, Los Angeles, Los Angeles, CA, USA
Background: Depressive symptoms are common among people liv-
ing with HIV (PLWH) and are associated with poor treatment out-
comes and nonadherence to antiretroviral treatment (ART). Data
regarding the prevalence of depression among Chinese PLWH are
limited and inconsistent.
Methods: Data were collected from 496 PLWH between July 5th 2009
and July 31st 2010 at two HIV treatment sites in Hunan, China.
Depressive symptoms were assessed using the Center for
Epidemiological Studies Depression scale (CES-D).                               
Results: The prevalence of depressive symptoms was high, with 309
(62%) subjects reporting a CES-D total score equal to or above 16.
Independent predictors of a CES-D equal to or above 16 included
active heroin use ((OR = 1.83, 95% CI 1.08 - 3.12), female gender (OR
= 1.66, 95% CI 1.04 - 2.64), low level of social support (OR = 0.91, 95%
CI 0.88 - 0.94), and lack of stable job (OR = 0.53, 95% CI 0.34 - 0.83).
Conclusions: The very high prevalence of depressive symptoms
among PLWH in Hunan, China, is of concern. Interventions to
address depression are called for to realize fully the benefits of ART
provided by Chinese government.
35 Implementing a Rapid HIVTesting/Linkage to Care Project
among Homeless Individuals in Los Angeles
County: A Collaborative Effort between
Federal, County, and City Government
Henry Anaya1 (presenting)
1 US Department of Veterans Affairs, GLA, Los Angeles, CA, USA
Background: Homeless individuals are at increased risk for negative
health outcomes.  HIV rates are high among the homeless, and are of
special concern, given the transient nature of the homeless popula-
tion, coupled with traditional HIV testing methods which impose a
significant gap between testing and receipt of results.   Same-day
HIV rapid testing can mitigate this gap.  We organized and imple-
mented an HIV rapid testing/linkage-to-care initiative in homeless
shelters via a multi-agency collaboration between federal and local
government in Los Angeles County.
Methods: Mixed methodology; HIV testing data was collected on-
site; qualitative data was collected by telephone. Post-intervention
interviews conducted with stakeholders evaluated barriers and facil-
itators. 
Results: A total of 817 homeless individuals were tested as part of
this effort.  Seven HIV-positives were identified; five of seven were
linked to long-term care.  Mean testing cost was $48.95 per client;
cost per-positive was $5,714. 
Conclusions: Costs were highest initially, and declined over time.
This effort was viewed positively by participants. Results suggest
that the high HIV seropositivity found among homeless shelter resi-
dents warrants project costs. This collaboration was successful,
both programmatically and based on key stakeholder responses.
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36 An Evaluation of Post-IncarcerationLinkage to Care for HIV/Hepatitis C-
Infected Veterans in Los Angeles County
Henry Anaya1 (presenting)
1 US Department of Veterans Affairs, GLA, Los Angeles, CA, USA
Background: Correctional institutions offer opportunities to identify
Veterans with Hepatitis C Virus (HCV) and Human Immunodeficiency
Virus (HIV), and for the US Department of Veterans Affairs Veterans
(VA) to link them to medical care upon release.  
Methods: This study provides the first description of barriers and
facilitators that HCV and/or HIV-infected Veterans face in seeking
medical care after community re-entry from Los Angeles County
(LAC) jails. Semi-structured interviews of two cohorts: 1)
clinical/non-clinical VA/LAC jail staff; 2) Post-incarcerated Veterans
with self-identified HIV and/or HCV.  Sixteen interviews were com-
pleted from cohort 1 and 9 from cohort 2. 
Results: Although some characterized current efforts positively, bar-
riers were highlighted. Veterans and staff described insufficient
strategies for identifying eligible Veterans, ineffective outreach, and
inadequate staffing. Strategies for improving linkage, including rou-
tine in-take identification of Veteran status, greater program dissem-
ination and increased staff were noted.
Conclusions: Results highlight existing gaps for Veterans transition-
ing to VA healthcare from LAC jails.  Findings can guide future efforts
to strengthen gaps in care between local and federal government.
40 Quality Assurance Investigation ofAntiretroviral Adherence in an
Outpatient HIV Clinic
Jessica Robinson1 (presenting), Pierre Giguere1
1 The Ottawa Hospital, Ottawa, ON, CANADA
Background: Adherence to antiretroviral (ARV) medication is impor-
tant for viral suppression and to avoid the development of resistance
in patients with Human Immunodeficiency Virus (HIV). The primary
objective was to describe and compare ARV adherence using two
methods: patient reported and provincial claims database informa-
tion. 
Methods: All consecutive patients attending an appointment at The
Ottawa Hospital (TOH) Immunodeficiency Clinic from February 13
until March 9, 2012 were approached for enrolment. 210 patients
were enrolled and each patient completed the Medication
Adherence Self-Report Inventory (MASRI), a self-reported adher-
ence questionnaire. Adherence was also calculated for each patient
using the Ontario Drug Benefit (ODB) Drug Profile, a provincial drug
claims database. Patient characteristics were collected from clinic
patient records. 
Results: The adherence results were heavily skewed in favor of
excellent adherence. The median MASRI reported adherence was
100%, and the median ODB reported adherence was 98%. When
adherence data was organized in 25% interval groups, MASRI and
ODB adherence weakly correlated (r = 0.188, p = 0.042).
Characteristics associated with ARV adherence less than 75% were
female gender (OR 2.73, 95% CI 1.62-4.61, p=0.005) and non-men who
have sex with men (OR 1.96, 95% CI 1.71-2.25, p=0.004). History of
missed appointments was associated with a discrepancy between
MASRI and ODB adherence score (OR 2.56, CI 1.18-5.56). No charac-
teristics were found to correlate with virologic failure and adher-
ence, because of the limited number of therapy failures (n=3).
However, past treatment failure was found to correlate with
detectable viral load (OR 2.79, CI 1.20-6.51). 
Conclusions: Patients in our clinic had excellent adherence when
measured by the MASRI and ODB database. The MASRI and ODB
calculated adherence were weakly correlated with each other.
Interventions towards improving adherence should target women liv-
ing with HIV.
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41Physical Activity and Health Outcomes among HIV-Infected MSM: 
A Longitudinal Mediational Analysis 
Aaron Blashill1 (presenting), Kenneth Mayer2, Heidi Crane3, 
Steven A. Safren1
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
2 The Fenway Institute, Boston, MA, USA
3 University of Washington, Seattle, WA, USA
Background: Low physical activity is associated with depression,
which may in turn, negatively impact antiretroviral therapy (ART)
adherence among HIV-infected individuals; however, prior studies
have not investigated the relationship between physical inactivity
and ART non-adherence. Thus, the purpose of the current study is to
examine the association of physical inactivity, depression, ART non-
adherence, and viral load in HIV-infected men who have sex with
men. 
Methods: The sample (N = 860) was from a large, multicenter cohort
of HIV-infected patients engaged in clinical care (the Center for AIDS
Research Network of Integrated Clinical Systems; CNICS). 
Results: Longitudinal mixed-level modeling revealed that across
time, depression mediated the relationship between physical inactiv-
ity and ART non-adherence, g = .075, and the relationship between
physical inactivity and viral load, g = .05. Furthermore, ART non-
adherence mediated the relationship between depression and viral
load, g = .002, and the relationship between physical inactivity and
viral load, g = .009. 
Conclusions: Low levels of physical activity predicted increased
depression and poor ART adherence over time, which subsequently
predicted higher viral load. Promoting physical activity as part of
treatment programs for individuals living with HIV and mood difficul-
ties may be worthy of further investigation. 
42 Appearance Concerns, Depression,and ART Non-Adherence in HIV-
Infected Individuals with a History of
Injection Drug Use: Prospective Analyses 
Aaron Blashill1 (presenting), Steven A. Safren1
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
Background: Appearance concerns are common among HIV-infect-
ed individuals, and previous cross-sectional and longitudinal data
indicate that these concerns are associated with antiretroviral ther-
apy (ART) non-adherence. However, to date, no known longitudinal
data have examined the mechanism behind this relationship. Thus,
the aim of the current study was to test depression severity as a lon-
gitudinal mediator of the relationship between appearance concerns
and ART non-adherence in HIV-infected individuals with a history of
injection drug use (IDU). 
Methods: Participants were 89 HIV-infected individuals with a histo-
ry of IDU who participated in a prospective, randomized controlled
trial of cognitive behavioral therapy for depression and medication
adherence. Clinician-administered measures of depression severity
and appearance concerns, along with electronic monitoring of ART
non-adherence were used. Data were analyzed via longitudinal lin-
ear mixed-level modeling, and mediation was tested with the Monte
Carlo Method of Assessing Mediation (MCMAM). 
Results: Appearance concerns were predictive of depression sever-
ity, g = .31, SE = .076, 95% CI [.16, .46], t = 4.1, p = .0001, and depres-
sion severity was predictive of ART non-adherence, g = 3.3, SE = 1.3,
95% CI [.8, 5.8], t = 2.6, p = .01. The effect of appearance concerns on
ART non-adherence, however, was significantly mediated by depres-
sion severity, g = 1.02, 95% CI [.21, 2.1]. 
Conclusions: Appearance concerns are associated with depression
severity, which subsequently is associated with ART non-adherence.
Integrative interventions addressing appearance concerns, depres-
sion and ART adherence are needed, as this is one potential pathway
towards worse health outcomes in HIV-infected individuals.  
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46 Stimulant Use is a Significant RiskFactor for Poor Engagement in HIV
Medical Care
Keith Horvath1 (presenting), Jane M. Simoni2, Adam Carrico3,
Edward Boyer4, K. Rivet Amico5, Andrew Petroll1
1 Center for AIDS Intervention Research - Medical College of
Wisconsin, Milwaukee, WI, USA
2 University of Washington, Seattle, WA, USA
3 University of California, San Francisco, San Francisco, CA, USA
4 University of Massachusetts, Worcester, MA, USA
5 University of Connecticut, Storrs, CT, USA
Background: Stimulant (e.g., cocaine, methamphetamine) use is a
recognized risk factor for poor prognosis among people with HIV,
however little is known of its impact on engagement in HIV medical
care. The purpose of this study is to assess: 1) the attitudes toward
HIV medical care among stimulant-using using men who have sex
with men (MSM); (2) whether recent stimulant use is associated with
poorer HIV medical care engagement.
Methods: MSM (n=276) living in the US and diagnosed with HIV for at
least 1 year completed an online survey in 2009. Participants self-
reported demographics, stimulant use (past month), engagement in
HIV medical care (past year), and attitudes toward HIV medical care.
Results: Men were on average 42 years old, White (71%), and highly
educated (43% with a college degree). Most (84%) reported no
recent stimulant use, while 16% reported using one or more types of
stimulants. In the past year, 69% of men attended all of their HIV med-
ical appointments, 22% missed at least one appointment, and 9% had
not attended any HIV medical appointments. Stimulant users (57%)
were significantly less likely than non-stimulant users (85%) to report
that HIV medical care is a high priority (p<.01). Nearly half (46%) of
stimulant-using men reported having low confidence in attending all
HIV medical appointments in the next year. Stimulant use was signif-
icantly associated with not attending any HIV medical appointments
in the past year in the unadjusted model (Relative Risk Ratio=2.84,
95%CI[1.07,7.58]), as well as in models adjusted for demographic
(RRR=3.16, 95%CI[1.13,8.84]) and psychosocial (RRR=3.44,
95%CI[1.17,10.15]) factors (ps<.05).
Conclusions: Stimulant use was significantly associated with not
engaging in HIV medical care in this sample of MSM. Interventions
that address the importance of HIV medical care and increase stim-
ulant user’s confidence in attending appointments may be critical to
fully engage this difficult-to-reach population in care.
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47Perceived Infectiousness and BeliefsAbout Treatment as Determinants of
ART Use and Adherence among High Risk,
HIV-Infected Patients in Chiang Mai, Lusaka,
and Rio de Janeiro: Qualitative Results from
HPTN 063
Matthew Mimiaga1 (presenting), Rose Closson1, Kenneth Mayer1,
Ayana T. Moore2, Arunrat Tangmunkongvorakul3, 
Kriengkrai Srithanaviboonchai4, Ruth Khalili Friedman5, 
Carla Alves5, Sarah Roberts6, Mohammed Limbada6, 
Vanessa Elharrar7, Susan Shurman8, Steven A. Safren9
1 The Fenway Institute, Boston, MA, USA
2 Family Health International, Research Triangle Park, NC, USA
3 Research Center for AIDS and STI, Research Institute for Health
Sciences, Chiang Mai University, Chiang Mai, THAILAND
4 Faculty of Medicine, Chiang Mai University, Chiang Mai, 
THAILAND
5 Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro,
BRAZIL
6 Centre for Infectious Disease Research in Zambia (CIDRZ),
Lusaka, ZAMBIA
7 National Institutes of Health/National Institute of Allergy and
Infectious Diseases, Bethesda, MD, USA
8 Center for Global Health, Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD, USA
9 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
Background: The availability of ART (antiretroviral therapy) for treat-
ment is rapidly expanding in developing world settings, and recent
data (HPTN052) support treatment as a biomedical prevention strat-
egy. However, the potential value of ART as prevention may be limit-
ed by poor adherence or uptake leading to uncontrolled virus.  HPTN
063 is an observational mixed-methods study of high-risk HIV-infect-
ed patients in Chiang Mai, Thailand, Lusaka, Zambia, and Rio De
Janeiro, Brazil to obtain data to optimize integrating HIV prevention
into HIV treatment.
Methods: From May 2010-June 2012, semi-structured qualitative
interviews were conducted with 80 in-care, HIV-infected individuals
who reported current transmission risk behavior. The qualitative
interview explored knowledge about HIV, experiences taking ART,
and psychosocial factors that potentially influence adherence to
ART. Interviews were recorded, transcribed, translated to English
and examined using thematic-analysis.
Results: Equal numbers of heterosexual men and women (n=30) par-
ticipated across the sites and 20 men who have sex with men (MSM)
were enrolled, equally, in Thailand and Brazil. While responses were
shaped by the socio-cultural contexts unique to risk groups and geo-
graphic locations, several broad themes pertaining to ART use and
transmission risk behavior emerged across settings: 1) confusion
about criteria for ART initiation; 2) perceiving an undetectable viral
load to be both an HIV risk reduction strategy and personal health
benefit; 3) reporting that ART adherence was connected to their per-
ceived level of HIV infectiousness; and 4) concerns about drug
resistance resulting from non-adherence.
Conclusions: Perceptions of HIV transmission risk are linked with
patterns of ART utilization and notions of ART effectiveness across
settings. Treatment as prevention efforts may benefit from address-
ing perceptions of how HIV treatment influences self-perceived
transmission risk and ART initiation/adherence.  Some patients’ con-
fusion about starting ART highlights the need for myriad prevention
efforts (i.e., PrEP, behavioral interventions, and ART as treatment for
prevention). 
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48 Adherence To HIV/AIDS AntiretroviralTherapy In a Tertiary Hospital In North
Central Nigeria
Oluwole Babatunde1 (presenting), Chukuma Anyaike1, 
Olusegun Elegbede1, Majekodunmi Ayodele1, Sunday Abidoye2
1 Federal Medical Center, Ido-Ekiti, NIGERIA
2 World Health Organization, Akure, NIGERIA
Background: Suboptimal medication adherence rates to antiretrovi-
ral therapy poses serious problems to the control of HIV/AIDS. This
study aims to assess the treatment adherence rate among HIV posi-
tive patients receiving treatment in a Nigerian Tertiary Hospital.
Methods: This was a descriptive, cross-sectional study conducted at
the HIV clinic of the University of Ilorin Teaching Hospital, Kwara
State. Self-reported treatment adherence rate was assessed among
adults accessing drugs for the treatment of HIV over the preceding 7
days to minimize recall bias. Systematic random sampling method
was used to select 550 participants out of a population of 2200. Data
was collected using semi-structured interviewer administered ques-
tionnaire and analysis was done using SPSS.
Results: A total number of 550 HIV patients were studied and the age
range of the respondents was 18 to 65 years with the mean age of
39.9±10 years. Mean duration of treatment period is 1.2±0.5 years
Pretreatment adherence instruction was given to 99.8%. More than
three quarter (86.9%) of the patients did not miss their drugs in the
last 3 months while 89.8% did not miss their drugs in the last 7 days.
The highest proportion (36.1%) of the patients who missed their drugs
in the last three months did so for 7 days and above and the mean
duration of missing drug among the patients was 4.6±2.5 days. The
treatment adherence rate of HIV patients was 92.6%. Reasons
patients gave for non adherence included: travel (44.4%), felt sick
and depressed (25%), ran out of drugs (33.3%), felt better (19.8%),
lack of money for transportation (50%), side effects (37.5%), forgetful-
ness (41.7%), perceived stigma (30.5%).                       
Conclusions: The adherence rate is still less than optimal despite
advancements made in treatment measures. Adherence monitoring
plans such as home visiting and care should be sustained and home
based care should be encouraged.
49 Prospective Memory andAntiretroviral Adherence in Youth
Living with HIV
Sylvie Naar-King1, Lisa M. Kuhns2 (presenting) 
1 Wayne State University, Detroit, MI, USA
2 Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL,
USA
Background: Neurocognitive impairment has been linked to lower
rates of adherence as well as higher rates of substance use, and
both of these behaviors are highly prevalent in youth living with HIV
(YLH). Emerging evidence suggests that prospective memory (PM)
could represent an important piece of the puzzle and explain why
“forgetting” is the most commonly cited reason for nonadherence.
PM is defined as the neurocognitive capacity to successfully form,
maintain, and execute an intention at a particular point in the future
in response to a specific cue. To date PM has not been examined in
YLH.  We present baseline data from a randomized clinical trial to
evaluate the relationship between PM and adherence in YLH.
Methods: 100 participants (ages 16 to 29) in Chicago completed self-
report measures of adherence (visual analogue scale) and PM
including the Prospective and Retrospective Memory Questionnaire
(PRMQ assessing PM complaints) and Prospective Memory for
Medications Questionnaire (PMMQ assessing PM-based strategies
to support adherence). Both measures include subscales for high-
demand (self-cued PM complaints and internal strategies such as
making plans to take medications) and low-demand (environmental-
ly-cued PM complaints and external strategies such as an alarm
clock). 
Results: The sample was 95% ethnic minority and 80% male (Mean
age= 23). Mean reported adherence over the last 30 days was 66%.
In univariate analysis, higher adherence was associated with fewer
self- and environmentally-cued PM complaints and greater use of
internal PM strategies.  In regression analysis controlling for psycho-
logical distress and substance use, only internal PM strategy use
was significantly predictive of higher adherence with the entire
model accounting for 19% of the variance.
Conclusions: PM is associated with adherence in YLH.  The use of
internal strategies may be particularly important for youth-specific
adherence interventions.  We present a new NIDA-funded transla-
tional PM intervention development initiative. 
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50 Trends in Single-Tablet ART RegimenUse and Association with Increased
Adherence in the Women’s Interagency HIV
Study, 2006-2012
David B. Hanna1 (presenting), Nancy Hessol2, Elizabeth Golub3,
Mardge Cohen4, Alexandra Levine5, Tracey Wilson6, Mary Young7,
Kathryn Anastos8, Robert Kaplan1
1 Albert Einstein College of Medicine, Bronx, NY, USA
2 University of California, San Francisco, San Francisco, CA, USA
3 Johns Hopkins Bloomberg School of Public Health, Baltimore,
MD, USA
4 Cook County Hospital, Chicago, IL, USA
5 City of Hope National Medical Center, Duarte, CA, USA
6 SUNY Downstate Medical Center, Brooklyn, NY, USA
7 Georgetown University Medical Center, Washington, DC, USA
8 Montefiore Medical Center, Bronx, NY, USA
Introduction: Single-tablet ART regimens (STRs) were developed to
improve adherence. Their uptake has not been well-described
among U.S. HIV-infected women, who often have contraindications
for certain formulations and competing factors resulting in lower
adherence.
Methods: Participants were enrolled during 1994/1995 or 2001/2002 in
the Women’s Interagency HIV Study (WIHS), a longitudinal cohort of
HIV-infected and -uninfected women in 5 U.S. cities. We examined
semiannual trends during 2006-2012 in STR use and ART adherence,
defined as 95% adherence in the past 6 months via self-report. We
tested for time trends using Poisson regression with generalized esti-
mating equations. In a subset of women who switched from a preex-
isting regimen to an STR, we tested for a post-switch increase in
adherence and virologic suppression among those remaining on an
STR for two visits, using conditional logistic regression.
Results: 13,675 person-visits (N=1,500 ART-treated women, 53%
black, 28% Hispanic, 27% IDU, median age 44), were included. STR
use increased from 7% in 2006 to 20% in 2012 (p<0.001), while adher-
ence increased from 75% to 80% (p=0.04). After taking into account
use of STRs, the secular increase in adherence was no longer statis-
tically significant (p=0.29), suggesting that improved adherence is
largely due to their uptake. Among those who switched regimens
(N=200), the STR was associated with increased adherence (80% to
87%, adjusted odds ratio [OR] 2.23, 95% CI 1.08-4.60) and virologic
suppression (72% to 80%, OR 1.78, 95% CI 0.86-3.68).
Conclusions: In this largely treatment-experienced group of women,
STR use increased to one-fifth of the population, with adherence
increasing significantly during the same period. Our findings provide
support that STRs are effective in improving adherence and clinical
outcomes. Despite this, 20% prescribed ART were still not fully adher-
ent; additional work is still needed to better understand the conditions
that optimize adherence and therapeutic benefits in women.
51Association of Time-VaryingAdherence to ART on Rates of
AIDS/Death: Cross-Cohort Analysis
Nicholas Turner1, Suzanne Ingle1, Bob Hogg2, John Gill3, Jan Tate4,
Heidi Crane5, Tracy Glass6 (presenting), Adriana Ammassari7,
Michael Saag8, Michael J. Mugavero8, Margaret May1, 
Jonathan Sterne1
1 School of Social and Community Medicine, Bristol, UK
2 BC Centre for Excellence in HIV/AIDS, Vancouver, BC, CANADA
3 Division of Infectious Diseases, Calgary, NA, CANADA
4 Yale University, New Haven, CT, USA
5 University of Washington, Seattle, WA, USA
6 Swiss Tropical and Public Health Institute, Basel, SWITZERLAND
7 National Institute for Infectious Diseases, (INMI L) Spallanzani,
Rome, ITALY
8 University of Alabama at Birmingham, Birmingham, AL, USA
Background: The association between adherence and viral suppres-
sion has been well characterized, but its direct effect on morbidity
and mortality is less well understood.
Methods: We examined data from three North American cohorts that
collect prescription refill data. Percentage treatment adherence over
one year was calculated for each subject for up to three years of anti-
retroviral therapy (ART). Adherence was categorized as low (²70%),
medium (71-90%) and high (>90%). Associations between adherence
and AIDS or death were estimated using Cox models with time-varying
adherence, adjusted for cohort, age, gender, transmission risk group,
baseline CD4 count, baseline AIDS, and further adjusted for time
updated virological suppression. Virological suppression was defined
as viral load <500 copies/ml on the most recent viral load measured
within the same time period as the adherence measurement.
Results: Data were available on 4,535 patients (mean age 41 years,
80% male, 33% IDU, mean baseline CD4 count 249 cells/mm3). There
were 124 AIDS events and 237 deaths in 10,390 person-years of fol-
low-up. 62% of patients had high adherence after year 1 and 64% after
years two and three. In adjusted models, the hazard of AIDS or death
increased with increasing non-adherence (compared to >90% adher-
ence: ²70%, hazard ratio (HR) 5.72, 95% confidence interval (CI): 4.32-
7.58; 71-90%, HR 1.99, 95% CI: 1.41-2.82). These HR were only modest-
ly attenuated after further adjusting for virological suppression (²70%,
HR 3.59, 95% CI: 2.56-5.05; 71-90%, HR 1.65, 95% CI: 1.14-2.38).
Conclusions: Greater levels of adherence to ART are associated with
reduced rates of AIDS or death, even after adjusting for viral suppres-
sion.  This implies that adherence is not only a strong predictor of clin-
ical success via viral load, but also an early indicator of declining
health status making it a valuable tool for clinicians in daily practice. 
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52 Implementing Behavioral Activationand Life-Steps for Depression and
Antiretroviral Therapy Adherence in an HIV
Community Health Center: Evaluating a
Modular, Group Approach
Jessica Magidson1 (presenting), Christopher Seitz-Brown2, 
Steven A. Safren1, Lance Morgan3, Carl Lejuez2, Stacey Daughters4
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
2 University of Maryland, College Park, College Park, MD, USA 
3 Whitman-Walker Health, Washington, DC, USA
4 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Introduction: Depression is highly prevalent among individuals living
with HIV/AIDS and associated with poor adherence to antiretroviral
therapy and worse disease outcomes. Empirically-supported cogni-
tive behavioral interventions exist to address improvements in
depression and adherence in this population; yet, these techniques
have been designed for individual treatment in mental health set-
tings. Dissemination and implementation studies are needed to
examine how to adapt these techniques in medical settings where
many individuals receive treatment.
Description: Primary aims of this study were to implement empirical-
ly supported cognitive behavioral techniques for depression (behav-
ioral activation; BA) and HIV medication adherence (Life-Steps) for
delivery in an outpatient community health center in a modular, group
format that did not rely on sequential session attendance. Feasibility
was examined over eight weeks (n = 13). Preliminary effects on
depression, health-related quality of life, and medication adherence
were examined and exit interviews were conducted with a subset of
participants (n = 4) to inform future modifications.
Lessons Learned: It was feasible to implement this evidenced-based
intervention into the HIV care setting.  Mean changes over 8 weeks
demonstrated clinically significant reductions in depressive symp-
toms, improvements in physical and mental health-related function-
ing, and antiretroviral therapy adherence. Exit interview feedback
revealed the importance of peer-led contributions, difficulties utiliz-
ing homework in this format, and positive effects of structure and
goal-setting for improvements in both mood and adherence.
Recommendations: Findings demonstrated the initial feasibility of
adapting BA and Life-Steps for delivery in a modular, group format in
outpatient HIV care. Future directions include testing the modified
intervention in a larger sample with a comparison control.
53Assessing Adherence in a WestAfrican Cohort in Guinea Bissau (the
AssAiA Project)
Charlotte Dyrehave1 (presenting), Christian Wejse1, Lotte Rodkjaer1
1 Department of Infectious Diseases, Aarhus University Hospital,
Skejby, Aarhus, DENMARK
Background: Non-adherence is a major barrier to antiretroviral ther-
apy (ART). Low adherence is a threat to ART programs and it is there-
fore crucial to address the factors leading to non-adherence. We
have previously found in a qualitative study that HIV patients in
Bissau have insufficient knowledge about HIV and ART. We showed
that the experience of treatment benefits and social support facilitat-
ed adherence, whereas the main barriers were: lack of HIV-knowl-
edge, and treatment-related costs.
Methods: We pilot tested a questionnaire designed for assessment
of adherence and description of barriers and facilitators to adher-
ence based on our previous findings. From October 2012 to March
2013, 350 HIV patients in the in the Bissau HIV cohort at the HIV clin-
ic on Hospital National Simao Mendes in Bissau, were enrolled in the
study. Patients were interviewed by a local trained nurse.
Results: Twenty-two percent were men, 34 % were illiterate. Forty
one per cent were married and only 17% of these had disclosed their
HIV-status to their partner. Non- adherence is a problem, as 25% did
not take the medicine during the last 4 days and 20% skipped their
medicine during weekends. The main barriers were lack of knowl-
edge about ART/ HIV (40%), and disclosure-related difficulties (70%).
The most frequent reasons for not taking medicine were side-effects
(30%), simply forgetting (12%), too ill to attend the clinic (8%), lack of
food (7%).
Conclusions: In a mobile urban West African population of HIV
patients, one quarter have not taken their medicine at least one of the
past 4 days, mainly because of perceived side effects and forgetting
to take the drugs, non-adherence was strongly associated with lack
of basic knowledge about HIV. There is an urgent need to improve
HIV knowledge if adherence rates are to be improved.
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59 Home Intervention ImprovesAdherence in Hunan, China
Honghong Wang1 (presenting), Xianhong Li2, Kristopher Fennie3,
Ann Williams4
1 Central South University, Changsha, Hunan, CHINA
2 School of Nursing, Central South University, Changsha, Hunan,
CHINA
3 Florida International University, Miami, FL, USA
4 University of California, Los Angeles, Los Angeles, CA, USA
Background: Free ART (antiretroviral therapy) is available through
the China CARES program, but treatment adherence remains an
issue. A Freirian home-nursing intervention improved ART adherence
in the United States, but has not been tested elsewhere.
Methods: A culturally adapted home-nursing adherence intervention
(Ai Sheng Nuo) was evaluated in a randomized pilot study among 110
patients in Hunan Province, China. All subjects self-reported less
than 90% adherence to prescribed ART or pre-ART medications and
had detectable viral load. Subjects were randomized to the 6-month
intervention (N=55) or usual care (N=55). Data were collected at
baseline, 6 months, and 12 months. Adherence was measured with a
visual analogue scale.
Results: At 6 months, 69% of the control group and 90% of the inter-
vention group were adherent.  At 12 months, 64% of controls and 87%
of the intervention group were adherent.  Controlling for baseline
adherence score and whether the subject was ARV naïve, the inter-
vention group had higher adherence compared to the control group
(p=.016).  Adherence did not differ significantly between 6 and 12
months in either group (p=.415).  There were no significant differ-
ences in detectable viral load between groups or over time.  In both
groups, the proportion of those with an undetectable viral load
increased at 6 months (52% in the control group; 59% in the interven-
tion group), and 12 months (70% in the control group; 73% in the inter-
vention group). 
Conclusions: Adherence improved for all subjects participating in
the study. The intervention group had significantly higher adherence
at 6 months and the effect was sustained after the conclusion of the
intervention. 
60Defining Self-Reported andPrescription Measures of Adherence
to ART: Multi-Cohort Analysis
Suzanne Ingle1 (presenting), Tracy Glass2, Heidi Crane3, Bob Hogg4,
John Gill5, Adriana Ammassari6, Michael J. Mugavero7, Jan Tate8,
Nicholas Turner1, Margaret May1, Jonathan Sterne1
1 School of Social and Community Medicine, Bristol, UNITED
KINGDOM
2 Swiss Tropical and Public Health Institute, Basel, SWITZERLAND
3 University of Washington, Seattle, WA, USA
4 BC Centre for Excellence in HIV/AIDS, Vancouver, BC, CANADA
5 Division of Infectious Diseases, Calgary, CANADA
6 National Institute for Infectious Diseases, (INMI L) Spallanzani,
Rome, ITALY
7 University of Alabama, Birmingham, AL, USA
8 Yale University, New Haven, CT, USA
Background: Early identification of poor adherers to ART could facil-
itate interventions to prevent treatment failure. However, cohorts col-
lect adherence data in diverse ways and defining levels of adher-
ence is not straightforward. We examined how different measures
may be used to identify those at risk of viral failure.
Methods: 6/19 cohorts collaborating in the ART Cohort Collaboration
(ART-CC) contributed adherence data: 3 from prescription refills (3
North American cohorts) and 3 from self-report questionnaires (2
European, 1 North American cohort). For prescription data, we
derived 1-year percentage adherence and viral suppression (²500
copies/ml) using the viral load closest to the 1 year time point. For
self-report data, we derived percentage adherence in the last 28
days and viral suppression using the closest viral load measure after
but within 6 months of the questionnaire. We plotted Receiver
Operating Characteristic (ROC) curves to assess discrimination of
percentage adherence for diagnosing viral suppression, and estimat-
ed the area under the ROC curve (AUROC): 0.5 corresponds to no and
1 to perfect discrimination.
Results: Adherence and viral load data were available from 13276
patients: 9591 and 3685 with prescription and self-report data respec-
tively. Greater proportions of patients were virally suppressed and
had ³95% adherence in cohorts with self-report compared with pre-
scription data. AUROCs varied from 0.56 to 0.85 between cohorts and
were systematically higher in cohorts with prescription data, likely
due to the categorical rather than continuous nature of the self-
report data.
Conclusions: Cohorts were heterogeneous in terms of viral suppres-
sion and adherence. Prescription and self-report data measure dif-
ferent aspects of adherence. Self-report items may provide a better
snapshot of current adherence enabling identification of inadequate
adherence before viral loads begin to climb. This real-time reporting
advantage of self-report questionnaires may constitute an interven-
tion which may explain the apparent lower discriminatory power
compared with prescription data.
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61Adherence Intervention ReducesDepressive Symptoms in Hunan, China
Xianhong Li1 (presenting), Honghong Wang2, Kristopher Fennie3,
Ann Williams4
1 School of Nursing, Central South University, Changsha, Hunan,
CHINA
2 Central South Univerisity, Changsha, Hunan, CHINA
3 Florida International University, Miami, FL, USA
4 University of California, Los Angeles, Los Angeles, CA, USA
Background: Free ART (antiretroviral therapy) is available through
the China CARES program, but medication adherence remains an
issue and mental health services are lacking. Depression has been
associated with sub optimal adherence in a number of cohorts.
Methods: As part of a pilot study of the efficacy of a culturally adapt-
ed home-nursing adherence intervention (Ai Sheng Nuo), depressive
symptoms were measured among 110 patients receiving ART in
Hunan Province, China. All subjects self-reported less than 90%
adherence to prescribed ART or pre-ART medications and had
detectable viral load. Subjects were randomized to the 6-month inter-
vention (N=55) or usual care (N=55). Data were collected at baseline,
6 months, and 12 months. Adherence was measured with a visual
analogue scale. Depressive symptoms were measured with the CES-
D (Chinese).
Results: At baseline 71% of controls and 58% of intervention subjects
reported symptoms suggestive of depression (ie CES-D score ³ 16).
The proportion of subjects in each group with CES-D of 16 or greater
decreased to 60% of control subjects and 50% of intervention sub-
jects at 6 months. Differences at baseline and at 6 months were not
statistically significant. However, the proportion of intervention sub-
jects with a symptom score of 16 or greater continued to decrease at
12 months (39%), while returning to baseline in the control group
(71%).  In multivariate analyses, controlling for whether a subject
was ART naïve, there was a significant difference in overall CES-D
scores between the two groups (p=.001), with the control group hav-
ing a higher proportion of people with a score of 16 or greater. There
was no association between adherence and CES-D scores.
Conclusions: In this cohort, depressive symptoms were prevalent
and not significantly related to self-reported adherence behavior.
However, receipt of the adherence intervention was associated with
reduced depressive symptoms at the long-term follow up visit.
62Every Dose Every Day: A Preview of aNew e-Learning Training Toolkit for
HIV Care Providers to Improve Adherence to
Antiretroviral Medications 
Kathleen Green1 (presenting), Rhondette Jones1, Janet Van Ness2
1 Centers for Disease Control and Prevention, Atlanta, GA, USA
2 John Snow Inc., Boston, MA, USA
Introduction: Adherence to anti-retroviral therapy (ART) is critical to
the success of HIV treatment and treatment as prevention.  However,
despite ART advances, more than 800,000 of the estimated 1.2 million
people living with HIV in the U.S. do not have a suppressed viral load.
In order to prevent treatment failure and drug resistance and to see
the prevention benefits of treatment, patients must have greater than
95% adherence.  Thus, an important challenge for providers is to sup-
port patients’ adherence to HIV treatment. 
Description: In Fall 2013, the CDC’s Division of HIV/AIDS Prevention
Capacity Building Branch will launch an e-learning training toolkit for
HIV care providers featuring four evidence-based behavioral inter-
vention strategies that were found to improve HIV adherence among
ART-naïve and/or experienced patients. These four strategies
include - Project HEART (Helping Enhance Adherence to Anti-retro-
viral Therapy); Partnership for Health - Medication Adherence; Peer
Support; and SMART (Sharing Medical Adherence Responsibilities
Together) Couples.  These interventions were identified as “good-
evidence” according to the CDC’s HIV/AIDS Prevention Research
Synthesis (PRS) Project. The e-learning training toolkit includes an
overview of each strategy, theoretical underpinnings, staff roles and
responsibilities, session content, videos demonstrating sessions in
action, and comprehensive guides for integrating the strategy into an
agency/clinic.  Finally, downloadable brochures, manuals and
posters are available to assist providers and staff with successful
implementation. 
Lessons Learned: The development of an e-learning training facili-
tates swifter movement in disseminating evidence-based interven-
tions into practice for intended users.  The original researchers play
a critical role in transferring knowledge of their research into prac-
tice.     
Recommendations: This e-learning training toolkit will be pilot-test-
ed among HIV clinical providers.  Continuing education will be given
to learners who complete the training. This training will assist HIV
providers in assessing and better understanding their patients’ chal-
lenges to achieve and support optimal adherence.     
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63 Stages of Change and Adherence toAntiretroviral Therapy
Becky Genberg1 (presenting), Yoojin Lee1, William Rogers2, 
Ira B. Wilson1
1 Brown University, Providence, RI, USA
2 Tufts Medical Center, Boston, MA, USA
Background: Research has consistently demonstrated the inability of
clinicians to predict non-adherent patients. The stages-of-change
model, originally described to understand smoking cessation, has
been widely applied to cessation of harmful behaviors. The objective
of the current study was to determine whether phases in the model
(i.e., pre-contemplation, contemplation, planning, action, and mainte-
nance) predicted adherence to antiretroviral therapy (ART).
Methods: Data for the current analysis comes from a randomized
trial of a provider-focused intervention. Individuals were eligible if
they were taking ART and had detectable HIV-RNA at the baseline
visit. Adherence was measured using MEMS (Medication Event
Monitoring System) and self-report. Data from 503 follow-up visits
from 141 individuals using MEMS were used. Descriptive statistics
characterized the sample and the stages-of-change over time. Linear
mixed models were used to determine the impact of stages-of-
change on repeated measures of adherence after controlling for
potential confounders.
Results: The sample was 23% female, 50% white, 26% African-
American, with a mean age of 42 years. The overall average MEMS
adherence was 73% and 17% were in the pre-contemplation, con-
templation, or planning phases for taking ART. Those in the pre-con-
templation, contemplation or planning phase had significantly lower
MEMS adherence (-18.4%, p<.0001) compared to those in the action
and maintenance phases, after adjusting for age, sex, race, educa-
tion, depression, and alcohol and substance use. No demographic
characteristics predicted adherence. Similar results were observed
for self-reported adherence.
Conclusions: The stages-of-change model may offer a potential
screening tool for clinicians to discover patients at-risk of non-
adherence to ART. Similar to prior research, demographic character-
istics did not distinguish ART adherence in this study, reinforcing the
need for clinicians to engage in dialogue with patients about their
adherence behaviors. Future research is needed to test the use of
this model as a screening tool in the clinical setting.
64 Disclosure of HIV Status andEnrollment in HIV Care in Western
Kenya: Findings from a Home-Based
Counseling and Testing Initiative
Becky Genberg1 (presenting), Violet Naanyu2, Joseph Hogan1,
Paula Braitstein3
1 Brown University, Providence, RI, USA
2 Moi University, Eldoret, KENYA
3 Indiana University-Kenya Program, Eldoret, KENYA
Background: Early identification and enrollment in care of HIV-posi-
tive individuals is crucial to the success of antiretroviral treatment
(ART) programs. While home-based counseling and testing (HBCT)
identifies individuals early in the course of disease progression, link-
age to HIV care is inadequate in many resource-limited settings. The
objective of this study was to determine the proportion and corre-
lates of enrollment in HIV care among a population-based sample of
individuals who had previously tested positive for HIV in western
Kenya.
Methods: As part HBCT, all households within 6 USAID-AMPATH
(Academic Model Providing Access to Healthcare) catchments were
visited. Of the 5,558 individuals identified as HIV-positive between
July 2009 and August 2011, 1,048 (19%) were previously known infec-
tions. Logistic regression analysis determined factors associated
with self-reported enrollment in HIV care.
Results: Sixty-six percent of the sample was female, with a mean age
of 35 years. On average, HIV testing occurred 2 years prior to HBCT.
Seventy-five percent (n=786) reported enrollment in HIV care.
Characteristics associated with enrollment in multivariate analysis
included: female sex (odds ratio (OR) = 1.57, 95% confidence interval
(CI): 1.04, 2.39), age over 26 years (OR=2.87, 95% CI: 2.46, 3.34), and
monthly income ³3000 Kenyan Shillings (OR=1.34, 95% CI: 1.03, 1.74).
Those who had disclosed their HIV status to at least one other per-
son were nearly 7 times more likely to report enrollment in HIV care
(OR=6.66, 95% CI: 5.06, 8.77) compared with those who had not dis-
closed.
Conclusions: One-quarter of individuals previously known to be HIV-
positive were not enrolled in care. Women, older adults, those with
higher income, and those who disclosed their HIV status were more
likely to enroll in care following HIV testing. Additional efforts to
engage men, young people, and those of lower income are urgently
needed to ensure the individual and population effectiveness of ART.
PO
ST
ER
  A
BS
TR
AC
TS
14 8th International Conference on HIV Treatment and Prevention Adherence
65 “I Don’t Believe that HIV TreatmentWill Help” - A Qualitative Inquiry
among HIV-Infected Russians in Addiction
Care on Access to HIV Services
Tetiana Kiriazova1 (presenting), Karsten Lunze2, Anita Raj3, 
Natalia Bushara4, Elena Blokhina4, Evgeny Krupitsky4, 
Laura Wulach1, Carly Bridden1, Jeffrey Samet1, Allen Gifford2
1 Boston Medical Center, Boston, MA, USA
2 Boston University, Boston, MA, USA
3 University of California, San Diego, La Jolla, CA, USA
4 St. Petersburg Pavlov State Medical University, St. Petersburg,
RUSSIA
Background: In Russia, HIV-infected injection drug users (IDUs) in
addiction treatment often do not access HIV care. To tailor an effec-
tive linkage intervention developed in the USA to the needs of
Russian IDUs, we conducted interviews to evaluate barriers and
facilitators for drug users in addiction treatment to access HIV care.
Methods: We conducted 3 focus groups with HIV-infected IDUs and
7 semi-structured in-depth interviews with their clinical providers in
St. Petersburg, Russia; interviews were in Russian and audio-record-
ed. We analyzed data directly from audio recordings to identify
essential themes.
Results: Both patients (n=25, [40% female, mean age 32 years]) and
staff (n=7) identified lack of motivation as a significant barrier to
accessing HIV care among IDUs. Other internal barriers stated by
IDUs included mistrust of HIV providers, fearing stigmatization due to
their drug use, lack of psychological support, and misperceptions
about HIV care per se. External barriers cited were transportation
difficulties, lengthy registration procedures, and lack of HIV-related
information. Consistently, IDUs equated HIV care with dispensing of
antiretroviral therapy. Poor health was infrequently mentioned as a
motivation to seek care.
All study participants liked the idea of using peer case management
to improve engagement of IDUs in HIV care. Most IDUs perceived
peer case managers as sources of psychological support and HIV-
related information; learning about peers’ positive HIV care experi-
ences was identified as a useful facilitator.
Conclusions: Programs to link HIV-infected IDUs in addiction treat-
ment to HIV care must focus on reducing logistical barriers and moti-
vating participants to access care. Peer case management might
have the potential to deliver education regarding the benefits of HIV
care and to provide examples of peers’ positive experiences with
such care. Exploratory qualitative research helped tailor a standard
HIV-care linkage intervention to one potentially helpful for Russian
HIV-infected drug users. 
69 Viral Suppression as PerformanceMeasure for Five Outpatient
Ambulatory Medical Care Programs 
Funded by Ryan White Care Act in the
District of Columbia
Christie Olejemeh1 (presenting), Damber Gurung1, 
Gunther Freehill1, Lawrence Frison1
1 Department of Health/HIV/AIDS, Hepatitis, STD and TB
Administration, Washington DC, USA
Introduction: Clients engaged in primary care have a positive meas-
urable health outcomes compared to clients who use primary care
sporadically that re-engages in care as a consequence of hospital-
ization or court ordered substance abuse treatment. Clients from
three ambulatory primary medical care programs were evaluated
using health outcome measures - viral load, CD4 count - compared to
their counterparts in two sub-acute primary care facilities during
2012.
Description: Clients’ 2012 laboratory values extracted from electron-
ic medical records and paper charts were evaluated. Client data for
engagement in treatment and continuity of care, using laboratory val-
ues from DC HIV surveillance and ADAP database will be analyzed
prospectively (2010 -2011) to make these conclusions that are also
observed elsewhere in the United States.
Lessons Learned: More clients at the sub-acute primary care sites
have viral load greater than 10,000 copies compared to the outpatient
primary care sites.  Only 54-59% clients are virally suppressed at sub-
acute sites compared to 83-95% in primary care sites. Clients at sub-
acute care are more likely to have AIDS diagnosis by CD4 count less
than 200, more irregular laboratory tests and higher likelihood of non-
compliance with treatment plans/regimen. In addition, they have
sporadic re-engagement into care as a consequence of hospitaliza-
tion or court ordered substance abuse treatment.
Recommendations: To end the epidemic, clients must be engaged in
care and remain treatment adherent to ensure durable viral suppres-
sion.  Review client’s characteristics at sub-acute sites for housing
status, mental health and other co-morbidities. There must be a con-
certed effort to reduce homelessness and perhaps provide longer
stay at sub-acute sites. As it takes 12 to 24 weeks to have a reason-
able durable viral suppression, perhaps every HIV positive client
court- ordered to substance abuse treatment should be allowed to
stay for 12 weeks/90 days instead of the present 28days and same
length of stay after hospitalization.
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72Comparing the Utility of SubstanceUse Measures in the Prediction of
Medication Adherence: Quantity, Severity, or
Pattern? 
Tyrel Starks1 (presenting), Brett Millar1, Jeffrey Parsons2
1 Center for HIV Educational Studies & Training, New York, NY,
USA
2 Hunter College and the Graduate Center of the City University of
New York, New York, NY, USA
Introduction: The CDC estimated that by 2015 more than half of those
living with HIV will be age 50 and older. The link between substance
use and reduced adherence to HIV medication is well established in
samples of younger adults; this association is less understood among
older adult populations. One challenge faced by researchers in this
area is appropriately quantifying substance use in a manner that per-
mits an accurate representation of use as well as the associations
between use and outcomes of interest, such as HIV medication
adherence.
Methods: HIV-positive men and women over age 50 from the New
York City area (n=540) completed survey interviews via telephone
about their demographic information; self-reported immunologic
functioning (viral load); recent (past 30 days) HIV medication adher-
ence and drug and alcohol use.  Respondents also completed the
AUDIT and DAST-10.
Results: Three measures of substance use were obtained: amount of
use (the sum of the number of days each drug was used); severity of
use (scores above the clinical cutoff on the AUDIT and/or DAST-10);
and use pattern (determined empirically using Latent Class Analysis).
Number of missed medication days was regressed simultaneously
on these three measures. Severity was uniquely and positively asso-
ciated with missed medication days. Substance use pattern was
uniquely associated with non-adherence for heterosexual women,
but not heterosexual or gay men. Quantity of substance use was not
significantly associated with non-adherence after accounting for
pattern and severity. 
Conclusions: Measures of quantity, severity, and pattern differ in
their predictive utility as well as their ability to inform the tailoring
and targeting of intervention. These results indicate the need to
explore multiple methods of operationalizing substance use. They
also suggest that the predictive utility of measures may vary across
demographic factors.
73Developing a Mobile HIV AdherenceApp, While Keeping a Homeless
Population in Mind
Pam Klein1 (presenting), Margaret Marini1
1 Boston Health Care for the Homeless Program, Boston, MA, USA
Introduction: Adherence to HIV medication (ARVs) can be challeng-
ing - exceptionally so for people who are homeless.  Many have
“competing priorities,” such as finding food or shelter, that interfere
with taking medication.  A plethora of smart phone applications
(apps) exists to assist with adherence. Boston Health Care for the
Homeless Program (BHCHP) participated in the development of one
such prototype app - hiVIVA.  Though most BHCHP patients do not
currently have access to smart phones, in all likelihood this technol-
ogy will be in the hands of even the most disadvantaged populations
within a few years.  It behooves their care providers to learn about
apps such as hiVIVA.
Description: BHCHP participated in MIT Media Lab’s 2013 Health and
Wellness Innovation event to help develop a prototype adherence
support app.  BHCHP’s focus was assuring the app’s relevance for
people who are homeless.  The team produced hiVIVA, a multi-
faceted app which includes: real-time adherence support/reinforce-
ment, visual simulation of ARVs working in the body which changes
depending upon lab values and adherence, patient/provider commu-
nication, and gamefication and social connection capabilities.
Lessons Learned:
• The “competing priorities” of team members presented a chal-
lenge.  Participants had varying agendas and it took time to devel-
op a common focus.
• This writer was initially skeptical about the app’s relevance for
BHCHP patients, given their lack of smart phones. Yet it became
clear that the app could be particularly relevant for this popula-
tion.  hiVIVA’s social connection and gamefication aspects might
provide the social support that these transient patients often don’t
have outside of their care providers.  Furthermore, hiVIVA’s inno-
vative HIV education/support components can be a useful office-
based tool. 
Recommendations: The homeless HIV+ population should beta test
hiVIVA so their feedback is incorporated into the final product.  Care
providers of people who are homeless should familiarize themselves
with health-related mobile app technology.
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76 HIV/AIDS Treatment at a TertiaryHospital Clinic in Ghana - Where are
the Men?
Natasha Kumar1 (presenting), Betty Norman2, Rebecca Reece3,
Awewura Kwara3, Timothy Flanigan4, Aadia Rana4
1 Brown University, Providence, RI, USA
2 Komfo Anokye Teaching Hospital, Kumasi, GHANA
3 Warren S. Alpert Medical School of Brown University,
Providence, RI, USA
4 Miriam Hospital, Providence, RI, USA
Background: In resource-limited settings, men may face formidable
barriers to accessing HIV care as early diagnosis and treatment
interventions tend to focus on women through antenatal care. This
study seeks to investigate gender differences in entry to care in a
large urban HIV clinic in Ghana, a country where men account for
almost half of the HIV epidemic.
Methods: We performed a retrospective chart review of all adults
who initiated care at Komfo Anokye Teaching Hospital (KATH) HIV
clinic in Kumasi between January 1 and December 31, 2011. Charts
were abstracted for demographic, medical, and behavioral variables
of interest. Differences between men and women were analyzed
using a correlations matrix in which covariates with p<0.05 were
considered significant.
Results: Of the 1,127 patients who initiated care during study period,
895 charts were available for review comprising of 279 (31.2%) men
and 616 (68.8%) women. Men were more likely than women to be
older (p<0.001), married (p<0.001), and more highly educated
(p<0.001). An equal proportion of men (n=54, 19.4%) and women
(n=121, 19.6%) did not return for CD4 assessment (p=0.92). CD4 count
at entry to care was lower for men compared with women (261 ver-
sus 312; p=0.02). Over 51% of men and 44.6% of women had a CD4
count below 200 (p=0.09). Men were more likely than women to use
their spouse for emotional support (p<0.001), to use alcohol (p<0.001),
and to be sexually active (p=0.01).
Conclusions: Efforts to test and link men to care should be intensi-
fied. Men account for 45.5% of HIV positive adults in Ghana but only
31.2% of KATH’s patients. Men may not be seeking care consistently
in Ghana and are accessing treatment at a later stage of their dis-
ease than women. Further research needs to be aimed at improving
factors impacting late diagnosis and access to care.
77 Risk Perception, Risk Reduction, andAdherence to PrEP for Ugandan
Serodiscordant Couples: A Qualitative
Analysis
Monique Wyatt1, Norma Ware1 (presenting), Jared Baeten2, 
Connie Celum2, Elioda Tumwesigwe3, Jessica Haberer4, 
David R. Bangsberg4
1 Harvard Medical School, Boston, MA, USA
2 University of Washington, Seattle, WA, USA
3 Kabwohe Clinical Research Center, Kabwohe, Bushenyi, 
UGANDA
4 Massachusetts General Hospital, Boston, MA, USA
Background: Pre-exposure prophylaxis (PrEP) is a promising new
strategy for HIV prevention. As with antiretroviral treatment for HIV,
adherence to PrEP is critical for effectiveness. A central yet largely
unexplored question is how perceptions of HIV risk influence risk
reduction behaviors, including adherence. Using qualitative data,
this presentation examines the dimensions and dynamics of risk per-
ception among serodiscordant couples participating in the Partners
PrEP Study clinical trial in Uganda.
Methods: In-depth interviews on adherence were carried out with 95
HIV-1 uninfected individuals randomized to PrEP or placebo and 26 of
their HIV-1 infected partners. A subset of 24 uninfected partners was
asked directly about perceptions of risk. Interview data were content
analyzed for the meaning of risk, and categories characterizing risk
perception were developed.
Results: Uninfected partners understood the risks of acquiring HIV
and were aware of multiple strategies to reduce risk. Risk reduction
strategies used by participants included abstinence, reduction in fre-
quency of sex or number of partners, and condoms. Perceptions of
higher HIV risk in study participants were largely shaped by engag-
ing in unsafe sexual practices, i.e., lack of condom use. Reasons for
not feeling at risk included self-reported condom use, repeated con-
firmations of HIV negative status both prior to and during the study,
“trust in God,” and “high hopes in the medicine.” Although PrEP was
expected to protect against HIV, participants did not directly associ-
ate adherence with protection against risk. Perception of risk was
frequently not reflected in risk reduction behaviors.
Conclusions: The relationship between risk perception, adherence to
biomedical HIV prevention strategies, and risk reduction is complex,
and warrants further study. Individuals who perceive themselves to
be at risk weigh competing priorities that may ultimately interfere
with risk reduction efforts. Understanding how risk perception moti-
vates risk reduction and adherence will contribute to PrEP imple-
mentation success.
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80 Factors Associated with LateEnrollment in HIV Care among HIV-
Positive Individuals in Odessa Region,
Ukraine 
Oleksandr Neduzhko1, Ihor Perehinets2, Oleksandr Postnov3, 
Jack A. DeHovitz4, Robert Kaplan5, David Odegaard4, 
Michael A. Joseph5,  Tetiana Kiriazova6 (presenting)
1 Ukrainian Institute on Public Health Policy, Kyiv, UKRAINE
2 WHO Country Office in Ukraine, Kyiv, UKRAINE
3 I.I.Mechnikov Ukrainian Research Anti-Plague Institute, Odessa,
OD, UKRAINE
4 SUNY Downstate Medical Center, Brooklyn, NY, USA
5 Stony Brook University, Stony Brook, NY, USA
6 Boston Medical Center, Boston, MA, USA
Background: Despite 3.3 million HIV tests performed in 2011 in
Ukraine, only 60% of those testing positive have been seen for HIV
care at specialized AIDS Centers. Late enrollment in care results in
higher HIV-related morbidity and mortality. This study’s objective was
to identify barriers associated with delayed enrollment in HIV care
among HIV-positive individuals in Odessa region, Ukraine.
Methods: A cross-sectional survey of 200 patients newly registered
at Odessa Regional and Municipal AIDS Centers was conducted
from September-November 2011. Independent factors associated
with late (more than 3 months since positive HIV test result) vs. time-
ly (3 months or less since positive HIV test result) enrollment in HIV
care were evaluated using multivariable logistic regression.
Results: Of 200 subjects (mean age 35±8.2 years, 47.5% female, 42.5%
had experience of injection drug use, 24% unemployed), 110 (55 %)
entered HIV care late. Odds of late enrollment were greater for those
not feeling ill (aOR: 2.9, 95% CI: 1.49_5.77), having high school or less
education (aOR: 2.3, 95% CI: 1.164_4.75), having disabilities unrelated
to HIV infection (aOR: 5.2, 95% CI: 1.37_19.39), and feeling ashamed in
front of health care providers (aOR: 6.3, 95% CI: 1.29_31.22). No asso-
ciation between drug use experience and delayed enrollment in HIV
care was found.
Conclusions: Programs to link HIV-positive persons to medical care
should focus on reducing barriers to accessing care. Strategies tar-
geting individuals and communities in Ukraine should include educa-
tion about benefits of HIV care at every stage of the disease, linguis-
tically appropriate counseling and referral services, additional sup-
port for persons with disabilities, and stigma reduction campaigns.
81People who were Traced After BeingLost to Follow-Up During Pre-ART Care
are More Likely to Stop Care than Self-
Transferring to Another Health Facility
Sulaiman Conteh1, John Kelly2 (presenting), Brian Temple3,
Momodu Sesay1, Thomas Giordano3
1 National HIV/AIDS Secretariat, Freetown, Western Area, 
SIERRA LEONE
2 Baylor College of Medicine, Manvel, TX, USA
3 Texas Tech University Health Sciences Center, Lubbock, TX, USA
Background: Few studies have traced people who were lost to fol-
low-up (LTFU) during pre-ART care.
Methods: We used mixed-methods to conduct a tracing study of
people who were LTFU during pre-ART care.  This population was
established from a prospective cohort of 348 persons newly diag-
nosed with HIV infection receiving care at Connaught Hospital in
Freetown, Sierra Leone.   Pre-ART care was described as the period
from HIV diagnosis to ART initiation. LTFU was defined as not having
attended a clinic visit in the last 150 days. People who were LTFU dur-
ing pre-ART care were traced as per standard of care, which
involved ascertaining their vital status and reasons for being LTFU.  A
purposive sample of tracing visits included 21 tape-recorded inter-
views.   Interviews were transcribed and thematically coded by two
independent readers.      
Results: 130 of 348 (37.4%) patients were LTFU during pre-ART care.
90 of 130 (69.2%) patients were traced, and vital status was ascer-
tained in 87 of these persons (96.7%).  22 of 87 (25%) were dead.  Of
the 65 persons who were alive, additional outcomes and reasons for
LTFU were determined in 38 persons.  12 of 38 persons self-trans-
ferred their care to another health facility, and 26 (68.4%) stopped
care.  15 of the 21 (71.4%) interviews were conducted with persons
who stopped care.  Multiple themes emerged from interviews and
explained why people were LTFU:  1) financial constraints limit their
ability to take transportation to clinic, 2) competing demands such as
child care, school studies, work, and food security are prioritized
over their HIV care, and 3) internalized stigma, hopelessness, and
mental distress make patient perceive clinic attendance as a risk. 
Conclusions: The majority of patients who were LTFU during pre-
ART care stopped care rather than self-transferring to another health
facility.  Financial constraints, competing demands, and mental dis-
tress were barriers to care.
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82 Greater Cleveland HIV HealthInformation Project
Ann Avery1 (presenting), Ashley Tillison2, Barbara Gripshover3, 
Alan Taege4, Steven Lewis1
1 The MetroHealth System, Cleveland, OH, USA
2 Kent State University, Kent, OH, USA
3 University Hospitals Case Medical Center, Cleveland, OH, USA
4 The Cleveland Clinic, Cleveland, OH, USA
Introduction: Optimizing patient engagement in the HIV care contin-
uum will be more effective and efficient if coordinated at a communi-
ty level rather than just at a clinic level. 
Description: The Greater Cleveland HIV Health Information Project
(CHHIP) is a provider-initiated collaborative created to improve the
quality and utilization of HIV care in the Greater Cleveland area.
Initial partners include five health systems, a standalone supportive
service provider and the local health department. CHHIP leverages
widespread use of electronic medical records (EMRs) to extract data
elements across systems to inform community-wide practice.
Partners selected data to be collected; the data storage framework
has been developed and beta tested. On a quarterly basis, all part-
ners will submit coded patient-level data. In addition to HIV related
labs and office visits, providers will also submit data related to insur-
ance coverage, primary language, mental health treatment, sub-
stance use, ED and inpatient visits, participation in support groups
and outreach efforts.
Data sharing between the two largest providers has begun. A stan-
dardized unique identifier is used to allow for merging of records and
account for patient movement between facilities. Using quality
measurements consistent with HRSA, NQF and other nationally rec-
ognized guidelines, community, practice level and provider level
quality reports will be generated. Providers meet regularly to discuss
progress and share best practice.   
Lessons Learned: EMRs are not static storage units, some elements
are not stored as readily exported variables and changes to the
EMRs affect secondary uses of data. In order to extract, store and
merge data from different EMRs, data manipulation or recoding is
often needed.
Recommendations: EMR data from remaining partner institutions will
be collected and merged into the data system. Analyses of the local
HIV care cascade by co-morbid conditions will allow for deeper
understanding of community needs.
84 Comparative Effectiveness ofDarunavir 1,200 mg Daily and
Approved Dosing Strategies for Protease
Inhibitor-Experienced Patients
James Mikula1 (presenting), Chiu-Bin Hsiao1, Joshua Sawyer1, 
Qing Ma1, Gene Morse1
1 University at Buffalo, Buffalo, NY, USA
Background: The HIV protease inhibitor (PI) darunavir, when dosed
with ritonavir, is approved for twice daily use in treatment-experi-
enced patients and once daily use in patients without darunavir
resistance-associated mutations. Patients who failed a PI regimen in
the past due to suboptimal adherence may find twice daily dosing a
barrier to treatment success. We present data on the rate of virolog-
ic suppression achieved with darunavir 1,200 mg once daily in PI-
experienced patients.
Methods: This retrospective, observational study included all
patients treated with darunavir 1,200 mg daily, 600 mg twice daily or
800 mg daily after documented use of another PI at an urban immun-
odeficiency clinic. Data collection from inception of darunavir use in
August 2006 through March 2012 included demographics, viral loads,
CD4+ cell counts, and resistance test results. The primary outcome
was defined as <50 HIV RNA copies/mL at 24 weeks according to the
time to loss of virologic response algorithm. Baseline characteristics
and virologic outcomes were analyzed across dosing groups via one-
way analysis of variance.
Results: 135 patients were included in the intention to treat analysis.
Demographics were similar across dosing groups. Patients treated
with 600 mg twice daily had a lower baseline CD4+ cell count (mean
259 cells/mL vs. 343 across all groups; p=0.003). Most patients had no
darunavir mutations at baseline. At 24 weeks, virologic suppression
was reached by 53.6% of patients on 1,200 mg daily, 52.3% on 600 mg
twice daily and 42.9% on 800 mg daily (p=0.568).
Conclusions: Darunavir 1,200 mg daily achieved similar virologic sup-
pression to approved dosing regimens. Advantages to this novel
dose include a lower pill burden, once daily dosing, and decreased
exposure to ritonavir. Randomized controlled trials, including adher-
ence and pharmacokinetic monitoring, are needed to determine the
best use of darunavir 1,200 mg daily.
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87Engagement and Retention in Care forHigh-Risk Populations in Oakland, CA
- Challenges and Opportunities
Robert Newells1 (presenting), Nichole Little2
1 Imani Community Church, Oakland, CA, USA
2 Sexual Health Education Resources and Outreach, Oakland, CA,
USA
Introduction: Biomedical human immunodeficiency virus (HIV) pre-
vention education for high-risk populations in Oakland, California,
including Black men who have sex with men (MSM), Latino MSM,
and Women of Color, is a key component in normalizing HIV testing,
reducing stigma, improving entry into and retention in care and anti-
retroviral (ARV) adherence, optimizing health outcomes, and reduc-
ing HIV-related health disparities, ultimately increasing the propor-
tion of people living with HIV/AIDS (PLWHA) with an undetectable
viral load.
Description: Oakland-specific challenges to retention and adher-
ence were explored during a train-the-trainer workshop conducted
for front-line staff and peers from community-based organizations
(CBOs) using the International Association of Providers of AIDS
Care/National Minority AIDS Council curriculum for extending the
peer educator’s role to patient navigation. Workshop participants
included staff and peers from AIDS Project of the East Bay, La Clinica
de La Raza, and Women Organized to Respond to Life-threatening
Diseases (WORLD).
Lessons Learned: Creating opportunities for agency staff to access
up-to-date information on biomedical HIV prevention interventions,
local research studies, and appropriate client referral options is
more important than ever due to the pending implementation of the
Patient Protection and Affordable Care Act. Increasing inter-agency
coordination and collaboration has shown potential for facilitating
re-entry into HIV care and improved ARV adherence; however, reten-
tion and adherence issues may be CBO-specific and should be
addressed as such.
Recommendations: A series of training opportunities designed
increase community and provider knowledge of biomedical HIV pre-
vention interventions (including how to access PrEP), local research
studies, and the most current HIV prevention and treatment science
is necessary to help people complete each step in the HIV treatment
cascade - both to improve individual health outcomes and to achieve
the public health goal of an AIDS-free generation.
88 Optimizing Adherence Assessmentamong Adolescents: Who? How?
When?
Shenell Evans1 (presenting), Claude Ann Mellins1, 
Cheng-Shiun Leu1, Katherine S. Elkington1, Curtis Dolezal1, 
Karina Santamaria1, Andrew Wiznia2, Elaine J. Abrams3
1 HIV Center for Clinical and Behavioral Studies, Columbia
University and New York State Psychiatric Institute, New York,
NY, USA
2 Albert Einstein College of Medicine and Jacobi Medical Center,
Bronx, NY, USA
3 International Center for AIDS Care and Treatment Programs,
Columbia University, New York, NY, USA
Introduction: Youth and caregiver self-reports of perinatally HIV-
infected (PHIV+) youth’s adherence to antiretroviral treatment (ART)
may be the only option for providers, given the significant costs of
objective measures (e.g., electronic monitoring devices). Using HIV
RNA Viral Load (VL) as a gold standard of ART-response, this study
compared its association to different adherence questions, inform-
ants, and time points to optimize assessment of adolescent ART
adherence.
Methods: PHIV+ youth (n=194) and their caregivers participated in a
4-site longitudinal study (CASAH) in New York City. Data came from
baseline (meanage=12), follow-up-1 (meanage=14), and follow-up-2
(meanage=17).  Adherence variables included youth, caregiver, and
youth-caregiver combined responses to: a) a single-item on the last
time medications were missed (dichotomized <1month vs. >1month),
and b) a procedure to assess percentage of missed pills adapted
from a standardized questionnaire assessing medications, dosing,
and missed doses in past 2-7 days (% Nonadherence). VL data clos-
est to interview date was abstracted from medical charts.
Results: Agreement between youth and caregivers on all questions
was generally poor across time points (kappa=.104-.354), with mod-
erate agreement only on %Nonadherence at follow-up-1
(kappa=.513).  Using Fisher’s exact test, the association between VL
(<400 copies/ml) and adherence reports was variable. At baseline,
the combined youth-caregiver response on the single item was the
only item significantly associated with VL. At follow-up-1, youth,
caregiver, and their combined reports on the single item; and their
combined report on %Nonadherence were associated with VL
(p<.05). At follow-up-2, VL was only associated with youth report on
the single item.
Conclusions: Results suggest that one adherence item focused on a
longer timeframe may be more accurate than multistep assessments
focused on shorter time periods. Using adherence data from both
youth and caregivers may be optimal for understanding adherence in
younger adolescents. With age, older youth alone may be better
informants. 
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90 Street HIV Testing of Youth IsPersuasive Prevention Technique
John Chittick1 (presenting)
1 TeenAIDS-PeerCorps, Norfolk, VA, USA
Introduction: With adolescent HIV rates still climbing, novel tech-
niques for prevention must be used to stem new cases. The advent
of home HIV test kits for over the counter sales in the U.S. is an effi-
cacious way to test youth publicly in a quick and easy manner. The
result is an underutilized tool that works as a deterrent to unprotect-
ed sex.
Description: Beginning in November 2012 after the introduction of
home HIV test kits in pharmacies, a Harvard-trained youth AIDS
expert began testing teens on the streets and at their favorite public
gathering spots in Norfolk, Virginia, the city with the highest HIV/STI
rates in the state. Because the oral swab technology is easy to
administer with results in 20 minutes (no CLIA lab work necessary),
the testing is popular among curious youth. No AIDS stigma to test-
ing exists among peers when done outside hospital/clinics.
Lessons Learned: Over 45 public tests were administered to at least
one person among groups of teens at parks, malls, beaches and on
the streets. During the 20 minutes waiting for test results, the tester
provided medically accurate information and counseling to the teens
that asked probing questions of peer concern. Youth were surprised
how easy the process was and that it could be done in private with a
sexual partner. In the case of two HIV-positive tests (a 16- and a 17-
year old), they were immediately taken for a confirmatory blood test.
Recommendations: Youth were impressed that tests were available
without a doctor’s visit, a prescription, the need to be tested in a hos-
pital or importantly, without parents’ knowledge. In every group of
three or more, one adolescent was willing to be publicly tested.
Immediately cell phones were sending texts and pictures to a wider
audience using favorable descriptions.
93 Treatment Outcomes in aDecentralized Antiretroviral Therapy
Program: A Comparison of Two Levels of
Care In Nigeria
Prosper Okonkwo1, Patricia Agaba2 (presenting), Solomon Sagay3,
Oche Agbaji2, Bolanle Banigbe4, Juliet Adeola4, Tinuade Oyebode3,
Stephen Yohanna4, John Idoko4, Phyllis Kanki5
1 AIDS Prevention Initiative in Nigeria, Abuja, NIGERIA
2 Department of Medicine, University of Jos/Jos University
Teaching Hospital, Jos, NIGERIA
3 Department of Obstetrics & Gynaecology, University of Jos/Jos
University Teaching Hospital, Jos, NIGERIA
4 AIDS Prevention Initiative Nigeria Lte, Abuja, NIGERIA
5 Infectious Diseases & Immunology, Harvard School of Public
Health, Boston, MA, USA
Background: Decentralization of antiretroviral therapy (ART) servic-
es is a key strategy to achieving the millennium development goal of
providing universal access to ART services for people living with
HIV/AIDS. However, as small concentrated programs expand and
scale out to increase utilization of services and improve coverage,
there are concerns about maintaining adequate quality of care and
treatment outcomes. Our objective was to compare ART treatment
outcomes in a decentralized ART program in Plateau State, Nigeria
Methods: The APIN Plus/Harvard PEPFAR program used the hub-
and-spoke model to decentralize ART services to 13 LGAs in Plateau
State from 2007-2011 from a tertiary hospital (Prime site) to 13 sec-
ondary-level hospitals (Satellites) using national and program guide-
lines. We obtained socio-demographic, clinical and immuno-virolog-
ic data on patients aged >15 years who received HAART for at least
6 months and compared treatment outcomes between the Prime and
Satellite sites
Results: Out of 14,418 patients, 7060(49.0%) were enrolled at the
Satellites. At baseline, the Satellites had more females (70.8% vs
65.5%, p=0.0001), younger patients (33+9 vs 34+9, p<0.001), higher
rates of TB-co-infection (6.4% vs 1.4%, p<0.001), and higher CD4
counts (218 vs 197cells/mm3, p<0.001) but viral loads were similar at
both sites (25,770 vs 26,983c/ml, p=0.12).
While on HAART, Prime site patients achieved better immune reconsti-
tution at 24 (365 vs 285cells/mm3, p<0.001) and 48 weeks (343 vs
304cells/mm3, p<0.001) and higher rates of viral suppression (<400c/ml)
at 24 (41.9 vs 39.7%, p=0.08) and 48 weeks (50.9 vs 43.8%, p=0.01).
Mortality was 2.3 % vs 5.0% (p<0.001) at Prime and Satellites sites,
while transfer rate was 8.7 vs 5.5% (p=0.001) at Prime and Satellites.
Conclusions: Our data shows that ART decentralization is feasible in
resource-limited settings but efforts have to be intensified to maintain
quality of care as we scale out to secondary and primary facilities.
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94 The Effect on Treatment Adherence ofAdministering Drugs as Fixed-Dose
Combinations versus as Separate Pills:
Systematic Review and Meta-Analysis
Katy van Galen1, Jeannine Nellen1, Pythia Nieuwkerk1 (presenting)
1 Academic Medical Center, Amsterdam, NETHERLANDS
Background: Fixed dose combinations (FDCs) have been proposed
as a strategy to simplify medication regimens with the purpose to
enhance treatment adherence. The question to what extent FDCs
lead to better adherence than the same active drugs administered as
separate pills has nowadays become highly relevant. Decoupling of
FDCs, from which patents have expired, into separate generic and
branded drugs could result in considerable cost savings but possibly
at the expensive of lower adherence.
Methods: We searched the PubMed database from inception to
December 2012 for randomized controlled trials (RCTs), comparing a
FDC with the same active drugs administered as separate pills, with
an oral administration route, medications being self-administered,
and the endpoints of the study including a quantitative estimate of
treatment adherence. We used the odds of non-adherence with
FDCs versus separate pills as common effect size. We used a random
effect model with Mantel Haenszel odds ratio to aggregate findings
into a pooled effect estimate with 95% confidence limits using
Review Manager 5.2.
Results: Of the 1258 unique papers identified only 6 RCTs fulfilled
inclusion criteria.  A total of 3 RCTs reported use of FDCs in the treat-
ment of tuberculosis, 2 RCTs in the treatment of HIV infection and 1
RCT in the control of hypertension. Use of FDCs did not result in sig-
nificantly lower odds of non-adherence than separate pills (pooled
OR; 95% CI: 0.89; 0.71 to 1.12). Despite the variety in medical condi-
tions and adherence assessment methods concerned, we observed
low and insignificant statistical heterogeneity (I2= 20%). 
Conclusions: We observed a remarkable paucity of RCTs investigat-
ing the effects of FDCs on adherence. Based on the results of only 6
RCTs the general assumption that FDCs improve medication adher-
ence was not supported. Further research is strongly recommended
to clarify the effect of FDCs on medication adherence.
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97 Predictors of Non-Adherence andVirologic Failure in a Large Scale
Multi-National Non-Inferiority Trial of Three
ARV Regimens in Diverse and Resource-
Limited Settings: Data from the ACTG
A5175/PEARLS Trial
Steven A. Safren1 (presenting), Katie Biello2, Laura Smeaton3,
Matthew Mimiaga4, Ann Walawander5, Javier Lama6, Aadia Rana7,
Mulinda Nyirenda8, Virginia Kayoyo9, Wadzanai Samaneka10, 
Anjali Joglekar11, Timothy Flanigan7, David Celentano12, 
Thomas Campbell13
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
2 The Fenway Institute/Harvard School of Public Health, Boston,
MA, USA
3 Harvard School of Public Health, Boston, MA, USA
4 The Fenway Institute, Boston, MA, USA
5 Frontier Science, Amherst, NY, USA
6 Investigaciones Medicas en Salud, Lima, PERU
7 Miriam Hospital, Providence, RI, USA
8 Johns Hopkins Research Project, Blantyre, MALAWI
9 University of North Carolina Project Malawi, Lilongwe, MALAWI
10 University of Zimbabwe College of Health Sciences, Belgravia,
Harare, ZIMBABWE
11 NARI Pune CRS, Pune, Maharashtra, ZIMBABWE
12 John Hopkins Bloomberg School of Public Health, Baltimore, MD,
USA
13 University of Colorado, Denver, Aurora, CO, USA
Background: PEARLS recruited from four continents (nine countries;
N= 1,575) showing that an antiretroviral regimen of ATV+DDI-EC+FTC,
but not EFV+FTC/TDF, was inferior to EFV+3TC/ZDV.   
Methods: Outcomes were nonadherence assessed via pill count
(PC=missed any pills), ACTG self-report questions (SR=score derived
via principal-components analysis) at regular intervals; and weeks to
virologic failure.  Predictors were quality of life (QOL; ACTG SF21),
substance use, binge drinking, social support, sexual behaviors, and
weeks since initiation. Life-Steps adherence counseling was provid-
ed.  Logistic and linear regression was used for analyses of adher-
ence at initiation (week 2), mixed-effects regressions for longitudinal
analyses, and cox proportional hazards for virologic failure analyses.
Results:
Initiation: Unique predictors of PC nonadherence were: QOL-health
(AOR=.99, p=.046), frequent binge drinking (AOR=2.12, p = .008), and
region (p=.037).  Unique predictors of SR nonadherence were Asia
(b=.42, p=.04), and hard drug use (b=1.59, p=.002), a trend for unpro-
tected sex (b=.51, p=.053), and assignment to the ATV-based regimen
(b=-.34, p =.01). 
Longitudinal: Unique predictors of PC nonadherence were weeks
(AOR=1.015, p<.0001), QOL-health (AOR=.991, p<.0001), assignment to
either once-daily regimen (ATV+DDI-EC+FTC or EFV+FTC/TDF)
(AOR=.662, p=.0003, AOR=.494, p<.0001), Africa (AOR=.52, p=.0002),
and hard drug use (AOR=2.632,p=.045).  Unique predictors of SR non-
adherence were weeks (b=-.063, p<.0001), QOL-health (b=-.007,
p<.0001), assignment to either once-daily regimen (ATV+DDI-EC+FTC
or EFV+FTC/TDF (b=-.223, p=.008, b=-.185, p=.028), Africa (b=-.298,
p=.020), and soft drug use (b=2.648, p<.0001), which decreased over
time (b=-.065, p<.001).
Weeks to virologic failure: Controlling for regimen, both PC (HR=1.64,
p=.0004) and SR (HR=1.102, p<.0001) were significant. In models
including either PC or SR, QOL-health, age, and region were signifi-
cant (all p’s < .01). 
Conclusions: Even in the context of a clinical trial, there were some
variations in adherence, with variables such as QOL-health, regimen,
drug-use, and region playing a role. Some psychosocial variables,
such as adherence, and QOL-health, associated with virologic failure.
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103 Translating a Theoretically Derived,Evidence-Based Adherence
Intervention for Electronic Training and
Wide-Spread Dissemination via the Web:
The Long and Winding Road of Project
HEART (Helping Enhance Adherence to
antiRetroviral Therapy)
Linda Koenig1 (presenting), Melody Palmore2, Rhondette Jones1,
Kathleen Green1, Janet Van Ness3
1 Centers for Disease Control and Prevention, Atlanta, GA, USA
2 Emory University School of Medicine, Atlanta, GA, USA
3 John Snow Inc., Boston, MA, USA
Introduction: Evidence-based adherence interventions (EBIs) have
been identified (http://www.cdc.govhiv/topics/research/prs/ma-
chapter.htm) but not yet packaged or disseminated. To bring adher-
ence EBIs to a wider audience at potentially lower cost, CDC con-
tracted to package several EBIs using e-learning (i.e., web-based)
trainings to train interventionists and support use. This presentation
describes issues encountered in creating a web-based curriculum to
teach the HEART intervention to providers.
Description: HEART was designed in the late 1990s for patients with
multiple adherence barriers initiating antiretroviral therapy. A multi-
component intervention, the core of HEART was based on the 5-
stage model of problem-solving and social problem-solving therapy,
employing a systematic approach to identifying adherence barriers
and generating and implementing adaptive solutions. Patient-identi-
fied support partners (SPs) were integrated into this process to pro-
vide adherence support outside the clinic. Translating HEART for cur-
rent-day use and electronic training required: (1) identifying the inter-
vention’s unique components (i.e., strategies that have not become
standard-of-care [e.g., medication education, regimen tailoring]) so
that new tools and techniques to expand the armamentarium of
adherence counselors could be created, (2) developing essential
training materials, assessment instruments and patient tools, and (3)
scripting and filming vignettes that demonstrate the problem-solving
process – and the integration of SPs – using different patient-SP
pairs addressing different adherence barriers. The intervention was
also adapted to include patients changing regimens due to prior
adherence challenges.
Lessons Learned: Demonstrating interaction with patients and SPs in
the problem-solving process without in-person modeling, practice
and correction presented the greatest challenge. Close attention to
the wording of scripts was required and comprehensive implementa-
tion guides developed. Feedback from pilot testing with providers will
be presented and incorporated into the final iteration.
Recommendations: Uptake, implementation barriers and need for
additional technical assistance will be monitored following web-
launch in 2013, and best approaches and venues for providing con-
tinuing assistance determined.
104 Evaluation of an HIV AdherenceCounseling Program in La Romana,
Dominican Republic
Meredith Winter1 (presenting), Natalie Neu1
1 Columbia University College of Physicians and Surgeons, New
York, NY, USA
Background: The impact of adherence to antiretroviral therapy (ART)
has been well studied, demonstrating both reduction in human
immunodeficiency virus (HIV)-1 viral load and lower rates of resist-
ance, morbidity, and mortality associated with HIV infection.
Adherence is particularly challenging in resource-limited settings;
thus implementation and evaluation of adherence intervention pro-
grams is critical.
Methods: A retrospective cohort study was designed to evaluate the
adherence counseling program for treatment-naïve patients ³18
years of age at Clinica Familia in La Romana, Dominican Republic
(CFLR).  Adherence to appointments and biological markers of dis-
ease progression were assessed in cases and controls to determine
whether counseling had an impact on adherence rates and clinical
outcomes.  Data were collected at baseline and monthly through 12
months. 
Results: In total, 101 subjects were included for analysis, with 61 con-
trols and 40 cases.  Mean age was 40.6 years.  Baseline CD4 lympho-
cyte count was 162 and 157cells/mm3 in controls and cases, respec-
tively. In a 9-month follow-up period, cases showed a 15-fold increase
in CD4 count compared with a 2.5-fold increase in controls (p=0.0578).
Cases were more likely to adhere to scheduled appointments with
adherence rates of 86% vs. 76% in controls (p=0.035).  No difference
was found in days late for appointments (0.91 in cases vs. 0.57 in con-
trols, p=0.18). There was no significant difference between rates of
abandonment of treatment (7.5% in cases vs. 18% in controls, p=0.13),
but all cases re-entered care within 12 months, compared with 3 of 14
controls.  There was no difference in rates of transfer of care, death,
or alive/in treatment at 12 months. 
Conclusions: Short-term evaluation markers including CD4 count and
appointment adherence improved, demonstrating the program’s ben-
eficial impact.  Long-term outcomes (e.g. abandonment, transfer of
care, death) did not show changes within 1 year.  Continued observa-
tion is necessary.
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105An Intervention to Optimize Uptakeand Adherence to Pre-Exposure
Prophylaxis (PrEP) in High-Risk MSM
Christina Psaros1 (presenting), Steven A. Safren1, 
Matthew Mimiaga2, Wade Taylor2, Steven Elsesser2, Jake Tinsley2,
David Pantalone3, Kenneth Mayer2
1 Massachusetts General Hospital, Boston, MA, USA
2 The Fenway Institute, Boston, MA, USA
3 University of Massachusetts, Boston, Boston, MA, USA
Introduction: To support pre-exposure prophylaxis (PrEP) adherence
for high-risk MSM, we developed, tested the feasibility and accept-
ability of, and solicited feedback from participants on a CBT-based
intervention to maximize PrEP adherence.
Description: Modeled after “Life-Steps,” an antiretroviral therapy
(ART) adherence intervention used both for treatment and preven-
tion, we developed a modular intervention to be completed in four
weekly visits and two booster sessions. Intervention content includ-
ed CBT-oriented adherence problem-solving skills, brief motivational
interviewing, and sexual risk-reduction strategies. Optional modules
addressed mental health and substance-use barriers to adherence.
Adherence to PrEP was measured daily via Wisepill and sexual risk
taking was assessed via daily text messages. The open-pilot includ-
ed six high-risk seronegative MSM (mean age 35) who reported at
least three unprotected anal intercourse (UAI) acts with at least two
sexual partners and/or any UAI with a seropositive partner in the pre-
vious three months.
Lessons Learned: Mean self-reported UAI acts at enrollment was
10.8 (SD=10.3) for the prior three months. Participants’ average daily
adherence for the first week on PrEP was 100%. Between months
one and two, and two and three, average adherence was 91% (SD
10.3) and 94% (SD 1.87) respectively. For the same time points, aver-
age UAI for the first week on PrEP was .43 (SD=.48), and 1.07
(SD=1.03) and 1.94 (SD=1.87) respectively. Results indicate partici-
pants took PrEP consistently in the context of continued HIV risk
exposures. Exit interviews revealed participants responded well to
intervention flexibility and suggested providing optional modules on
disclosing PrEP use to health providers and sexual partners. 
Recommendations: Providing PrEP adherence counseling in the con-
text of continued high-risk sex among MSM may be a way to optimize
PrEP adherence.  It is recommended that PrEP prescription be
accompanied by a flexible intervention for those who engage in high-
risk behaviors but may have difficulties with consistent adherence.
108 Association of Quality of Sleepwith Antiretroviral Therapy Uptake
and Adherence in HIV-Positive Individuals
Parya Saberi1 (presenting), Torsten Neilands1, Samantha Dilworth1,
Mallory Johnson1
1 University of California, San Francisco, San Francisco, CA, USA
Background: Over 73% of HIV+ individuals report quality of sleep
(QOS) disturbances, versus 10-35% of the general population. QOS
reductions may result in antiretroviral (ARV) non-adherence, leading
to treatment failure, drug resistance, and increased HIV transmis-
sion. Therefore, recognition and treatment of poor QOS may benefit
personal and public health. Our study aims were to: 1- examine time
to ARV uptake based on QOS, 2- estimate QOS changes after ARV ini-
tiation, and 3- assess the association between QOS and non-adher-
ence.
Methods: QOS in the past 30 days (range=0-28) was estimated quar-
terly for 12 months using nine questions assessing number of sleep
hours/night, QOS rating, use of sleep aids, trouble staying
awake/falling asleep, nocturnal awakenings, experience of night ter-
rors/pain, and daytime concentration. Self-reported non-adherence
(range=0-100%) was calculated using a visual analog scale in past 30
days. For aims one and two, we used proportional hazards and mixed
model analysis, respectively. For aim three, we modeled percent non-
adherence as a function of QOS using zero-inflated Poisson regres-
sion, clustering on repeated subject ID, and adjusted for demograph-
ics, homelessness, IVDU, alcohol use, CD4+, viral load, time since
HIV diagnosis, and number of cigarettes/day.
Results: Data from 219 participants with mean age=44.3, 83% male,
mean baseline CD4+=246 cells/mm3, 3.7% with baseline undetectable
viral load, and mean baseline QOS=12.4 were examined. In 12
months, 64% had initiated ARVs. QOS was not associated with ARV
uptake (HR=1.00, p=0.99). Mean QOS did not change after ARV initia-
tion (p=0.62). Worse QOS was marginally associated with lower odds
of perfect adherence (aOR=0.91, p=0.06). Among those who had any
level of non-adherence, for every one unit worsening of QOS, there
was a 4% increase in mean non-adherence (p=0.03).
Conclusions: We observed a significant association between poor
QOS and non-adherence. Interventions designed to enhance QOS
among HIV+ individuals may lead to improved adherence.
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109A Pilot Study to Engage HIV-Positive Black-American Youth 
via Telehealth Technology
Parya Saberi1 (presenting), Mallory Johnson1, Patrick Yuan1,
Nicolas Sheon1, Malcolm John1
1 University of California, San Francisco, San Francisco, CA, USA
Background: Non-adherence is a strong determinant of virologic fail-
ure and correlated with survival. Black individuals have higher rate
of HIV infection, enter care later in course of disease, are less likely
to initiate antiretrovirals, and report lower antiretroviral adherence
than other populations. Innovative interventions to improve access to
medication counseling, treatment knowledge, and treatment
engagement are needed to address these disparities. Telehealth
(remote videoconferencing) shows promise as a potential approach.
The goal of this study was to assess feasibility and acceptability of a
telehealth medication counseling intervention.
Methods: HIV-positive Black youth (18-29 year-old), taking antiretro-
virals for ³30 days were enrolled in a 30-minute individual telehealth
medication counseling session with an HIV clinical pharmacist fol-
lowed immediately by a semi-structured qualitative interview by
study staff. Interviews explored likes/dislikes of the telehealth for-
mat, modality, and content; potential impact on adherence; privacy
issues; interaction quality; and whether participants would recom-
mend telehealth to others.
Results: Fourteen participants, mean age=24 years, 86% male, mean
CD4+=607 cells/mm3, 64% with undetectable viral load, and mean
self-reported adherence in past week=87% were interviewed. All
participants stated that they “liked” telehealth, would use it if offered
in clinic or research settings, and would recommend it to others.
Participants described telehealth as convenient, efficient, and com-
fortable to use, with positive impact on their HIV-related knowledge.
Telehealth provided a modality to interact with providers that some
participants described as less intimidating than in-person visits.
Specifically, participants reported that telehealth made it easier to
disclose barriers to adherence. Most participants indicated that their
privacy was maintained.
Conclusions: Telehealth is a feasible and acceptable approach to
delivering medication counseling to Black HIV-positive youth and
may improve quality of communication and provider-patient dia-
logue. Use of telehealth for medication counseling may also lead to
more disclosure of treatment difficulties, increased patient comfort,
and improved health education.
110 High Prevalence of SyndemicConditions Associated with
Suboptimal ART Adherence in a Large
Multinational Online Sample of HIV-Infected
MSM
Matthew Mimiaga1 (presenting), Katie Biello2, Conall O’Cleirigh3,
Joshua Rosenberger4, David Novak5, Kenneth Mayer1, 
Steven A. Safren3
1 The Fenway Institute, Boston, MA, USA
2 The Fenway Institute/Harvard School of Public Health, Boston,
MA, USA
3 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
4 George Mason University, Fairfax, VA, USA
5 OLB Research Institute, Cambridge, MA, USA
Background: Suboptimal antiretroviral therapy (ART) adherence
among HIV-infected who have sex with men (MSM) in the U.S. and
other settings occurs in the context of intertwined mental health and
substance use problems, or syndemics. This has not been examined
in Spanish or Portuguese speaking settings. 
Methods: Members (N=36,477) of a sexual networking site for gay,
bisexual, and other MSM in Latin America, Spain, and Portugal com-
pleted an anonymous online survey. Seven potential syndemic fac-
tors-depression, hard drug use during sex, alcohol abuse/depend-
ence, childhood sexual abuse, intimate partner violence, suicidal
ideation, and sexual compulsivity-were assessed and their additive
effect was examined in relation to suboptimal ART adherence (<100%
of prescribed doses in the past month) using logistic regression.
Results: Self-reported HIV prevalence was 9.1% overall [Latin
America (82%), Spain (6%), and Portugal (12%)]; 71.4% reported
being on ART (2,049/2,851).  Among those on ART, 66.5% reported tak-
ing 100% of prescribed doses in the past month. Among those on
ART, distribution of syndemic factors was: zero=11.2%, one=28.8%,
two=26.6%, three=15.3%, four=11.5%, five=4.8%, six=1.3%, and
seven=0.4%. In a multivariable model adjusted for age, survey source
(Latin America, Spain, or Portugal), sexual orientation, education,
income, and urbanicity, the additive syndemic measure resulted in a
lower odds of optimal ART adherence (referent group=zero) (all p-
value<.05): one/two syndemic factors=(OR=0.64, 95%CI=0.44, 0.93);
three/four=(OR=0.60, 95%CI=0.40, 0.90); and five or more=(OR=0.39,
95%CI=0.23, 0.65).
Conclusions: Adherence to ART among MSM in Latin America, Spain,
and Portugal occurs in the context of intertwined mental health and
substance use problems, or syndemics.  The impact of these syn-
demics on adherence is additive. As has been suggested in the U.S.
setting, adherence interventions for MSM need to address these
problems as they may moderate the degree to which HIV-infected
MSM would benefit from adherence skills building and counseling.
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111Perinatally Infected Adolescents:An Economic Empowerment
Intervention Aimed at Increasing Adherence
to ART
Vilma Ilic1 (presenting), Fred Ssewamala1
1 Columbia University, New York, NY, USA
Background: While the proliferation of first-line antiretroviral thera-
py (ART) in developing countries is a positive direction in slowing the
spread of HIV, ART has a host of side effects that may contribute to
sub-optimal adherence rates. One side-effect includes increased
appetite, even intolerable hunger, which can present a barrier in
adhering to treatment among HIV-positive populations in resource-
constrained settings (Bangsberg, 2010). Economically disadvantaged
populations in developing regions face compounding issues related
to poverty and living with HIV. The resources needed for increased
hunger pose additional financial burden on already economically
constrained households, creating obstacles in adhering to HIV treat-
ment. Other factors, including travel to clinics for follow-up appoint-
ments, also create economic-centered obstacles to adherence. The
key question, therefore, is: would an economic empowerment pro-
gram impact adherence to HIV medication among poor youth?
Methods: Our study, Suubi+Adherence: Evaluating a youth-focused
economic empowerment approach to HIV treatment adherence,
uses self-report as well as cellular technology to measure ART
adherence among youth ages 11-16 years in southern Uganda. Two
groups of participants will be compared in this longitudinal cluster
randomized controlled trial. One group will receive an economic
empowerment intervention with proven success among a compara-
ble demographic in the same region (Ssewamala et al., 2009; 2010a;
2010b) as well as a package of bolstered standard of care for youth
living with HIV, which includes counseling sessions on the impor-
tance of adhering to treatment. The other group will receive only the
bolstered standard of care. 
Results: We hypothesize that the group receiving the evidence-
based economic empowerment intervention will show higher rates
of adherence over a sustained period of time, as well as improved
levels of psychosocial functioning, and decreased levels of sexual
risk-taking intentions and behavior. 
Conclusions: Economic empowerment interventions may have policy
and practice implications for HIV treatment adherence among poor
youth in sub-Saharan Africa. 
112Linking HIV+ Persons to Care:Building a Network Collaborative
with a Shared Mission of Engaging the
“Invisible”
Nicholas Alvarado1 (presenting), Dennis Browe1, Danielle Gordon1,
Debra Allen1, Rosario Noble1, Cynthia Gómez1
1 San Francisco State University, Health Equity Institute, San
Francisco, CA, USA 
Introduction: In today’s economic climate collective efforts to
improve HIV services and linkage-to-care networks are critical. The
Bay Area Network for Positive Health (BANPH) had the goal of link-
ing the most marginalized and hardest-to-reach HIV+ persons back
into care through building HIV service and linkage infrastructure with
an inter-agency collaboration that broke down service silos and
actively shared resources.
Description: In order to address multiple HIV service gaps, an aca-
demic team pooled together agencies with complementary
strengths, resources and abilities to create a collaborative linkage
and service network comprising 12 agencies in San Francisco and
Oakland in 2010. Service gaps were closed by assessing capacity of
agencies and supporting them in: resource acquisition and provision;
outreach training; technical assistance; system change efficacy; and
ongoing meetings, communication and follow-up. In applying mixed
methodologies BANPH demonstrated the efforts required to link the
most disenfranchised persons into HIV care. HIV+ clients were locat-
ed using street outreach, syringe exchange, jails, prisons, surveil-
lance and clinic records. Clients completed a survey for
barriers/needs assessment and then were linked to care and auxil-
iary services.
Lessons Learned: Nearly 400 PLWHA were linked to HIV care by
BANPH. Individuals linked were out of care for an average of 10
years since diagnosis, and took nearly 2 months from first contact
with BANPH to make their initial medical appointment. Partnerships
at various levels can always improve service delivery and structural
systems. Building such a linkage network requires buy-in from
administrative and front-line staff and takes significant time.
Recommendations: Building collaborative networks for linking the
most disenfranchised to HIV care may be a more effective strategy
than working in silos or in competition. A linkage-to-care network
model built with respect and a common mission has proven to be an
effective approach to systems change with marginalized populations
in hard economic times.
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114 Biopsychosocial DistinctionsBetween HIV-Positive Youth with
High Versus Lower Viral Loads
Donna Marschall1 (presenting), Megan McCormick King1, 
Yaphet Bryant1, Benitra Johnson1
1 Children’s National Medical Center, Washington, DC, USA
Background: High viral load (VL; over 100,000 copies) in HIV is asso-
ciated with significantly poorer prognosis for those patients as com-
pared to others with lower VL. Understanding factors associated
with elevated VL can provide insight into interventions for this very
high risk population. 
Methods: The current study included 58 youth, ages 11-23, living with
HIV (Mage = 18.0±3.3; 91% African American; 52% male; 69% perina-
tally affected). Primary variables of interest were extracted through
medical record review and included VL readings and concurrent
Acuity Scale Ratings (ASRs). ASRs are completed by the patient’s
medical case manager and rate the patient’s level of functioning and
need for services in a number of social, medical, and psychological
domains. The sample was divided into two groups: High VL (³100,000
copies; n=8) and Lower VL (<100,000 copies). 
Results: One-way ANOVAs between the two groups showed High VL
individuals to have significantly higher ASRs (indicative of poorer
functioning and greater need for services) in the following areas:
Basic Needs (e.g., access to food, clothing), Addiction (e.g., drugs,
alcohol, sex), Knowledge of HIV (e.g., understanding of diagnosis,
risks, medications), Nutrition (e.g., weight loss, eating problems),
Family Functioning (e.g., family stability), and Support Systems (e.g.,
peers, social activities). These differences only were apparent when
the High VL threshold was 100,000 copies or above; including even
Moderate VL individuals (10,000-99,999 copies) showed no differ-
ences between groups. 
Conclusions: Results indicate that High VL individuals show a distinct
profile of difficulty and disadvantage in a number of areas, ranging
from basic life needs to psychiatric illness, as compared to patients
with lower VL. Such factors should be assessed and addressed as
part of comprehensive medical care plans given that such factors
can be formidable obstacles to effective adherence.  This may be
especially true for patients with high VL.
115 Psychosocial Needs and ViralSuppression in a Sample of Youth
Living with HIV
Megan McCormick King1, Yaphet Bryant1, Benitra Johnson1, 
Donna Marschall1 (presenting)
1 Children’s National Medical Center, Washington, DC, USA
Background: For people living with HIV, Viral Load (VL) is an impor-
tant marker of disease activity, medication adherence, and treatment
success. Understanding correlates of VL can highlight critical points
of intervention for these high-risk patients. Given that research with
this sample previously has not identified associations between VL
and more concrete “barriers to adherence” measures, the current
investigation sought to examine whether broader psychosocial
issues are salient factors associated with viral suppression among
HIV positive youth. 
Methods: Medical chart review was utilized to garner two primary
variables of interest: VL and Acuity Scale ratings (ASRs). ASRs are
completed by medical case managers to determine a patient’s level
of functioning and need in a number of medical, social, and psycho-
logical areas. Based on the level of need, the scale outlines the fre-
quency and intensity of engagement required.  The current sample
consisted of 58 youths ranging in age from 11 to 23 years of age
(Mage = 18.0 ± 3.3; 48% female). Patients identified themselves as
African American (91%), Caucasian (2%), Hispanic (5%), or Other
(2%). 69% acquired HIV vertically, 28% were infected horizontally,
and 3% had unknown mode of transmission. 
Results: Bivariate correlations were used to examine relationships
between VL and ASRs in 18 domains, with higher ASRs representing
poorer functioning and greater need for services. Results indicated
that higher ASRs on the Family Functioning scale were associated
with high VL (r = .271, p = .040). Total Acuity Score also was positive-
ly correlated with VL (r =.299, p = .023). 
Conclusions: Results indicate that, for HIV positive youth, family sta-
bility is a key factor associated with viral suppression and disease
control. In general, environmental and psychosocial factors should
be considered, in addition to more proximal, concrete barriers to
treatment success, when working with complex and traditionally
underserved patient populations.
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117 Higher Levels of PsychosocialSyndemics Associated with Non-
Adherence in HIV-Positive Individuals
Screening for a Depression Treatment Trial
Steven A. Safren1 (presenting), Aaron Blashill1, Jonathan Lerner1,
Conall O’Cleirigh1, Megan Pinkston2, Andres Bedoya1, 
Johannes Wilson1, Gregory Robbins1, Debra Herman3, Erna Kojic4,
Michael Stein5, Kenneth Mayer6, Matthew Mimiaga6
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
2 Brown University, Providence, RI, USA
3 Butler Hospital, Providence, RI, USA
4 Alpert Medical School at Brown University, Providence, RI, USA
5 Brown University, Rhode Island Hospital, Division of General
Medicine, Providence, RI, USA
6 The Fenway Institute, Boston, MA, USA
Background: Depression, one of the most common comorbidities to
HIV, is consistently associated with worse ART adherence.
Depression in the context of HIV, places one at risk for significant addi-
tional psychiatric and intertwined psychosocial or syndemic problems;
which may have an additive negative effect on ART adherence.    
Methods: Individuals with HIV (N=333) participated in an assessment
for a depression treatment trial at three sites (2 in Boston, MA 1 in
Providence, RI) that included a structured psychiatric diagnostic
interview (inclusive of alcohol and other substance abuse/depend-
ence), and a self-report assessment of childhood sexual abuse,
childhood violence, and recent interpersonal violence.  They then
monitored their adherence to ART electronically for two weeks using
MEMs, yielding a percent, on-time score, which was corrected for
self-reported pocketed-doses.  The syndemics variable was catego-
rized as “none” (0), “some” (1 or 2), “a lot” (3 or 4) or “many” (5 or
more).  MEMS-based adherence, the outcome variable in a logistic
regression analysis, was categorized as non-adherent (²80%) or
adherent (>80%). 
Results: Distribution of the syndemics variable was none=3%,
some=33%, a lot=40%, and many=24%.  Per MEMs-based adherence,
66% of the sample was categorized as non-adherent.  Syndemics
was a significant negative predictor of adherence (p=.01), with hav-
ing “a lot” (OR=-1.61, p<.05) and having “many” (OR=-2.138, p=.01) dif-
ferentiating from the referent group,  “none”.  A trend was observed
for having “some” (OR=-1.43, p=.08). 
Conclusions: In a sample of individuals with HIV opting to screen for
a depression treatment trial, the majority had more than two co-
occurring psychosocial problems (syndemics), indicating that
depression, in the context of HIV, has a complex clinical presenta-
tion.  The additive effect of co-occurring psychosocial syndemics
was associated with significantly worse MEMs-based adherence.
This underlies the importance of considering additional psychosocial
syndemics when attempting to treat depression and improve treat-
ment adherence in individuals with HIV.
118Medication Adherence andOptimism-Pessimism in a
Population of People Living with HIV/AIDS
Clinton J. Thompson1 (presenting), Suzanne Willard2, 
Laura A. Guay3, Heather J. Hoffman1, Patrice Nicholas4, 
Manya Magnus1
1 George Washington School of Public Health and Health Services,
Washington, DC, USA
2 College of Nursing Rutgers, The State University of New Jersey,
Newark, NJ, USA
3 Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC,
USA
4 Brigham and Women’s Hospital/Massachusetts General Hospital,
Boston, MA, USA
Background: Adequate adherence to antiretroviral therapy (ART)
reduces morbidity and mortality, preserves immune function, and is a
critical element of the “treatment as prevention” strategy for curbing
transmission of HIV.  A consensus on which factors, especially psy-
chological ones, improve adherence has yet to be reached.  We
investigated the relationship between adherence and optimism in a
population of people living with HIV/AIDS.
Methods: Using data from a randomized controlled trial conducted
by the University of California San Francisco School of Nursing
examining the efficacy of a symptom management manual, we per-
formed a secondary analysis using two proxy measures of adher-
ence, two expressions of optimism-pessimism, and several potential
confounders.  The first adherence measure was the self-reported
frequency with which a person missed taking their medications for
various reasons and the second inquired about confidence to take
medications as prescribed by a health care provider.  Optimism-pes-
simism was quantified as a single, bipolar metric and as two distinct,
unipolar metrics.  The first adherence measure was analyzed with
robust Poisson regression and the second analyzed with ordinal
regression.
Results: Our sample (n=353) was 62% male, 35% African American/
Black, and mean age was 44 years (±9.2).  While 25% of the sample
reported perfect adherence, 50% reported total confidence.  In age-
stratified multivariable models, a one-unit increase in bipolar opti-
mism-pessimism reduced non-adherence by 3.6% (p<0.001) and
increased the odds of reporting higher confidence in taking medica-
tions by 7.0% (p<0.05) among patients <44 years.  The unipolar meas-
ure of optimism also reduced non-adherence (4.8%, p<0.001) and
increased confidence (12.2%, p<0.05) among the same subjects.  Of
the potential confounders, higher quality of life was most consistent-
ly associated with adherence (p<0.05 in all <44 models).
Conclusions: Adherence to ART is positively associated with opti-
mism in HIV/AIDS patients <44 years old.  Our findings indicate a dif-
ferential relationship exists between adherence, optimism, and age.
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Raymond Ownby1 (presenting), Drenna Waldrop-Valverde2, 
Robin Jacobs1, Rosemary Davenport1, Joshua Caballero1
1 Nova Southeastern University, Fort Lauderdale, FL, USA
2 Emory University School of Nursing, Atlanta, GA, USA
Background: The difference between adherence (the proportion of
prescribed doses of medication taken) and persistence (time over
which the medication is taken) has been recognized as important.
The permissible gap between doses varies but is likely to be at most
several days for HIV treatment. These analyses evaluated the char-
acteristics of persons who with medication impersistence.
Methods: As part of another study, 124 participants completed a bat-
tery of measures that included the Test of Functional Health Literacy
in Adults (TOFHLA), the HIV Health Literacy scale (HIV-HL), and cog-
nitive measures such as the Trail Making Test (Trails). Participants
also completed the LifeWindows IMB scale. Medication adherence
was monitored (Medication Event Monitoring Systems) for one
month. Those with and without impersistence (medication free inter-
val of 72 hours or more) constituted groups for comparison using chi-
square and t tests.
Results: No relation between impersistence and gender, race, or age
was found. Participants with impersistence had lower levels of health
literacy (TOFHLA; t [df = 119] = 2.44, p = 0.02; HIV-HL t [df = 118] = 2.08,
p = 0.04) and HIV-knowledge (LifeWindows scale; t [df = 113] = 2.14, p
= 0.03). Impersistent participants had poorer executive function as
assessed by the Trail Making Test (t [df = 1138] = -2.38, p = 0.02).
Conclusions: Results show that low levels of health literacy and cogni-
tive function may be associated with medication impersistence in per-
sons treated for HIV. Interventions to improve HIV knowledge and health
literacy skills may be useful in addressing medication persistence.
120 A New Measure of Health LiteracyPredicts Medication Adherence in
Persons Treated for HIV
Raymond Ownby1 (presenting), Amarilis Acevedo1, 
Ana-Maria Homs1, Robin Jacobs1, Drenna Waldrop-Valverde2,
Rosemary Davenport1, Joshua Caballero1
1 Nova Southeastern University, Fort Lauderdale, FL, USA
2 Emory University School of Nursing, Atlanta, GA, USA
Background: Health literacy is related to HIV knowledge and medica-
tion adherence in persons with HIV. Current measures of health liter-
acy assess a limited range of skills. As part of a project to develop a
new computer-administered measure of health literacy with
improved characteristics, test items were administered to a group of
50 HIV+ persons who had previously participated in a study of HIV
and health literacy.
Methods: Participants completed 208 new items assessing general
health literacy (HL), numeracy (NUM), listening comprehension (LIS)
and health-related knowledge (FACT). They had previously complet-
ed the LifeWindows IMB measure, a measure of HIV-related health
literacy (HIV-HL) and their adherence had been electronically
assessed. Correlations evaluated measures’ interrelations and a
regression model evaluated the new measure’s relation to adher-
ence.
Results: The numeracy scale of the new measure correlated signifi-
cantly with the LifeWindows Information scale (r = 0.30, p = 0.04) and
the HIV-HL (HL scale r = 0.51, p < 0.001; NUM r = 0.51, p < 0.001; FACT
r = 0.46, p < 0.001; VID r = 0.39, p = 0.01). In a regression model that
included demographic variables and the new measure’s scales, the
HL scale was significantly related to participants’ medication adher-
ence (chi-square = 4.75 [df=1], p = 0.03).
Conclusions: These results support the usefulness of the new measure
of health literacy in understanding patients’ health-related knowledge
and behaviors. The new measure’s scales predicted participants’
report of their own HIV-related information as well as their actual med-
ication adherence. Development of the new measure is ongoing.
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122 The Healthcare Attitudes Scale(HAS) in HIV
Robin Jacobs1 (presenting), Raymond Ownby1, Amarilis Acevedo1,
Drenna Waldrop-Valverde1
1 Nova Southeastern University, Fort Lauderdale, FL, USA
2 Emory University School of Nursing, Atlanta, GA, USA
Background: The Healthcare Attitudes Scale (HAS) is a ten-item self-
report measure developed to assess patients’ general attitudes
toward health. Items assess beliefs about the likelihood of positive
outcomes from efforts to improve one’s health. We report here on the
relation of the HAS to other measures in order to help establish its
usefulness and validity.
Methods: As part of a study of an intervention to improve health liter-
acy, participants completed a battery of cognitive and psychosocial
measures. The battery included the Test of Functional Health Literacy
(TOFHLA), and measures of self-efficacy (item A1 from the AIDS
Clinical Trials Group adherence questionnaire, ACTG), HIV-related
information, motivation, and behavioral skills (LifeWindows IMB
scale), mood (Center for Epidemiological Studies Depression scale,
CESD), stress (Perceived Stress Scale, PSS), and adherence
(Medication Event Monitoring System, MEMS).
Results: One hundred twenty-four participants completed assess-
ments. Cronbach’s alpha for the HAS was 0.77. It was correlated with
health literacy (TOFHLA reading r = 0.35, p < 0.001), self-efficacy (ACTG
item r = 0.22, p = 0.02), and elements of the IMB (Information r = 0.33, p
< 0.001; Motivation r = 0.45, p < 0.001; Behavioral Skills r = 0.44, p 
< 0.001). It was inversely related to depression (CESD r = -0.49, p 
< 0.001) and stress (PSS r = -0.41, p < 0.001). In a regression model that
controlled for age, education, gender, and race, the HAS significantly
predicted medication adherence (chi square [df = 1] = 7.01, p = 0.01).
Conclusions: The HAS may be useful in understanding patients’ atti-
tudes toward health maintenance and promotion and in predicting
medication adherence.
126 Newly Diagnosed HIV Infections in Non-Urban Virginia: Portrait of a
Population and Delayed Linkage to Care
Katherine Schafer1 (presenting), Karen Ingersoll1, 
Rebecca Dillingham1
1 University of Virginia, Charlottesville, VA, USA
Background: The South is the new epicenter of the HIV/AIDS epi-
demic in the United States. In 2010, the South had the highest num-
ber of AIDS cases in both urban and non-urban settings as well as
the largest number of people living with AIDS diagnoses outside of
metropolitan areas. Compared to other regions, Southerners living
with HIV start antiretroviral therapy later and have higher HIV-relat-
ed morbidity. Because of these trends, we reviewed the data on all
newly diagnosed HIV-infected patients in our clinic.
Methods: Data on all newly diagnosed HIV-infected patients from a
semi-rural public HIV clinic were abstracted from the University of
Virginia (UVA) Clinical Data Repository and clinic database
(CareWARE) from 2008 through 2011.  Analyses were performed
using SPSS (IBM, version 20, 2011).
Results: One hundred and forty-nine people were newly diagnosed
with HIV at the UVA HealthSystem from 2008 through 2011.  Thirty-nine
percent of people met criteria for AIDS at time of diagnosis. The aver-
age age was 42 years (range 4-69 years). Seventy-seven percent of the
newly diagnosed were male, 38.9% of individuals were black/African-
American, 5.4% were Hispanic, and 49% qualified as indigent. The
mean absolute CD4+ count at first measure was 362 (range 1-1280) and
the mean HIV viral load was 381897 copies/mL (range 0-7650000).
Newly diagnosed patients missed an average of 22% of clinic visits
(range 0-86%) after linkage to care. There was an average of 358 days
(range 0-1679) between diagnosis and entry into care.
Conclusions: With the movement of the U.S. HIV epidemic outside of
urban areas and specifically into the southeast, a more complete
portrait of the newly diagnosed individuals is an important step
towards creating targeted programs for testing, linkage to care,
treatment, and prevention. Our cohort demonstrates that delayed
linkage remains a problem which requires further attention.
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128Patient Navigation for Retention of HIV-Positive 
Patients in Washington, DC
Jason DuBroff1 (presenting)
1 Johns Hopkins Bloomberg School Public Health, Baltimore, MD,
USA
Introduction: The intervention aimed to improve appointment truancy
among undeserved HIV-positive patients from a Community Health
Center in Washington, D.C. between 2009 and 2011. 
Description: A patient navigator (PN) identified 75 candidate patients
by searching the electronic medical record (EMR) to find patients
with a history of missed appointments.  Reasons for missed appoint-
ments included lack of transportation, substance abuse, depression,
feeling unwell and forgetting.  After scheduling a future appointment
with a provider, the PN worked closely with these patients creating
individualized plans to ensure appointment attendance that included
travel arrangements and assistance, flexible scheduling and appoint-
ment reminders.   Once engaged in care, patients received continued
support from the PN and nurse case managers to support appoint-
ment attendance, medication adherence and social services as
needed.
Lessons Learned: After working with the PN, the patient cohort saw
a 134.2% increase in kept appointments per patient per quarter.
Among patients who had an appointment fifteen months before
4/1/2009 none were virally suppressed.  Twenty-one months after
4/1/2009 when the PN began reengaging out-of-care patients, over
half had viral loads less than 50 copies/ml.  While implementation
was not problematic, culling intervention data from the EMR present-
ed several issues, namely due to a lack of standardized data entry.
This resulted in fewer query results from the EMR.  Additionally, com-
paring HIV biomarkers before and after working with the PN was dif-
ficult as many patients were previously out-of-care, eliminating the
possibility of a baseline.
Recommendations: This intervention shows the marked, potential
impact one PN can have.  Future steps could broaden the scope of
the intervention by hiring more PNs or training front desk staff to
adopt the intervention’s practices.  Ultimately, this intervention pro-
vides a potential strategy for addressing retention in care and viral
suppression as part of the HIV-treatment cascade, while highlighting
the importance of appointment attendance.
129 Feasibility, Safety, Acceptability,and Preliminary Efficacy of
Measurement-Based Care Depression
Treatment for HIV Patients in Bamenda,
Cameroon
Brian Pence1 (presenting), Bradley Gaynes2, Julius Atashili3, 
Julie O’Donnell2, Alfred Njamnshi4, Dmitry Katz2, Peter Ndumbe5
1 Duke Global Health Institute, Center for Health Policy and
Inequalities Research, Durham, NC, USA
2 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3 Department of Public Health and Hygiene, Buea, CAMEROON
4 The University of Yaounde I, Yaounde, CAMEROON
5 University of Buea, Buea, CAMEROON
Background: Depression affects 18-30% of HIV-infected patients in
Africa and is associated with greater stigma, lower antiretroviral
adherence, and faster disease progression.  However, the region’s
health system capacity to effectively treat depression is limited.
Task-shifting models may help address this large mental health treat-
ment gap.
Methods: We adapted a task-shifting model, Measurement-Based
Care (MBC), for depressed HIV-infected patients in Cameroon and
completed a pilot study to assess its feasibility, safety, acceptability,
and preliminary efficacy.  MBC trains a Depression Care Manager
(DCM) to guide HIV providers in prescribing and managing antide-
pressant treatment.  Key informant interviews guided the adaptation
of medication and dosing recommendations and staffing.  We then
enrolled 55 HIV-infected patients with major depression who
received acute management for 12 weeks and maintenance man-
agement for 9 months. 
Results: A primary adaptation reflected the fact that amitriptyline
was the only antidepressant on the government formulary.  All partic-
ipants started amitriptyline 25-50mg daily; by 12 weeks, most
remained at 50mg (range 25-125mg daily).  Median (interquartile
range) PHQ-9 depressive severity scores declined from 13 (12-16)
(baseline) to 2 (0-3) (week 12); 87% achieved depression remission
(PHQ9<5) by 12 weeks.  Intervention fidelity was high: HIV providers
followed MBC recommendations at 96% of encounters.  Most diver-
gences reflected a failure to increase dose when indicated.  No seri-
ous and few bothersome amitriptyline side effects were reported.
The prevalence of suicidality decreased from 62% (baseline) to 8%
(12 weeks); most suicidality was either passive or low-risk.
Participant satisfaction was high (100%), and most participants (89%)
indicated willingness to pay for medications if MBC were implement-
ed in routine care. 
Conclusions: The adapted MBC intervention demonstrated high fea-
sibility, safety, acceptability, and preliminary efficacy in this uncon-
trolled pilot study, even with only one available antidepressant.
Further research should assess whether MBC could improve adher-
ence and HIV outcomes in this setting.
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131Fidelity in Implementation of aDecision Support Intervention for
Depression Management in HIV Clinics
Brian Pence1 (presenting), Bradley Gaynes2, Julie Adams3, 
Amy Heine2, Malaika Edwards2, Julie O’Donnell2, Riddhi Modi4, 
E. Byrd Quinlivan2
1 Duke Global Health Institute, Center for Health Policy and
Inequalities Research, Durham, NC, USA
2 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3 Duke University, Durham, NC, USA
4 University of Alabama at Birmingham, Birmingham, AL, USA
Background: Depression is highly prevalent in HIV-infected patients
and negatively affects antiretroviral adherence and clinical out-
comes, yet is largely undiagnosed, untreated, or under-treated, due
to barriers to accessing specialty mental health services and lack of
expertise in HIV clinics.  Decision support models have the potential
to improve HIV providers’ recognition and quality of treatment of
depression. 
Methods: The SLAM DUNC Study is implementing Measurement-
Based Care (MBC), a decision support depression treatment model,
to test the effect of depression treatment on antiretroviral adherence
and clinical outcomes.  The MBC model generates a treatment rec-
ommendation (start antidepressant, increase dose, maintain dose)
based on standardized patient assessments (measures of depressive
severity and medication tolerability) that the provider may follow or
not. Here, we examine the frequency with which MBC recommenda-
tions were followed and the reasons for divergence.
Results: Through November 2012, 115 participants had enrolled and
been randomized to the MBC condition, encompassing 115 baseline
and 377 follow-up encounters.   MBC recommendations were not fol-
lowed at 49 encounters (10.0%), with divergence more frequent at
baseline (18.3%) than follow-up (7.4%).  Most baseline divergences
were patient-driven and involved not starting an antidepressant
when indicated (e.g., ambivalence about antidepressants or viewing
symptoms as situational).  Most follow-up divergences were also
patient-driven and involved not increasing the antidepressant dose
when recommended.  Provider-driven divergences at baseline and
follow-up usually related to deciding to treat other presenting comor-
bidities before starting antidepressants, viewing symptoms as situa-
tional, or concern about side effects
Conclusions: Overall, fidelity to MBC treatment recommendations
was high.  Divergence most commonly tended toward inertia (failure
to increase doses when recommended).  These data suggest high
acceptability of MBC to HIV providers and patients, supporting its
likely real-world effectiveness and potential to positively impact HIV
adherence and clinical outcomes.
133 The Pill Count Effect: DoUnannounced Pill Counts to
Measure Adherence Change Pill-Taking
Behavior?
Elise Nelson1 (presenting), Quinn Williams1, Julie O’Donnell1,
Marcus Hawley1, Bradley Gaynes2, E. BYRD Quinlivan2, 
Brian Pence1
1 Duke University Center for Health Policy and Inequalities
Research, Durham, NC, USA
2 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Introduction: Adherence to antiretroviral (ARV) medications
improves the health of people living with HIV and AIDS (PLWHA) and
decreases the risk of transmission.  Among methods to measure
adherence, the unannounced pill count (UPC) is increasingly used in
research studies.  However, UPCs themselves may influence adher-
ence.  We assessed patients’ perspectives regarding the effect of
UPCs on adherence. 
Methods: As part of the SLAM DUNC randomized controlled trial
testing the effect of depression treatment on ARV adherence, partic-
ipants’ adherence is measured by phone-based UPCs monthly for 12
months. At study completion, a set of study acceptability questions
assesses participants’ perception of whether and how UPCs affect-
ed their pill-taking habits.
Results: Of the 69 participants who have completed these questions
to date, two-thirds are male, 70% are African American, and ages
range from 22-64 years. Forty-one percent of participants reported
some change in pill-taking behavior as a result of the UPCs. Twenty-
nine percent reported that the monthly UPCs changed the way they
took their ARVs, 29% reported that the UPCs changed the way they
organized their ARVs, and 17% reported that the UPCs changed the
way they took their antidepressants. In open-ended questions, par-
ticipants described most changes as positive (e.g., improved organi-
zation).  Self-reported behavior change was positively associated
with study engagement: 50% of participants who completed 11-13 (of
13 possible) UPCs reported behavior change, compared to 33% of
participants who completed 7-10 counts, and 25% of those who com-
pleted 0-6 counts. 
Conclusions: Medication adherence among PLWHA is important for
maintaining health and preventing drug resistance, and accurate
measurement of adherence is central to many research studies.
These preliminary data indicate that phone-based UPCs, while
intended as a data-collection method, may actually affect pill-taking
behavior, potentially by providing an opportunity for self-monitoring.
Further research is necessary to more fully understand the effect. 
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138 Patient-Tailored HIV PreventionStrategies 
José Castro1 (presenting), Deborah Jones1, Inna Granovsky1, 
Bader AL-Shehri1, Stephen Weiss1
1 University of Miami Miller School of Medicine, Miami, FL, USA
Background: More information is needed to understand how the
newer HIV prevention methods should be positioned and which mix
of prevention methods should be offered and promoted within the at
risk populations. This study sought to obtain data about the prefer-
ences for effective biomedical interventions by individuals from the
diverse ethnic and racial backgrounds that comprise the STD clinic
populations in Miami
Methods: A cross sectional survey was used to assess knowledge
and preference of traditional (condoms) and new biomedical meth-
ods to prevent HIV (Circumcision -C-, Pre-exposure prophylaxis -
PrEP and microbicides -M) in STD clinic patients.  After an initial
assessment, the study coordinator provided basic simple descrip-
tions of three new methods of HIV prevention by pamphlets and/or
recorded video. The relative preference for each of all the prevention
strategies was re-assessed information was provided.
Results: Thirty five participants are reported in this interim analysis;
55% were female; 58% were African American; 25% were Hispanic
and 12% were Haitians. Most of the participants were not aware of
the efficacy of C (68%), PrEP (77%) or M (79%) in decreasing the risk
of acquiring HIV infection. At baseline, participants described as
their preferred method to prevent HIV the use of male condoms (77%)
and had marginal preference for the newer methods C (3%), M (6%)
and PrEP (3%). After the information about the new methods was
provided, most of the participants reported to be aware of these
methods (80%) and although male condoms was still the first choice
for most of the participants (46%) a higher percentage of participants
preferred M (20%) and PrEP (14%).
Conclusions: STD clinic patients who participated in this study had
very limited knowledge about the new biomedical strategies to pre-
vent HIV infection. A brief informational session can increase their
willingness to use the newer HIV preventive strategies.
139 Gender-Specific Awareness andAcceptability of Pre-Exposure
Prophylaxis to Prevent HIV Infection among
Youth in Western Kenya: Implications for
Implementation
Jasmine Buttolph1 (presenting), Irene Inwani2, Kawango Agot3,
Eunice Omanga3, Lorraine Ogange2, Dorothy Walawanga3, 
Charles M. Cleland1, Ann Kurth1
1 New York University, New York, NY, USA
2 University of Nairobi, Nairobi, KENYA
3 Impact Research and Development Organization, Kisumu, KENYA
Background: Youth ages 15-24 in sub-Saharan Africa are more
impacted by HIV/AIDS than any other age group in any other region
globally.  In Kenya, young females are 4 times more likely to be posi-
tive than males.  Gender-specific HIV prevention combining behav-
ioral, structural, and biomedical modalities is necessary to impact
the epidemic.  Trials of pre-exposure prophylaxis (PrEP) showed effi-
cacy in reducing HIV risk when adherence ³85%. Risk-perceptions
and knowledge affect adherence and ultimately intervention effica-
cy.  The study examined youth knowledge, acceptability, facilitators,
and barriers to PrEP adherence.
Methods: Twelve focus groups were conducted in Nyanza, Kenya
composed of youth ages 15-24, parents and teachers of youth, and
community, district, and religious leaders. Youth focus groups were
gender and age (15-17 and 18-24 years old) specific.
Results: Forty six females and 66 males participated (n=112). A con-
tent analysis identified themes and sub-themes related to PrEP. Four
major themes emerged:  (1) limited knowledge of PrEP as an HIV pre-
vention method; (2) PrEP advantages; (3) concern about side effects;
(4) belief that it could result in risk compensation.  Sub themes high-
lighted a desire for sensitization campaigns, the idea of PrEP as life
saving, and potential adherence challenges.    
Conclusions: Findings indicate a need for increased PrEP aware-
ness.  Youth expressed willingness to use PrEP when coupled with
pre-counseling and adherence support. Potential adherence to the
PrEP regimen is linked to knowledge, widespread use, and accept-
ability.  Adherence remains a challenge with variability in access to
medicines, risk perceptions, and concerns about side effects. Some
participants believed HIV risk reduction outweighed potential side
effects. Overall, participants indicated PrEP could be an effective
tool in HIV prevention.  
Considering the efficacy of recent PrEP trials, combination HIV pre-
vention studies should explore incorporating PrEP. Interventions
need to provide gender-specific options to reduce PrEP misconcep-
tions, reduce risk compensation, and support adherence.
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140 Crofelemer for HIV-AssociatedDiarrhea: Sustained Efficacy,
Safety, and Adherence During a 6-Month
Randomized, Placebo-Controlled Trial 
Patrick Clay1 (presenting), Andrew Barrett2, Pam Golden2, 
Craig Paterson2, Enoch Bortey2, William Forbes2
1 UNT System College of Pharmacy, Fort Worth, TX, USA
2 Salix Pharmaceuticals, Inc., Raleigh, NC, USA
Background: Diarrhea remains a significant burden in HIV-positive
individuals taking antiretroviral therapy (ART), and negatively
impacts adherence and quality of life. Crofelemer (CRO), a botanical-
ly-derived, minimally absorbed, first-in-class antidiarrheal agent was
recently approved for symptomatic treatment of non-infectious diar-
rhea in adults with HIV/AIDS on ART. A 6-month study assessed the
efficacy, safety, and adherence profile of CRO 125mg bid.
Methods: This randomized, double-blind, placebo (PBO)-controlled,
adaptive design trial in HIV-positive adults on stable antiretroviral
therapy (ART) incorporated dose selection (Stage I) and dose
assessment stages (Stage II). Each stage included a 4-week, PBO-
controlled phase and a 20-week, PBO-free phase. Primary efficacy
endpoint was proportion of clinical responders, defined as ²2 watery
stools/week for ³2 of 4 weeks during the PBO-controlled phase.
Secondary efficacy assessments included daily watery stools, daily
stool consistency, daily abdominal pain/discomfort, and days/week
of fecal incontinence. Adverse events were recorded. Adherence
was measured by pill counts.
Results: Demographic and baseline characteristics were similar
between CRO (n=136) and PBO (n=138) groups. Overall, subjects
(mean age: 45; race: 58-61% non-White) experienced 18.9-21.0
watery stools/week, and 75% attributed diarrhea to ART (RTV-con-
taining: 34-36%; EFV/TDF/FTC: 15-22%; NFV: 0%). During the PBO-
controlled phase, the proportion of clinical responders was signifi-
cantly higher for CRO vs. PBO (p=0.0096), with greater efficacy asso-
ciated with more severe baseline diarrhea (p=0.026), longer history of
diarrhea (p=0.03), or history of unsuccessful antidiarrheal medication
use (p=0.025). Daily watery bowel movements, stool consistency,
abdominal pain/discomfort, and days/week of fecal incontinence
improved over the PBO-free phase. Interestingly, PBO-controlled
phase adherence rates of 96.5% improved to 100% in PBO-free
phase. The safety of CRO was comparable to PBO and no changes in
ART effectiveness were discernible.
Conclusions: The addition of crofelemer 125mg to stable ART regi-
mens in HIV-positive individuals is well-tolerated and results in sus-
tained decreases in diarrhea and associated symptoms.
141Combination HIV Prevention forYouth in High Burden Settings (MP3
Youth): A Pilot Study
Ann Kurth1, Irene Inwani2, Kawango Agot3, Charles M Cleland1,
Ramzi Alsallaq1, Jasmine Buttolph1 (presenting)
1 New York University College of Nursing, New York, NY, USA
2 University of Nairobi, Nairobi, KENYA
3 Impact Research and Development Organization, Kisumu, KENYA
Introduction: Young females and males (15-24 years old) in sub-
Saharan Africa have disproportionately high risk of HIV infection
compared to adults. High coverage of HIV testing and counseling
(HTC) is essential for early linkage to care and prompt initiation of
ART by positive youth, and for facilitating delivery of evidence-based
gender-specific primary prevention interventions.  Our research
team explored the most effective combination HIV prevention inter-
vention package for female and male youth in Kenya.
Description: A systematic review of the literature and expert panel
were used to select HIV prevention interventions effective for youth
in sub-Saharan Africa.  The combination package includes offering
HTC and ART at ²350 cells/mm3 for all youth; voluntary medical male
circumcision (VMMC) and condoms for males; and pre-exposure
prophylaxis (PrEP), conditional cash transfer, and contraceptives for
females.
We estimated the potential impact of providing the combination
package, including female- and male-specific interventions, by using
an age-sex-risk stratified mathematical model representing HIV het-
erosexual transmission in Nyanza, Kenya.  The package will be deliv-
ered using mobile health teams.  A longitudinal cohort will be fol-
lowed using cell phone SMS surveys to prospectively assess uptake,
adherence, and risk compensation behaviors.
Lessons Learned: The mathematical model predicts halving HIV inci-
dence in ten years among youth if the full package of interventions is
implemented and continued at specific coverage levels. The decision
to include PrEP, which requires ongoing clinical contact, in a mobile
delivery intervention, was a challenge. We are conducting intensive
field visits to explore clinical capacity for PrEP inclusion.
Recommendations: The literature indicates behavioral, biomedical,
and structural interventions can significantly reduce HIV risk.
Mathematical modeling shows interventions tailored to young males
and females could have substantial impact when combined.
However, to be effective in the overall population, interventions need
to be implemented at relatively high coverage levels. 
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142 Unmet Need among HospitalizedHIV Patients who are Out of Care
Jessica Davila1 (presenting), Christine Hartman1, Jeffrey Cully2,
Melinda Stanley1, K. Rivet Amico3, Thomas Giordano1
1 Baylor College of Medicine, Houston, TX, USA
2 Veterans Administration and Baylor College of Medicine,
Houston, TX, USA
3 University of Connecticut, Storrs, CT, USA
Background: Unmet needs among persons hospitalized with HIV who
are out of care may delay or prevent engagement in HIV care follow-
ing discharge. Unmeet needs among hospitalized HIV patients have
not been well documented. Using data from a hospitalized cohort of
HIV patients who were out of care, we examined unmet needs and
their association with CD4 and VL.    
Methods: Baseline data from a cohort of hospitalized HIV-infected
patients at a large publically-funded hospital who were out of care
and enrolled into a randomized intervention trial between July 2010
and June 2012 was used. The baseline survey included 19-items on
personal and medical needs in the 6 months before hospitalization
and whether these needs were met. Level of unmet need was deter-
mined by the count of unmet needs. Baseline CD4 and VL were col-
lected. Univariate analyses were conducted to examine associations
between unmet need and CD4 and VL.
Results: 274 HIV-infected patients were enrolled. 93% reported hav-
ing at least one need in the past 6 months. The most frequently
reported needs were dental (66%), financial (55%), food (46%), trans-
portation (44%), and housing (42%). Patients age<30 years (p=0.05)
and black race/ethnicity (p=0.03) had significantly higher levels of
need compared to other age and race groups. 88% of patients with
needs reported having ³1 need that was not met. The average num-
ber of unmet needs was 3.59 (s.d. = 2.8). Only 19% of dental, 27% of
financial, 49% of food, 40% of transportation, and 23% of housing
needs were met. Blacks had a greater number of unmet needs than
other race/ethnicities (p<0.01). Unmet need was not associated with
baseline CD4 or VL.      
Conclusions: The vast majority of hospitalized out-of-care persons
with HIV report unmet needs. Efforts to address unmet needs in hos-
pitalized HIV patients may improve linkage and retention in care.      
143 Barriers to Medication AdherenceRemain in the Era of Potent HIV
Therapy 
David Wohl1, Shawn Jones1 (presenting), Jazmin Brown1, 
Abigail Panter1, Eric Maiese2
1 The University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA
2 Merck & Co., West Point, PA, USA
Background: Optimal antiretroviral therapy (ART) adherence is
essential to personal and public health.  Barriers to ART adherence
have been well described but much of this work pre-dates the avail-
ability of more potent and convenient ART regimens.  We examined
perceptions regarding ART and adherence among persons living
with HIV (PLWH) receiving ART. 
Methods: Focus groups were conducted with 36 PLWH in NC (11
female, 25 male; 29 African-American, 5 White; 12 on initial ART).
Focus groups were audio-recorded, and transcripts were reviewed
to identify salient themes.
Results: Participants viewed ART as being important to well-being,
but described struggling to adhere to these medications.  Many who
started earlier ART regimens reported having to overcome side
effects and pill burden of these older therapies. For some, adverse
effects, especially nausea, continue to challenge adherence. Among
the major adherence obstacles participants currently experience
was HIV stigma and a fear that taking ART risks disclosure of
serostatus.  One participant stated, “I was living with someone and I
didn’t want them to know that I was taking meds so I just stopped at
one point for about, whew, maybe three or four months…” In addi-
tion, some endorsed developing medication fatigue after years of
treatment.  “I’m telling you it’s very depressing, you got to take it
every day, every day, every day … and sometimes you want to say,
Lord, I want to take a break. I’m tired of taking pills.”  Despite these
challenges, most reported being able to maintain adherence.
Conclusions: PLWH continue to experience obstacles to ART adher-
ence, including adverse effects that impact quality of life, and fears
that medication can lead to unwanted HIV status disclosure.  Despite
advances in HIV treatment, barriers to adherence remain a signifi-
cant challenge.  A validated measure for identifying these barriers
among PLWH may help tailor discussions for optimizing adherence.   
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145 Telepsychiatry Use for HIV-InfectedAfrican-American Women with
Depression Living in the Deep South
Mirjam-Colette Kempf1 (presenting), Christina Psaros2, Corilyn Ott1,
Natalie Wilson1, Steven A. Safren2
1 University of Alabama at Birmingham, Birmingham, AL, USA
2 Massachusetts General Hospital, Boston, MA, USA
Background: Mental health co-morbidities and structural factors are
consistently associated with decreased antiretroviral therapy adher-
ence (ART) and retention in HIV care. Among HIV-infected women in
the rural Southeast (U.S.) high rates of depression and transportation
barriers are prevalent; hence the potential use of telepsychiatry for
treatment. The current study explores barriers and facilitators to
depression treatment and acceptability of telepsychiatry use among
HIV-infected women in the rural Southeast.
Methods: 33 African American HIV-infected women with a history of
depression were recruited from five outpatient clinics providing
health care and social services to people living with HIV in 47 pre-
dominately rural counties in Alabama. Five focus group sessions
were conducted ranging from 3-11 participants. Content analysis
was used to analyze and interpret the data. Data coding and sorting
was conducted by using QRS NVivo 10© software.
Results: Participants ranged in age from 30 to 73 years (mean = 46.5
years), with an average time since HIV diagnosis of 12.1 years. Most
participants (66%) reported an annual household income of <$10,000,
with 39% not having completed high school or college. Participants
described their experience with depression diagnosis/treatment and
reported a preference for psychotherapy over antidepressant med-
ication. While denial of depression diagnosis impacted treatment-
seeking behavior, spiritual beliefs provided strength to cope with
depression. Only 18% of participants had received prior telemedicine
services through their HIV care provider, however the majority of
participants were receptive of using telepsychiatry for depression
treatment.
Conclusions: Findings from the current study highlight preferences
and coping mechanisms critical for culturally appropriate depression
treatment among HIV-infected women living in rural areas of the
Southeastern U.S. Because of the close relationship between
depression, ART non-adherence and retention in care, interventions
that address barriers to mental health care are sorely needed to
improve health outcomes among HIV-positive women residing in
rural areas. 
146Willingness to Take PrEP andPotential for Risk Compensation
among Highly Sexually Active Gay and
Bisexual Men
Jeffrey Parsons1 (presenting), Jonathon Rendina2, Ana Ventuneac2,
Christian Grov3
1 Hunter College and the Graduate Center of the City University of
New York, New York, NY, USA
2 Center for HIV Educational Studies & Training (CHEST)/ The
Graduate Center of CUNY, New York, NY, USA
3 Center for HIV Educational Studies & Training (CHEST)/Brooklyn
College, CUNY, New York, NY, USA
Background: PrEP may be an effective strategy for groups at high
risk for HIV, such as highly sexually active gay and bisexual men
(GBM). However, little is known about acceptability and potential risk
compensation among such groups.
Methods: Data were gathered from 187 highly sexually HIV-negative
GBM (³9 partners in 90 days) who completed a survey including
demographic, psychosocial, and PrEP-related measures, and a time-
line-followback interview of sexual behavior.
Results: A total of 54 men (28.9%) said they would probably or defi-
nitely take PrEP. Although no demographic, sexual behavior, or psy-
chosocial factors differentiated those willing and not willing, GBM
with higher levels of hypersexuality, sexual compulsivity, impulsivity,
and self-efficacy for controlling sexual thoughts and behaviors
(p<.05, p<.01, p<.001, p<.001) were significantly more likely to proba-
bly or definitely take PrEP. Among those willing to take PrEP, those
who believed PrEP would increase their condom use were higher on
sexual compulsivity (p=.03), hypersexuality (p=.03), sexual excitation
(p=.05), and sexual inhibition (p=.02) than men who believed PrEP
would decrease their condom use. Moreover, GBM who believed
PrEP would decrease their condom use reported significantly more
HIV-positive partners (p=.02) and more unprotected anal sex acts
(p=.008) than those who believed PrEP would increase their condom
use.
Conclusions: For highly sexually active GBM, willingness to take
PrEP is associated with loss of behavioral control. Further, our find-
ings suggest a contrast to risk compensation for some highly sexual-
ly active GBM who seem to demonstrate an inability to control sexu-
al thoughts and behaviors – PrEP as both behavioral and biomedical
risk reduction. Men already engaging in lower risk behavior indicat-
ed they would use condoms more with PrEP and would therefore
have added protection. Men already engaging in HIV risk behavior
indicated they would continue to engage in risk, or increase their lev-
els of risk, while taking PrEP.
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147HIV+ MSM in China RecommendStrategies for Care Engagement,
Retention, and Adherence
Jane M. Simoni1 (presenting), Lu Yin2, Han-Zhu Qian2, 
K. Rivet Amico3, Yuhua Ruan4, Yiming Shao4, Sten Vermund2
1 University of Washington, Seattle, WA, USA
2 Vanderbilt, Nashville, TN, USA
3 University of Connecticut, Storrs, CT, USA
4 National Center for AIDS/STD Control and Prevention, Beijing,
CHINA
Background: Free HIV treatment has been available in China since
2006, but acute stigma and lack of awareness limit the extent to
which Chinese men who have sex with men (MSM) get tested for
HIV, engage in care, and then remain in care with high levels of anti-
retroviral ARV adherence.
Methods: Four focus groups with HIV+ MSM were conducted in
Beijing, China in 2011. Eligible participants were Mandarin speaking,
self-reported MSM, and at least 18 years of age. They were recruit-
ed through peer networks of a local CBO.
Results: Group sessions were audio-recorded, transcribed, and then
translated. Content analysis conducted by 3 coders (2 fluent in
Mandarin and 1 English only) identified multiple strategies to promote
engagement and retention in care at the structural and individual lev-
els, many of which focused on the psychological impact of the diag-
nosis and ongoing psycho-social support. Recommended approach-
es included involving members of the individual’s support network
and training peer advocates to disseminate accurate, high quality
information; foster motivation through enhancing beliefs about posi-
tive outcomes of engaging in HIV care; and develop skills to navigate
HIV-care, advocate for one’s self, and adhere to ARV.
Conclusions: China’s current resources for treating HIV will need to
evolve to be able to provide the suggested structural changes and to
adopt creative strategies to address mental health-related concerns.
148 Determinants of Adherence to cARTin HIV-Infected Children and
Adolescents: Preliminary Results of a Long-
Term Cohort Study, 2004-2012
Laura Costa1 (presenting), Flávia Ferreira1, Fabiana Kakehasi1,
Marcelle Martins1, Jorge Pinto1
1 UFMG, Belo Horizonte, Minas Gerais, BRAZIL
Background: The complexity of cART - multiple medications, formu-
lations, and dosing intervals - makes adherence challenging for chil-
dren and adolescents. The objective of this study is to compare
adherence in a cohort from children in two distinct moments in 2004
and 2012.
Methods: This study is being carried out at the UFMG AIDS Pediatric
Immunology Clinic. Of the 103 children evaluated on 2004, 86 (83%)
are still in follow-up in 2012, 4 (4%) died, 7 (7%) were lost to follow-up
and 6 (6%) were transferred to adult clinic. Subjects or caregiver
responded to the same adherence questionnaire that was used in
the first time. The questionnaire was adapted from the PENTA net-
work. Good cART adherence was defined as no missed doses in the
last 3 days.
Results: From the initial group in 2004, 39 (47%) children were
reassessed  from Jul 2012 to Dec 2012. Current ARV regimens were:
2 NRT + 1 NNRTI - 41%; 2 NRTI + 1 PI- 41%; MDRT (Multi-drug rescue
therapy) - 18%. Only 8 (20.5%) were in their initial t cART.
Approximately half (22/39= 56.4%) of participants reported that taking
ARV did not interfere in their daily routine, 33 (84.6%) reported at least
one reason for not taking the dose. Good adherence rates were sim-
ilar in both periods: 73.7% and 64.1%, for 2004 and 2012, respectively
(p=0.5). In subjects evaluated in 2012, adherence was  influenced by
monthly income (p=0.027)  and viral load (p=0.037). Gender, age, hos-
pitalization or caregiver education did not affect adherence. This
study is ongoing and evaluation of the remaining subjects is antici-
pated to be completed by May/13.
Conclusions: Adherence rates did not change substantially over time
in this cohort of children and adolescents, suggesting that more
interventions to improve adherence should be implemented.
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152 Is Pre-ART Interval Associated withImmunologic Outcomes among HIV
Seropositive Patients on HAART?
Chinenye Ugoji1 (presenting), Rukeme Ake-Uzoigwe1, 
Gabou Mendy1, Patrick Dakum1, Manhattan Charurat2, 
Okey Nwanyanwu3, William Blattner2
1 Institute of Human Virology Nigeria, Abuja, NIGERIA
2 Institute of Human Virology, University of Maryland, Baltimore,
MD, USA
3 Center for Disease Control, Nigeria, Abuja, NIGERIA
Background: Patients’ treatment preparedness is accepted as a cru-
cial Pre-ART requirement because it’s been shown to improve reten-
tion. However, little is known of the effect of the pre-ART duration on
treatment outcome. We determined the association between pre-
ART interval and immunologic stability among HIV-infected patients
on ART in Nigeria.
Methods: In March 2011, we collected retrospective clinical and lab-
oratory information for 5320 randomly-selected HIV-positive adults
receiving care at 37 facilities. Eligible patients were enrolled ³15
months prior to the evaluation. We excluded 2381 patients who were
pre-ART, transferred, discontinued care, died or were lost-to-follow-
up. Outcome was “Absence of CD4 count <350 cells/ml in1 year peri-
od”. Association between Pre-ART interval and immunologic out-
comes was determined by logistic regression.
Results: Of 2939 patients who received ART, 2561(87.1%) had ³1 CD4
test done in the review period, 1667 (65.1%) Females; 887 (34.6%)
Males; Median age: 35.8 years. In univariate analyses, significant cor-
relates of high CD4 counts were: PreART interval (²2 Weeks OR=1.33,
p=0.001) vs >2weeks; Gender (Male OR=0.52, p<0.001) vs Females;
Baseline CD4 count; >350 Cells/ml (OR=2.93, p<0.001) vs <350cells/ml;
Baseline weight (OR=1.01, p<0.001 per1kg increase); Baseline WHO
Stage (Stage2 OR=0.82, p=0.06; Stage3 OR=0.68, p=0.001; Stage4
OR=0.51, p=0.003) vs Stage 1; Level of facility (Secondary OR=0.50,
p=0.02) vs Primary Care Centers; Urban location of facility (OR=1.32,
p=0.003 vs Rural); However, in our multivariate model, preART interval
did not predict high immunologic outcomes. Baseline weight and CD4
counts, gender and time on ART were the only significant predictors of
our outcome.
Conclusions: Patients undergo treatment preparation during the
PreART phase and this has been shown to improve retention.
However, PreART time did not predict immunologic outcomes in our
study. Time on ART was the most significant predictor of high CD4
counts. These results support the test-and-treat strategy especially
in PMTCT where delays in treatment initiation may be risky. The deci-
sion on the treatment preparation interval should be flexible and
depend on whether retention or timely outcomes is the major focus.
153 Predictors of Adherence to HAARTUsing Doctor’s Appointment
Attendance Measure of Adherence
Roseline Aderemi-Williams1 (presenting), Fola Tayo2, Aba Sagoe3,
Mathew Zachariah3
1 University of Lagos, Lagos, NIGERIA
2 West Africa Postgraduate College of Pharmacist, Lagos, 
NIGERIA
2 Lagos State University Teaching Hospital, Lagos, NIGERIA
Background: The gain in the provision of antiretroviral therapy in
resource limited settings has put pressure on the available infra-
structure including the care providers. High patient load has lead to
weak monitoring of the patients on HAART. The aim of this study was
to determine patients’ adherence to Doctor’s appointment atten-
dance over time and to predict factors affecting adherence in
patients assessing care in a treatment centre in Lagos, Nigeria.
Methods: The study was longitudinal in design, carried out between
December, 2006 to December, 2010 using validated questionnaires
and monitoring of patients’ clinical progress. Doctor’s appointment
attendance was calculated as Total # of appointment scheduled - #
of doctor’s appointment missed/ Total # of appointment scheduled
*100. Patients with 95% or more were considered adherent. An inter-
vention reducing patients’ doctors; appointment to quarterly and
tying it to drug refill was done in 2010. SPSS version 15.0 was used to
analyze the data collected from 248 patients. Predictors of adher-
ence were determined using Logistic regressing model.
Results: Social and clinical demographic data analysis showed that 134
(54.0%) were married, 148 (59.7%) females, 106 (42.7%) had secondary
school education and 208 (56.4%) employed. Mean age was 40.4+-8.8
years, mean baseline CD4 cells of 143.5 +- 92.7cells/microlitre. Trend in
adherence rate was 51.3% in 2007 (N=119), 35.9% in 2008 (N=248), 14.9%
in 2009 and 93.1% in 2010. Average rate of patients’ adherence was
48.8%.
None of the socio-demographic variable was a predictor of adher-
ence. Statistically significant predictors of adherence were: in 2007,
patients’ knowledge of management; 2008 knowledge of adherence;
and in 2010, patients’ smoking and alcohol consumption habit.
Conclusions: Average adherence rate was 48.8%. Intervention sta-
tistically improved patients’ adherence to doctor’s appointment.
Patients’ knowledge of management, adherence, and some social
habit were identified as predictors of adherence.
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154 Challenges in Testing for CD4 UponReceipt of HIV-Positive Diagnosis:
Experience at Three Public Sector Clinics in
Durban, South Africa 
Theresa Exner1, Dinesh Singh2, Naomi Lince3, Sarah Roberts4,
Suraya Dawad2, Jessica Phillip2, Gita Ramjee2, 
Susie Hoffman1 (presenting)
1 HIV Center for Clinical and Behavioral Studies at NYSPI and
Columbia University, New York, NY, USA
2 Medical Research Council, HIV Prevention Research Unit,
Westville, Durban, SOUTH AFRICA
3 Ibis Reproductive Health, Dunkeld West, Johannesburg, SOUTH
AFRICA
4 Ibis Reproductive Health, Cambridge, MA, USA
Background: CD4+ count is a key determinant of whether a newly-
diagnosed HIV+ individual is eligible for ART.  South African treat-
ment guidelines recommend that blood for CD4+ count be obtained at
the initial HIV diagnosis.  We examined whether blood was drawn on
the day of diagnosis and reasons why it was not among 327 newly-
diagnosed women and men who subsequently enrolled in a prospec-
tive cohort study.
Methods: Participants were recruited from three public sector clin-
ics in Durban.  They were interviewed prior to HIV testing, immedi-
ately after, and up to one month later by trained interviewers in
isiZulu or English.
Results: Most participants were women (70%), mean age was 30
years (range=18-57), and 72% were currently unemployed.  Only 23%
reported a blood draw on the same day they tested HIV+, although an
additional 19% reported having blood drawn prior to the additional
interview within one month. Of those without blood drawn by this
interview (N=186), reasons included no time to stay (24%), need to
return home to care for family or others (6%), clinic was closing (12%),
too shocked to take further steps (5%), fear of learning CD4+ results
(3%), and desire to go elsewhere for CD4+ testing (2%); 26% reported
a pending appointment, but 7% indicated they were unaware or
weren’t informed that a blood draw for CD4+ was needed.
Conclusions: Only one quarter of this sample of newly-diagnosed
individuals had blood drawn for CD4+ count on the day of diagnosis.
Reasons for delay were largely due to individuals’ need to return
home, clinic-related factors, and emotional distress.  Given the
importance of CD4+ count results for staging HIV+ individuals, strate-
gies to ensure prompt blood draws and reduce barriers to returning
to the clinic warrant investigation.
155 Investigating Cognitive, Behavioral,and Environmental Barriers to
HIV/AIDS’ Patients Adherence in Nigeria
Zacchaeus Omogbadegun1 (presenting), Sena Okuboyejo1
1 Covenant University, Ota, Ogun State, NIGERIA
Background: Much of health care today involves helping patients
manage conditions whose outcomes can be greatly influenced by
lifestyle or behavior change. HIV/AIDS is an imminent life-threaten-
ing disease. HIV/AIDS patients’ adherence to health behaviors is
related to their perceptions of the severity of a potential illness or the
consequences of not preventing or treating the illness.
Nonadherence involves patients taking medications incorrectly or
not at all, forgetting or refusing to make essential behavioral changes
for their care, and persisting in behaviors including high-risk sexual
activity that jeopardize their health. Adoption of technology is slow in
behavioral healthcare. This paper investigates the inherent individual
and environmental barriers to HIV/AIDS’ patient adherence in an
ongoing research on Women’s Health in Nigeria.
Methods: A mix of both qualitative and quantitative indicators are
used to develop case studies of the inherent individual and environ-
mental barriers to patient adherence. Focus groups discussions and
semi-structured interviews. The study currently covers a clinic and a
university teaching hospital each in case selected across rural and
urban Ekiti, Lagos, Ogun, Ondo, and Oyo States of Nigeria.
Results: The primary causes of nonadherence are poor provider-
patient communication, lack of understanding of the treatment and
its importance, lack of trust and mutual caring in the therapeutic rela-
tionship, and provider behavior that is controlling and paternalistic.
Depressed patients with HIV have decreased adherence to antiretro-
viral therapy. Increased patient adherence to diagnostic and thera-
peutic plans leads to greater clinical efficiency and effectiveness.
Conclusions: The main drivers fuelling Nigeria’s HIV/AIDS epidemic
include low risk perception, multiple concurrent sexual partners,
informal transactional and intergenerational sex, lack of STI servic-
es, gender inequalities, stigma and discrimination, and inadequate
health services. HIV/AIDS’ patients are required to take 95% or more
of antiretroviral medications to control the disease.
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156 Longitudinal Predictors ofAdherence to ARV Treatment (ART)
as Prevention (TasP) in HPTN 052, A Large-
Scale, Multi-Site, International Trial of Early
ART to Prevent HIV Transmission in Sero-
Discordant Couples
Steven A. Safren1 (presenting), Kenneth Mayer2, 
Marybeth McCauley3, San-San Ou4, Beatriz Grintszejn5,
Mina Hosseinipour6, Nagalingeswaran Kumarasamy7, 
Theresa Gamble8, Irving Hoffman9, David Celentano10, 
Myron Cohen9
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
2 The Fenway Institute, Boston, MA, USA
3 Family Health International, Washington, DC, USA
4 The Statistical Center for HIV/AIDS Research & Prevention,
Seattle, WA, USA
5 Instituto de Pesquisa Clinica Evandro Chagas, Manguinhos, Rio
de Janeiro, BRAZIL
6 University of North Carolina at Chapel Hill, Center for Infectious
Disease, Lilongwe, MALAWI
7 YRG CARE Medical Center., VHS Chennai CRS, Chennai, Tamil
Nadu, INDIA
8 Family Health International, Research Triangle Park, NC, USA
9 University of North Carolina School of Medicine, Department of
Medicine, Division of Infectious Diseases, Chapel Hill, NC, USA
10 John Hopkins Bloomberg School of Public Health, Baltimore, MD,
USA
Background: HPTN052, a treatment as prevention (TasP) trial,
demonstrated early ART prevented the sexual transmission of HIV in
1750 sero-discordant couples in 9 countries. Because ART adher-
ence maximizes the chances of suppressing HIV RNA, and therefore
decreasing HIV transmissibility, studying adherence in HPTN052 par-
ticipants can inform global TasP scale-up. 
Methods: Outcomes: adherence via pill count (PC=did not miss any
pills), ACTG self-report adherence questions (SR=derived via princi-
pal-components analysis). Predictors: quality of life (QOL), substance
use, binge drinking, social support, sexual behaviors, and demo-
graphics. Life-Steps adherence counseling was adapted and provid-
ed at study visits.  Analyses: Logistic and linear regression models 1
month after ART initiation and GEE model accounting for within-sub-
ject correlations for longitudinal (two years) analyses; reported
results are p².05.  A checklist of reasons for non-adherence was also
used.
Results: Adherence was generally high: forgetting, traveling, and
side-effects being the most frequently reported reasons for non-
adherence at initiation. At initiation, psychosocial and demographic
variables were not predictive of adherence.  Longitudinal multivari-
able models, however, are as follows: For PC, significant predictors
were QOL-mental health (OR=1.04), social support to help remember
pills [perceiving highest level (OR=1.19), moderate level (OR=1.26), or
n/a, did not ask (OR=.63) compared to “none”)], and Asia (OR=2.07;
North/South America=referent group).  For SR, significant predictors
were age (b=.01), QOL-mental health (b=.014), satisfaction with social
support (b=.16 for somewhat dissatisfied versus very dissatisfied),
social support to help remember pills [perceiving somewhat (b=.14),
n/a did not ask (b=-.15) compared to none], being a woman (b=.06),
and not from Asia (b=-,19). 
Conclusions: In the context of a TasP trial for globally diverse sero-
discordant couples, adherence counseling, and generally high
adherence, psychosocial variables such as mental-health and social
support remain important longitudinal predictors.  Including behav-
ioral science interventions to address these mental-health factors
are important in supporting global TasP efforts.
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158 Lessons-in-Progress: Case Study ofa Partnership Between a Pharmacy
School and Community Pharmacy to Pilot
Test a Pharmacy-Based ART Adherence
Intervention
Jennifer Cocohoba1 (presenting), Dao Lieu2, Emily Dane1, 
Hai-Dang Lam2, Laura Sezonov2, Mallory Johnson1
1 University of California San Francisco, School of Pharmacy, San
Francisco, CA, USA
2 AIDS Healthcare Foundation, San Francisco, CA, USA
Introduction: Pharmacy-based programs can be effective in improv-
ing antiretroviral (ART) adherence in HIV-positive persons. A partner-
ship between a community pharmacy and a School of Pharmacy pro-
vides an ideal opportunity for both groups to design, methodically
implement, and rigorously test brief, patient-centered pharmacy
adherence interventions.
Description: Initial discussions between the University of California
San Francisco School of Pharmacy (UCSF-SOP) and a community
pharmacy began in June 2010, to include two of the pharmacies as
sites for an NIH-funded pilot study. The block-randomized controlled
study (n=20) would test feasibility of a conducting a telephone inter-
vention based in motivational interviewing for patients late picking up
ART refills. First participants were enrolled in January 2013; recruit-
ment is ongoing.
Lessons Learned: When conducting research in community pharma-
cies, various unpredictable elements can come into play that the
team must adapt to. Identifying proper institutional review board
(IRB) procedures can be confusing when dealing with two institu-
tions. Most pharmacies do not conduct research regularly, may not
have a Federalwide Assurance Number, and may not be allowed to
defer to the University IRB. Obtaining a concise pharmacy data
report in a usable research format may require persistent communi-
cation with information technology (IT) staff. Unexpected events
such as board inspections and setting up new pharmacy locations
may cause delays in research. Having dedicated pharmacy staff
involved in the research is invaluable to identifying key contact per-
sonnel when problems arise and to serve as a familiar bridge to the
research subjects.
Recommendations: University partnerships with community pharma-
cies combine the expertise of persons from both groups to study
interventions to improve ART adherence. Early questions prior to
engaging in a research study should center on IRB processes and IT
support. Having a flexible timeline and identifying one or more phar-
macist champions can ensure the success of the research.
159 HIV Counselors’ Beliefs About ARTand Childbearing among HIV+
Women and Men in Durban, South Africa 
Elizabeth Kelvin1, Ilundi deMenezes2, Suraya Dawad3, 
Joanne Mantell1, Kelly Blanchard4, Gita Ramjee3, 
Susie Hoffman1 (presenting)
1 HIV Center for Clinical and Behavioral Studies at NYSPI and
Columbia University, New York, NY, USA
2 Ibis Reproductive Health, Dunkeld West, Johannesburg, SOUTH
AFRICA
3 Medical Research Council, HIV Prevention Research Unit,
Westville, Durban, KwaZulu-Natal, SOUTH AFRICA
4 Ibis Reproductive Health, Cambridge, MA, USA
Background: Healthcare providers’ opinions may influence the care
they provide.
Methods: We conducted qualitative interviews with five HIV coun-
selors at one public-sector clinic in Durban, South Africa, to develop
a structured questionnaire, which was then administered to 20 coun-
selors at three other public-sector clinics.  We assessed beliefs and
counseling practices around ART initiation, care and treatment, and
HIV and childbearing.
Results: In qualitative interviews, some counselors believed that
smokers and drinkers should not initiate ART because of increased
risk for liver and lung problems and the potential to develop resist-
ance due to poor adherence. Among those assessed quantitatively, a
sizeable minority agreed that HIV+ people who were unwilling to take
ARVs for life (N=8), would not stop drinking and smoking (N=7), and
would have difficulty adhering (N=4) should be discouraged from ini-
tiating ART.  These views were not associated with whether the
counselor reported always discussing ART at post-test counseling.
Regarding childbearing, in qualitative  interviews counselors indicat-
ed they believed HIV+ individuals had the right to have biological
children, but some were concerned about the risks to the child’s
health, risk of transmitting HIV to an uninfected partner, and care for
the child should the HIV+ parent(s) become sick or die.  In the quan-
titative interviews, the majority (n=13) agreed that although an HIV+
person has the right to have a child, this should be discouraged.
Those who held this belief were more likely to always discuss where
to get family planning services during their first post-test counseling
session than those who did not endorse this belief (80% vs. 29%,
p=.06).
Conclusions: HIV counselors’ opinions on childbearing were associ-
ated with whether they prioritized counseling around family planning
services, but their opinions on contraindications for ART were not
associated with counseling practices.  Because of our small sample
size these findings merit further investigation.  
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160 Preliminary Support forTransgender-Specific Predictors of
Uptake and Adherence to ART and Viral
Load among HIV+ Transgender Women
Jae Sevelius1 (presenting), Mallory Johnson2
1 University of California, San Francisco/CAPS, San Francisco, CA,
USA 
2 University of California, San Francisco, San Francisco, CA, USA
Background: Transgender women have disproportionately high HIV
rates, and those living with HIV have a three-fold higher viral load
than other groups and are less likely to be taking antiretroviral ther-
apy (ART).  Among those who initiate ART, transgender women report
lower rates of ART adherence and more difficulty integrating treat-
ment into their lives than non-transgender adults.  These findings
strongly suggest that transgender women face culturally unique
challenges to uptake and adherence to ART. 
Methods: We administered quantitative surveys to 137 transgender
women; 63 were HIV+ (46%) and were part of the current analyses.
The majority were African-American (N=46, 71%).  We assessed
transgender and HIV-specific psychosocial influences on uptake and
adherence to ART guided by two novel models: the Model of Gender
Affirmation and the Model of Health Care Empowerment (HCE).
Results: Overall, 100% reported having ever been seen by a health
care provider, 86% reported having ever been on ART, 83% reported
currently being on ART, and 67% reported having an undetectable
viral load. We found that access to gender affirmation was positive-
ly associated with self-reported ART adherence (r=.433, p<.01), need
for gender affirmation was positively associated with having a
detectable viral load (t(52)=1.97, p<.05), body appreciation was asso-
ciated with current ART use (t(59)=2.28, p<.05), and stress appraisal
of transphobic experiences was associated with self-reported viral
load (t(50)=3.03, p<.01). Both HCE scales (informed, collaborative,
committed, engaged and tolerance for uncertainty) were associated
with self-reported adherence (r=.40, p<.01; r=.43, p<.01).
Conclusions: These results provide preliminary support for two mod-
els that may help elucidate health care disparities observed among
transgender women living with HIV.  These models may be useful in
guiding interventions that aim to improve health outcomes among
this disproportionately impacted group by addressing transgender
and HIV-specific factors associated with engagement in and adher-
ence to HIV treatment.
161A Qualitative Investigation ofBarriers to Treatment Initiation and
Engagement among Transgender Women
Living with HIV
Jae Sevelius1 (presenting), Enzo Patouhas1, Mallory Johnson2
1 University of California, San Francisco/CAPS, San Francisco, CA,
USA
2 University of California, San Francisco, San Francisco, CA, USA
Background: Transgender women are among the most highly impact-
ed groups in the HIV epidemic, and yet are under-researched and
underserved. This examination of culturally unique barriers to
engagement and retention of transgender women in HIV care will
provide insight and guidance to those wishing to better engage and
serve this population, and contribute to efforts to understand and
mitigate the forces that result in disproportionately poor health out-
comes for transgender women. 
Methods: This qualitative study explored HIV+ transgender women’s
experiences, perspectives, and life contexts of engagement and
retention in HIV treatment through 5 focus groups and 20 individual
interviews (total N=58).  Data was coded and analyzed using the
Behavioral Model of Health Services Use and the Model of Health
Care Empowerment as theoretical frameworks.
Results: Transgender women living with HIV face unique challenges
in initiating and adhering to HIV care, such as limited access to and
avoidance of healthcare due to stigma and past negative experi-
ences, prioritization of gender-related healthcare, and concerns
about adverse interactions between ART and hormone therapy. Once
engaged in care, the cultural competency of the provider and envi-
ronment of the clinic is extremely important to retention.  Facilitators
to retention include the provider’s ability to provide both hormones
and HIV care, knowledge of trans-related medical issues, and ability
to treat the patient with dignity and respect. 
Conclusions: Primary themes that emerged from the data included
delays in diagnosis, difficulties with adjustment to diagnosis, prioriti-
zation of transition-related care, substance use, and low provider
cultural and clinical competency in the provision of care for trans-
gender patients. Interventions must fully attend to the social, eco-
nomic, and psychological context of transgender women’s lives and
address the multiple barriers to health care engagement, treatment
adherence, and empowerment that serve to create, maintain, and
deepen HIV-related health disparities among transgender women.
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166Measurement of the HIV Cascade ofCare Using Surveillance Data in
Cuyahoga County
Nora Colburn1 (presenting), Barbara Gripshover2, Alan Taege3, 
Ann Avery4
1 Case Western Reserve University School of Medicine, Cleveland,
OH, USA
2 University Hospitals Case Medical Center, Cleveland, OH, USA
3 The Cleveland Clinic, Cleveland, OH, USA
4 The MetroHealth System, Cleveland, OH, USA
Introduction: Despite the development of effective combination anti-
retroviral therapy (ART), many patients do not access HIV clinical
care for a variety of reasons.  Early linkage after a new diagnosis has
been associated with favorable clinical outcomes.  Integrating pub-
lic health surveillance data and programs with local clinical services
may increase rates of linkage to care.
Description: An evaluation of HIV care linkage and retention in
Cuyahoga County was performed using surveillance data of new HIV
cases reported in 2009 and 2010 from the Ohio Department of Health.
Medical records were examined at local HIV clinics to determine if
patients were linked to care within 3 months, retained in care for 12
months, prescribed ART, and achieved viral suppression in the 12
month period after diagnosis.   
Lessons Learned: The lack of integration of public health and clini-
cal services resulted in redundancy of efforts.  Nearly 10% of the
patients reported to the health department were previously diag-
nosed, but may not have been reported.  More than half the patients
that were unable to be located by the health department had
accessed clinical services in the year following diagnosis.  The cas-
cade of care in Cuyahoga County is similar to previously reported
national estimates with less than half of the patients retained in care
and only one quarter with a suppressed viral load 12 months after
diagnosis. 
Recommendations: Increased collaboration between health depart-
ment partner services and HIV clinicians could improve HIV linkage
and streamline the workflow of both organizations within the context
of a complex and fragmented healthcare system.  Strengthening the
partnership between public health and clinical care will result in
more accurate and robust data for both parties in order to provide
more comprehensive care to people living with HIV.
167Barriers to Treatment andAdherence among Vulnerable
Women and Sex Workers in South Africa
Wendee Wechsberg1 (presenting), Jacqueline Ndirangu1, 
William Zule1
1 RTI International, Durham, NC, USA
Introduction: South Africa has the most people living with HIV and
although PEPFAR and South African government programs proclaim
success in linking HIV positive people to care, many with reduced
CD4 count, like sex workers face barriers. Those who are receiving
ARVs face structural and economic barriers for adherence.
Description: A NIDA-funded (R01 DA032061) study is currently reach-
ing vulnerable drug-using women using a prospective, geographical-
ly clustered, randomized design to compare the impact of HIV testing
with a woman-focused HIV prevention intervention on treatment link-
age and ARV adherence. This on-going study uses community out-
reach to find and test vulnerable women in Pretoria, South Africa.
With HIV among 57% (105/184) of all women tested and 67% among
sex workers, only 16% (17/105) are currently on ARVs.  A majority of
these women face barriers that prevent them from initiating treat-
ment. Those who do initiate treatment face barriers that lead to low
rates of retention and adherence. These barriers include; lack of fol-
low through with pre-ARV counseling, lack of referral linkages
between clinics, fear about ARVs, and stigma toward sex workers.
Structural issues of food insecurity, lack of ARVs in nearby clinics,
having ARVs stolen, mandatory ID requirements for ARV initiation,
and concomitant substance abuse with lack of affordable drug reha-
bilitation programs are major challenges. 
Lessons Learned: Because many clinic barriers are related to shifts
in PEPFAR funding priorities, our community advisory board has
helped with their access and linkages.   Study participants have been
escorted for clinical staging and ARV initiation, getting help acquir-
ing IDs and in demystifying ARVs. Regular contact to ensure ARV
adherence and storing ARVs has become essential.
Recommendations: Strategic planning across groups responsible for
reaching vulnerable women to problem solve the gaps in service
delivery, reduce structural barriers and implement this in combina-
tion with behavioral interventions is essential.
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169 Providing Drug-Level Feedback toUS Men who have Sex with Men
(MSM) Using Pre-Exposure Prophylaxis
(PrEP) in the iPrEx Open Label Extension
(OLE): A Qualitative Evaluation of Participant
Perspectives
Albert Liu1 (presenting), K. Rivet Amico2, Kim Koester3, 
Vanessa McMahan4, Pedro Goicochea4, David Lubensky5, 
Hailey Gilmore6, Christopher Chianese7, Kristine Santos8, 
Susan Buchbinder6, Kenneth Mayer7, Sybil Hosek9, Robert Grant4
1 San Francisco Department of Public Health, San Francisco, CA,USA
2 University of Connecticut, Storrs, CT, USA
3 University of California, San Francisco, San Francisco, CA, USA
4 J. David Gladstone Institutes, San Francisco, CA, USA
5 Bagatto Inc., San Francisco, CA, USA
6 Bridge HIV, San Francisco Department of Public Health, San
Francisco, CA, USA
7 The Fenway Institute, Boston, MA, USA
8 Ruth M. Rothstein CORE Center , Chicago, IL, USA
9 Stroger Hospital of Cook County, Chicago, IL, USA
Background: There is emerging interest in providing PrEP study partici-
pants with pharmacokinetic results from drug-level testing to improve
accuracy of self-reported adherence and guide counseling. In iPrEx OLE,
plasma samples collected in the first 12 weeks of study participation were
tested for tenofovir/emtricitabine. Study clinicians shared results
(detectable/undetectable) with participants at their 24-week visit. We eval-
uated participant perspectives on receiving these results at US study sites.
Methods: OLE participants (MSM and transwomen) enrolled in San
Francisco, Boston, and Chicago were purposefully sampled to
include those with detectable and undetectable levels. In-depth
interviews (IDIs) explored experiences with drug-level feedback,
including perceived usefulness and recommendations. IDIs were
transcribed, coded, and analyzed for themes.
Results: From April-September 2012, we conducted 49 IDIs (17 had
undetectable drug-levels). Chicago participants were younger and
more likely African-American or Latino. Generally, participants had
positive attitudes towards receiving drug-levels, citing curiosity and
a desire to “know” if enough drug was present to provide protection.
Participants with detectable drug felt affirmed, safer/more protected,
and experienced a sense of accomplishment. Participants reported a
desire for greater specificity, particularly quantitative drug levels
needed for protection. Several participants noted they would lever-
age other prevention strategies during periods of low drug detection.
In a few cases, undetectable results led to increased efforts to take
PrEP consistently. Overall, participants were inclined to provide
accurate self-reported adherence because of drug-level monitoring.
Conclusions: Drug-level feedback was acceptable and possibly sup-
portive of enhancing accuracy of self-report in iPrEx OLE. Strategies to
increase the salience of drug-level results should be explored, including
using feedback to target counseling, and expediting testing to ensure
feedback reflects recent PrEP-use. Future studies should evaluate the
feasibility of providing quantitative drug-levels using biomarkers of
longer-term PrEP exposure (hair/dried blood spots) and the impact of
sharing these results on drug detection and self-report accuracy.
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170 Adherence and HIV“Transmissibility” in High-Risk 
HIV-Infected Individuals from Diverse
Geographic Settings: Baseline Data from
HPTN063
Steven A. Safren1 (presenting), Matthew Mimiaga2, 
Ayana T. Moore3, James Hughes4, Kriengkrai Srithanaviboonchai5,
Ruth Khalili Friedman6, Mohammed Limbada7, Xin Li4, 
Vanessa Cummings8, Charlotte Gaydos8, Corey Kelly4, 
Vanessa Elharrar9, David Celentano10, Kenneth Mayer2
1 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
2 The Fenway Institute, Boston, MA, USA
3 Family Health International, Research Triangle Park, NC, USA
4 Fred Hutchinson Cancer Research Center and University of
Washington, Seattle, WA, USA
5 Faculty of Medicine, Chiang Mai University, Chiang Mai, 
THAILAND
6 Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro,
BRAZIL
7 Centre for Infectious Disease Research in Zambia (CIDRZ),
Lusaka, ZAMBIA
8 Johns Hopkins School of Medicine, Department of Pathology,
Baltimore, MD, USA
9 National Institutes of Health/National Institute of Allergy and
Infectious Diseases, Bethesda, MD, USA
10 John Hopkins Bloomberg School of Public Health, Baltimore, MD,
USA
Background: With global expansion of ART-treatment, and subse-
quent reduced transmissibility, data are needed to inform treatment-
as-prevention (TasP) approaches. HPTN063 is an observational study
in Rio de Janeiro, Brazil, Chiang Mai, Thailand, and Lusaka, Zambia,
of high-risk HIV-infected heterosexual men (HM), heterosexual
women (HW), and MSM (Brazil and Thailand only).
Methods: Assessments: adherence, depression, alcohol-use, sub-
stance-use (yes/no), quality of life, social support, HIV-disclosure,
and transmission risk behavior (TRB with HIV-negative/unknown-
status partners via ACASI) (N=750, approximately 100 per risk-group,
per site), HIV-RNA (extracted from charts, Brazil/Thailand only), and
STIs (via testing). 
Logistic regression (OR for continuous predictors=per 1 unit
increase on scale) modeled two outcomes: non-adherence (6 cate-
gories, ordinal), and “infectious/risky” (bivariate: engaged in TRB
with detectable viral load or STI). 
Results: 86% of the sample reported taking ART. In bivariate analy-
ses, adherence was significantly worse with increased depression
(OR=1.01) and alcohol use (OR=1.05). However adherence was better
with better QOL-general health (OR=.99) and QOL-social (OR=.96);
and in Brazil (OR = 0.53) and Zambia (OR = 0.48) compared to
Thailand.  In the multivariable model, increased alcohol (OR=1.04)
was associated with worse adherence, and better QOL-general
health (OR=.99) and being from Brazil (OR=.41) or Zambia (OR=.58)
compared to Thailand with better adherence.
Infectious/risky: 29% of 448 (Brazil/Thailand only) met criteria for
infectiousness/TRB.  Bivariate analyses: High transmission risk was
associated with Brazil (OR=2.84) compared to Thailand, with HW
(OR=1.79) and MSM (OR=3.49) compared to HM, and with higher HIV
disclosure (OR=1.87).  Multivariable: HW (OR=1.58) and MSM
(OR=3.05) and patients from Brazil (OR=2.43) compared to Thailand
were more likely to meet criteria. 
Conclusions: TasP approaches require interventions to maximize
adherence, with health perceptions and alcohol use being of poten-
tially high importance.  Providing more intensive behavioral interven-
tions to the subset of individuals at higher biological risk for transmis-
sibility, may amplify the effectiveness of TasP.
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171Feasibility and Acceptability of aReal-Time Adherence Monitoring
Device among HIV-Positive Patients in
China
Mary Bachman DeSilva1, Allen Gifford2 (presenting), Keyi Xu3,
Zhong Li4, Cheng Feng5, Mohamad Brooks1, Mark Harrold6, 
Yueying Hu7, Christopher Gill1, Wubin Xie8, Taryn Vian1, 
Jessica Haberer9, David R. Bangsberg9, Lora Sabin1
1 Center for Global Health and Development, Boston University
School of Public Health, Boston, MA, USA
2 Boston University, Boston, MA, USA
3 Ditan Hospital, Beijing, CHINA
4 Family Health International, Beijing, CHINA
5 Global Health Strategies, Beijing, CHINA
6 Family Health International, Bangkok, THAILAND
7 Guangxi CDC ART Clinic, Nanning, CHINA
8 Family Health International, Nanning, CHINA
9 Massachusetts General Hospital, Boston, MA, USA
Background: We collected preliminary data on feasibility and
acceptability in China of a real-time web-linked adherence monitor-
ing container which uses wireless technology to track on-time med-
ication dosing. “Wisepill” transmits a signal by general packet radio
service to a central server each time it is opened. Wisepill has been
used to monitor adherence in various studies, but its potential as an
adherence support tool is unknown.
Methods: The study was conducted at the Guangxi Center for
Disease Control HIV clinic in Nanning, China.  Ten patients on anti-
retroviral therapy (ART) used Wisepill for one of their ART medica-
tions for one month.  We monitored device use and ART adherence,
and collected data on acceptability of the device among patients,
and feasibility of monitoring adherence wirelessly in China.
Results: Subjects were current and former injection drug users
(90%); 70% had a history of depression.  Mean adherence levels
were 76% (SD 27%) using Wisepill data, but 98.5% by self-report
(visual analogue scale).  Half of the subjects reported a positive or
very positive overall experience with Wisepill (the other five report-
ed “somewhat negative”); seven were willing or very willing to par-
ticipate in a larger effectiveness study. Eight found the device very
easy to use. However, seven said that it was inconvenient or very
inconvenient, supported by comments that it was large and conspic-
uous. Five were somewhat or very worried about disclosure of their
HIV status due to the device; no disclosures were reported.  Minor
technical difficulties were encountered and addressed.
Conclusions: Use of a real-time, SMS-enabled web-linked ART
adherence monitoring system among predominantly IDU HIV patients
in China is feasible; further analysis of acceptability is warranted.
Concerns about disclosure and stigma should be explored. The
device shows potential for adherence interventions that deliver rapid
adherence-support behavioral feedback directly to patients, as well
as in clinical settings.
173 STaR Study: Single Tablet RegimenRilpivirine/Emtricitabine/Tenofovir
DF Is Non-Inferior to Efavirenz/
Emtricitabine/Tenofovir DF in ART-Naïve
Adults Regardless of Adherence
Calvin Cohen1, David Wohl2, José Arribas3, Keith Henry4, 
Jan Van Lunzen5, Mark Block6, Hui Wang7, Danielle Porter7,
Shampa De-Oertel7, Todd Fralich7, Olga Lugo-Torres8 (presenting)
1 Community Research Initiative of New England, Boston, MA,
USA
2 The University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA
3 Hospital Universitario La Paz, Madrid, Madrid, SPAIN
4 Hennepin County Medical Center, Minneapolis, MN, USA
5 Medizinische Kilnk und Poliklinik, Hamburg, Hamburg, GERMANY
6 Holdsworth House Medical Practice, Darlinhurst, New South
Wales, AUSTRALIA
7 Gilead Sciences, Foster City, CA, USA
8 Gilead Sciences, Miami Beach, FL, USA
Background: HIV medication adherence can be improved with regi-
men simplification and better tolerability. In previous studies efficacy
of regimens has correlated with optimal adherence rates.
Rilpivirine/Emtricitabine/Tenofovir DF (RPV/FTC/TDF) and Efavirenz/
Emtricitabine/Tenofovir DF (EFV/FTC/TDF) are once-daily, single
tablet regimen (STR) HIV treatment options.
Methods: STaR is an ongoing, open-label, international, 96-week
study evaluating the safety and efficacy of the STR RPV/FTC/TDF com-
pared to the STR EFV/FTC/TDF in treatment-naïve HIV-1 infected sub-
jects. Subjects were randomized 1:1 to RPV/FTC/TDF or EFV/FTC/TDF.
The primary endpoint was the proportion of subjects with HIV-1 RNA
<50 c/mL at Week 48 as determined by FDA snapshot algorithm (12%
pre-specified non-inferiority margin). Outcomes stratified by <95%
and ³95% adherence according to pill count were also analyzed.
Results: A total of 786 subjects were randomized and received at
least one dose of study drug (394 RPV/FTC/TDF; 392 EFV/FTC/TDF).
RPV/FTC/TDF was non-inferior to EFV/FTC/TDF (86% vs 82%) at Week
48 for HIV RNA <50 c/mL (difference 4.1%, 95% CI [-1.1%, 9.2%]) per
FDA snapshot analysis. Non-inferiority was demonstrated for HIV-1
RNA >100,000 c/mL (n=276), 80% RPV/FTC/TDF vs 82% EFV/FTC/TDF
(difference -1.8%, 95% CI [-11.1%, 7.5%]) and a statistically significant
difference was seen for baseline HIV-1 RNA ²100,000 c/mL (n=510),
89% RPV/FTC/TDF vs 82% EFV/FTC/TDF (difference 7.2%, 95% CI
[1.1%, 13.4%]), and.  In the RPV/FTC/TDF arm, 76.3% of subjects had
optimal adherence of ³95% vs 77.1% in the EFV/FTC/TDF arm.
RPV/FTC/TDF was non-inferior to EFV/FTC/TDF for those with adher-
ence <95%, 75.3% (70/93) vs 65.9% (58/88), difference 9.1%, 95% CI [-
4.3%, 22.4%], and for those with adherence ³95% , 89.6% (268/299) vs
88.2% (262/297), difference 1.3%, 95% CI [-3.8%, 6.4%].
Conclusions: The STR RPV/FTC/TDF demonstrated overall non-inferi-
or efficacy compared to STR EFV/FTC/TDF in treatment-naïve HIV-1-
infected subjects.  Most subjects were highly adherent to their STR;
adherence was correlated with efficacy.
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174 Time Preferences PredictAdherence to Antiretroviral
Therapy and Mortality among HIV-Infected
Adults in Kenya
Harsha Thirumurthy1 (presenting), Kami Hayashi1, Noel Brewer1
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Background: Antiretroviral therapy (ART) adherence may be thought
of as an inter-temporal choice of whether to incur immediate costs
that yield delayed health benefits. Costs include inconvenience of
taking medications daily and side effects, while health benefits
include viral suppression and reduced morbidity. Economic theory
suggests that such choices are partially influenced by individuals’
time preferences, which describe the extent to which they prefer
immediate vs. delayed rewards. While previous research has identi-
fied various barriers and facilitators to adherence, few studies have
measured patients’ time preferences and examined their association
with adherence and mortality.
Methods: 671 HIV-infected adults in Kenya who initiated ART partic-
ipated in a randomized trial of text message reminders and were fol-
lowed for 18 months. All participants were administered a baseline
questionnaire in which they were asked to choose between hypo-
thetical monetary payments offered immediately or in the future. We
classified responses as demonstrating patient or impatient time pref-
erences. The main outcomes were 12-month Medication Event
Monitoring System (MEMS) adherence >0.90 and 12-month mortality.
Regression analyses examined the association between time prefer-
ences and outcomes.
Results: When presented with the hypothetical choice of receiving
money today versus a larger amount of money in one year, 39%
chose money today (impatient preferences). 50% had 12-month
MEMS adherence >0.90 and 5% were deceased at 12 months. In
regression analysis that controlled for demographic characteristics,
wealth, and alcohol use, having impatient preferences was associat-
ed with a 6.9% decrease in the likelihood of adherence >0.90 (p<0.05)
and a 3% increase in likelihood of mortality (p<0.05).
Conclusions: Simple measures of the time preferences of patients
initiating ART can predict adherence and mortality. Time preference
measurement could be utilized more widely in HIV care and treat-
ment programs. The improved understanding of adherence behavior
can pave the way for better targeting of adherence interventions.
176 Promoting Access and Adherenceto HIV Prevention, Care, and
Treatment among Public Sector Workers in
Uganda 
Gloria Ekpo1 (presenting), Erasmus Tanga2, Melanie Lopez1
1 World Vision, Washington, DC, USA
2 World Vision, Entebbe, UGANDA
Background: The Government of Uganda (GoU) is at the forefront of
integrating HIV/AIDS interventions into workplace to increase
employee access to services for the last two decades. The
Supporting Public sector workplaces to Expand Action and
Responses against HIV/AIDS project (SPEAR) implements work-
place-based HIV/AIDS prevention, care and treatment interventions
for public sector workers (PSW) in Uganda since 2008.
Methods: Assessing Drivers of HIV Infection (ADHI) was a cross-
sectional descriptive study to evaluate overall knowledge, behaviors
and risk factors and perceptions for HIV transmission and the factors
that impact adherence to HIV/AIDS prevention, care and treatment
services among PSW in three ministries in Uganda: Ministry of
Education and Sports (MoES), Ministry of Internal Affairs (MoIA), and
Ministry of Local Government (MoLG). Data was collected and
entered using EpiInfo version 3.5.1 and analyzed using Stata version
9.2. This abstract documents the role on Behavior Change Agents
(BCAs) in promoting and maintaining adherence among PSW in the
SPEAR Project.
Results: Over 3,000 trained BCAs served as SPEAR project-trained
conduits for information and access to HIV services between the
three ministries and PSWs, reaching over 40,000 individuals with HIV
counseling and testing services and over 58,000 individuals with
behavior change communication (BCC). Availability of BCAs
increased by 41% in the ministries, with higher representation at
MoES (57%), and UPS (50%). BCAs contributed to reduction of HIV-
related stigma by 24%, with 91% reporting HIV testing, service uptake
range from 32%-75%, 70% being aware of workplace HIV policies,
62% receiving BCC, and 94%  reported family approval of services.
Conclusions: BCAs are effective agents to improve access to infor-
mation, utilization HIV services and increase adherence to HIV pre-
vention, care and treatment services among PSW. The use of BCAs
should form an integral part of all HIV services among PSW and their
families.
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177Missed Opportunities for PromotingARV Use among Established
Patients in Care
Christine Oramasionwu1 (presenting), Stacy Bailey1
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Background: National guidelines recommend antiretroviral therapy
(ARVs) for all HIV-infected individuals to reduce the risk of disease
progression and transmission. Poor continuity of care and lack of
access are frequently cited as root causes of non-treatment. To look
beyond these factors, this study sought to identify determinants of
ARV coverage among established patients visiting their usual source
of care. The relationship between ARV coverage, healthcare utiliza-
tion, and visit disposition was also examined.
Methods: HIV-related visits for adult patients (age >18) were identi-
fied from the 2009-2010 National Hospital Ambulatory Medical Care
Survey using primary ICD-9-CM codes for HIV (042, V08, 079.53). Only
established patients receiving services from their usual source of
care were included. Healthcare utilization was calculated as the
number of clinic visits within the last year. Visit disposition was
coded as either: return to the clinic, refer to other physician, or refer
to the emergency department (ED) or hospital for admission.
Bivariable analyses were conducted for comparisons on the basis of
treatment status (ARV-treated vs. non ARV-treated).
Results: Approximately 2.5 million HIV-related clinic visits were ana-
lyzed. Overall, 69% of visits were for patients with ARV coverage.
Lack of ARV coverage was more prevalent among women, African-
Americans, Medicaid recipients, and patients living in impoverished
neighborhoods (p<0.001). Healthcare utilization did not differ by treat-
ment status. Compared to ARV-treated patients, non-treated patients
were less likely to be instructed to return to the clinic (p<0.001) and
were more likely to be referred to the ED or hospital for admission
(p<0.001).
Conclusions: Many patients lack ARV coverage despite having a
usual source of healthcare. Established non-ARV treated patients
utilize care at similar rates as ARV-treated patients, yet their visits
are more likely to result in ED or hospital admission. Routine clinic
visits may be missed opportunities to promote ARV use for these vul-
nerable patients.
178 Barriers to HIV Care enrollment,Retention, and Timely ART
Initiation: Provider Perspectives at Four
Ethiopian HIV Clinics
Sarah Kulkarni1 (presenting), Susie Hoffman2, Tsigereda Gadisa1,
Mesganaw Fantahun3, Kavita Misra4, Muluneh Yigzaw1, 
Shalo Daba5, Zenebe Melaku1, Denis Nash4, Batya Elul1
1 International Center for AIDS Care and Treatment Programs,
Columbia University, New York, NY, USA
2 HIV Center for Clinical and Behavioral Studies at NYSPI and
Columbia University, New York, NY, USA
3 School of Public Health, Addis Ababa University, Addis Ababa,
ETHIOPIA
4 CUNY School of Public Health at Hunter College, New York, NY,
USA
5 Oromia Regional Bureau of Health, Addis Ababa, ETHIOPIA
Background: Despite increased access to HIV testing, and care and
treatment services in Ethiopia, initiation of antiretroviral therapy
(ART) late in disease remains common. Health care providers can
provide insight into barriers to prompt linkage, sustained engage-
ment in HIV care, and timely ART initiation.  
Methods: Trained interviewers conducted in-depth interviews with
12 providers (4 VCT counselors, 4 doctors, and 4 nurses) and 4 HIV-
positive peer educators at clinics with varying levels of late ART ini-
tiation in Oromia, Ethiopia.  Interviews were translated, transcribed,
and content-coded.
Results: Patient-level barriers to timely linkage and retention in care
cited by providers and peers included patients’ difficulty accepting
their HIV diagnosis, fear of stigma, prioritization of non-allopathic
treatments (such as holy water), living far from the clinic, lack of
understanding regarding the need for services early in disease, and
a general reluctance to start ART resulting from concerns about
potential side effects and fear of being seen taking medication.
Additionally, some providers indicated that patients diagnosed as
part of provider-initiated testing were unprepared for their diagnosis
and received insufficient post-test counseling following diagnosis,
placing them at risk for delayed linkage to care.  Structural barriers
cited included long wait times for pharmacy and laboratory services
and staff who were not supportive or empathetic.   Conversely, HIV-
positive peers believed that the experiential-based support they pro-
vided was especially helpful to HIV-positive individuals.
Conclusions: Providers recognize that prompt linkage to HIV care,
sustained engagement in HIV care and timely ART initiation require
attention to patients’ social context and treatment literacy, as well as
proper interactions with providers and a clinic environment con-
ducive to efficient patient care.  Providers and peer educators may
be useful allies in developing interventions to improve linkage and
retention in HIV care.  
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179 Association Between Self-Efficacyand Adherence to Antiretroviral
Therapy In Brazilian Children and
Adolescents
Aline Ernesto1, Renata Lemos1, Maria Uehara1, Andre Morcillo1,
Maria Vilela1, Marcos Da Silva1 (presenting)
1 State University of Campinas Medical School, Campinas, Sao
Paulo, BRAZIL
Background: Brazilian public health provides free access to HAART,
but patient adherence remains challenging. Evaluation of self-effica-
cy, characterized by the individual self-evaluation over his/her abili-
ty to perform specific behaviors, has been proposed for adherence
assessment. We aimed to evaluate the association between self-effi-
cacy and adherence to HAART in pediatrics.
Methods: A population comprising 108 HIV-infected patients on
HAART (60 boys), from 8 to 19 years-old, was assessed cross-sec-
tionally. Self-efficacy was measured by a validated scale, scoring 0
to 100. Adherence was evaluated in patient-caregiver dyads by stan-
dardized questionnaires and pharmacy refill data (PRD). Patients
who received less than 95% of prescribed doses in 24 hours or 7 days
before the interview, or who had an interval >37 days between refills,
were considered nonadherent. The association between adherence
outcomes and independent variables related to demographical, med-
ical and psychosocial conditions was estimated. Statistical analysis
was performed by multivariate Odds Ratios, Mann-Whitney test, and
Spearman Correlation Coefficient. Results were statistically signifi-
cant if p ² 0.05. The study was approved by the Internal Review Board
of the State University of Campinas Medical School.
Results: Nonadherence prevalence varied from 11.1% (nonadherent
in 3 instruments), 15.8% (24-hour self-report), 27.8% (7-day self-
report), 45.4% (PRD) to 56.3% (at least one of the outcomes). Self-effi-
cacy scores were lower in non-adherent patients according to 24h
and 7-day self-report, and PRD. After multivariate analysis, inde-
pendent variables associated with lower self-efficacy were: difficul-
ty of ministration by caregiver, lack of virological control, lower
CD4/CD8 ratio, HAART ministration by patient, missed consultations
in the former 6 months, lack of religious practice by patient and lower
per capita income.
Conclusions: A high prevalence of HAART nonadherence was
observed in the study population, being PRD the most sensitive
measurement. Additionally, an association was observed between
adherence outcomes and self-efficacy scores.
180 Understanding How RiskPerception Frames HIV-Positive
Adults’ Decision to Refuse Antiretroviral
Treatment at an HIV Testing Center in
Soweto, South Africa 
Ingrid Katz1 (presenting), Janan Dietrich2, Thandekile Essien2, 
David R. Bangsberg3, Norma Ware4, Glenda Gray2
1 Brigham and Women’s Hospital, Cambridge, MA, USA
2 Perinatal HIV Research Unit, Soweto, Diepkloof, SOUTH AFRICA
3 Massachusetts General Hospital, Boston, MA, USA
4 Harvard Medical School, Boston, MA, USA
Background: South Africa has the largest antiretroviral treatment
(ART) program in the world. Despite this, many treatment-eligible
individuals are choosing not to initiate care. To date, few studies
have addressed why HIV-positive adults are not starting treatment.
We identified one likely cause of delayed ART initiation:  20% of ART-
eligible individuals presenting for Voluntary Counseling and Testing
(VCT) in Soweto declined ART upon learning their CD4 count. We
inductively identified and characterized reasons for ART-refusal in
this population, to develop an explanatory framework for under-
standing why HIV-positive adults choose not to engage in care.
Methods: Using a qualitative approach, we purposively-sampled 50
ART-eligible adults presenting for VCT across a spectrum of decision
making and their care providers, and performed in-person, semi-
structured interviews from 3/2012-2/2013. The goal of this strategy
was to perform in-depth investigation by tapping multiple perspec-
tives, to gain a detailed understanding of factors driving ART-refusal.
An inductive approach to category construction, based upon ground-
ed theory methodology, was used to analyze these data.
Results: Our data indicate that ART- refusal may be driven by a
weighing of the perceived risks of taking ART.  Individuals may
decide taking ART ultimately does more harm than good, despite
widespread recognition of its efficacy. Refusers reported that ART
was efficacious and life-saving, however, they expressed a higher
concern for risks associated with starting ART, including an inability
to adhere, stigma resulting from taking ART or being seen at the clin-
ic, and medication side-effects. Ultimately, the costs of being on
treatment outweighed the benefit for those who refused to initiate.
Conclusions: Optimizing engagement and long-term retention of HIV-
positive individuals in care will require understanding their motiva-
tion for treatment refusal. Our explanatory framework using a risk
perception model provides a basis for further research and interven-
tions designed to engage HIV-positive individuals in care.
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184 Validation of the MassachusettsGeneral Hospital Virologic Failure
Prediction Rule
Chad Pendley1 (presenting), Vishal Sethi2, Sara Lammert3, 
Kristin Johnson3, Jordan Hughes4, Sreevalli Atluru4, 
Steven A. Safren5, John Fangman4, Gregory Robbins3
1 Rush Medical Center, Chicago, IL, USA
2 Chase Brexton Health Services, Baltimore, MD, USA
3 Massachusetts General Hospital, Boston, MA, USA
4 Medical College of Wisconsin, Milwaukee, WI, USA
5 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
Background: A rule predicting virologic failure (VF) in virologically
suppressed HIV-infected patients was developed at Massachusetts
General Hospital (MGH) and validated at Brigham and Women’s
Hospital, an affiliated hospital. Whether the 1-year VF prediction rule
could be generalized to other settings has not been tested.
Methods: Data from a community-based HIV clinic, the AIDS
Resource Center of Wisconsin (ARCW), was used to further validate
the prediction rule. Study period was 4/1/2006 to 4/1/2008.  Inclusion
criteria:  HIV+ and ³2 clinic visits.  Study entry:  first clinic visit with
RNA ²400 while on combination antiretrovirals.  The MGH 1-year VF
prediction rule uses the “risk score,” the sum of seven risk factors:
suboptimal adherence (<85%); CD4 <100 cells/µL; highly ART experi-
enced; drug/alcohol use; missed ³1 appointment; prior VF; and sup-
pressed <12 months. VF was defined as at least 2 consecutive HIV
RNA measurements >400 copies/mL documented in the electronic
health record within the first year of follow-up or 1 HIV RNA meas-
urement >400 copies/mL and no confirmatory test in the subsequent
3 months. VF rates and univariate/multivariate associations were cal-
culated. Chi-square and c statistics were used to test the calibration
and discrimination of the risk scores and Kaplan-Meier curves and
Log-Rank were used to compare risk categories (score 0-1, 2-3, ³4).
Results: 356 patients with two-years of follow-up data were includ-
ed in the analysis. Sixty-eight (19.1%) and 99 (27.8%) experienced VF
at year 1 and year 2, respectively. The 1-year VF model showed rea-
sonable discrimination (c statistic, 0.72) and calibration (x2 = 5.7;
p=0.57). Stratifying patients into low (0-1), medium (2-3), and high (³4)
risk categories resulted in 1-year VF rates of 7.5%, 15.6%, and 36.8%,
respectively.  
Conclusions: The MGH 1-year VF prediction rule has reasonable dis-
crimination using community-based HIV clinic data and could be
used to identify patients for adherence interventions.
185 Patterns and Motivation for HIVTesting and Time from HIV
Diagnosis to Antiretroviral Treatment (ART)
Initiation at Six Clinics in Ethiopia 
Sarah Kulkarni1 (presenting), Tsigereda Gadisa1, Susie Hoffman2,
Harriet Nuwagaba-Biribonwoha1, Yingfeng Wu1, Batya Elul1,
Zenebe Melaku1, Denis Nash3
1 International Center for AIDS Care and Treatment Programs,
Columbia University, New York, NY, USA
2 HIV Center for Clinical and Behavioral Studies at NYSPI and
Columbia University, New York, NY, USA
3 CUNY School of Public Health at Hunter College, New York, NY,
USA
Background: HIV testing plays an important role in the timeliness of
diagnosis and ART initiation, with the potential to reduce morbidity
and onward HIV transmission. We examined HIV testing history
among persons initiating ART at six clinics in Oromia State, Ethiopia.
Methods: Using a structured questionnaire, adults (n=563) initiating
ART at six clinics during 2012 were interviewed at the time of HIV
treatment initiation about HIV testing history and circumstances,
including timing, reasons for testing, and location of HIV-positive
tests.
Results: Common reasons reported for testing among those initiating
ART included feeling sick (54%); death, sickness or HIV diagnosis of
a spouse or partner (17%); and a provider recommendation (14%).
55% reported receiving their HIV diagnosis via a provider-initiated
test.  In addition to the positive test that resulted in enrollment into
HIV care, 223 (40%) reported an additional prior HIV test (57% report-
ed a prior positive test and 42% a prior negative test).  One-third of all
participants reported doubt about their HIV-positive status after diag-
nosis, and this was more common among individuals with multiple
HIV-positive tests (OR 6.1, 95% CI 4.0-9.4, p<0.0001).  Among 168
patients who delayed care enrollment by >1 month after diagnosis or
reported >1 HIV-positive test, reasons included feeling healthy (19%),
disbelief about HIV positive status (19%), concern about being seen
at the clinic (14%), work or family responsibilities (10%), and reluc-
tance to start ART (8%).  The median time between diagnosis and
ART initiation among patients with only one HIV-positive test was 2.0
months (IQR 1.0-11.9) and 21.2  months among those who had ³1 HIV-
positive test (IQR 7.6-51, p<0.0001). 
Conclusions: We observed high levels of provider-initiated testing,
combined with missed opportunities for prevention and timely care
initiation among those with prior HIV tests, underscoring the impor-
tant role of post-test counseling. 
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187Healthcare-Related and Other MajorDeterminants of Recent HIV Testing
among New York City (NYC) Adults, 2010
Ashraf Fawzy1 (presenting), Denis Nash2
1 Stony Brook University Health Sciences Center, School of
Medicine, Stony Brook, NY, USA
2 CUNY School of Public Health at Hunter College, New York, NY,
USA
Background: HIV testing guidelines increasingly call for systematic
screening for HIV infection in clinical settings. We examine health-
care related and other major correlates of recent HIV testing in a
population-based sample of NYC adults.
Methods: The 2010 NYC Community Health Survey (CHS) is a strati-
fied random sample of 8,665 non-institutionalized adults aged >18
years. The association of recent HIV testing (last 12 months) with
receipt of other medical screening tests was investigated using mul-
tivariate logistic regression, accounting for other factors related to
HIV testing (age, gender, race/ethnicity, socioeconomic status, sexu-
al activity/behaviors, health insurance, and marital status). Subgroup
analysis by gender and sexual activity was performed. Estimates
were weighted and age-adjusted to the 2010 US standard population.
Results: Among all participants, sexual activity in the last 12 months
(adjusted odds ratio [AOR]: 2.8;95%CI: 2.2-3.6), Black and Hispanic
(vs. White) race/ethnicity (AOR: 3.5;95%CI: 2.7-4.5 and 2.6;95%CI: 2.0-
3.5, respectively) were the strongest predictors of recent HIV testing.
Among all sexually active participants, number of sex partners, his-
tory of anal sex, and condom use at last sex were not significantly
associated with recent HIV testing. Among women<65 years old, Pap
smear was significantly associated with recent HIV testing (AOR:
4.3;95%CI: 2.8-6.6) while mammography (among women >40 years)
showed a weaker association (AOR: 1.5;95%CI 1.0-2.3). Among older
sexually active adults, while condom use was associated with recent
HIV testing among those eligible for mammography (AOR: 1.7;95%CI
1.0-2.7) and colonoscopy (AOR: 2.7;95%CI 1.7-4.3), actual receipt of
these screening tests was not.
Conclusions: Receipt of medical screening may be an important
determinant of HIV screening. However, there may be missed oppor-
tunities among sexually active adults at high risk for HIV infection.
Availability and accessibility of HIV testing outside of clinical settings
remains important for those at risk for HIV who may not routinely
access medical care.
188 Identification of Intentional Non-Adherence to HAART in
Routine Care
Rob Fredericksen1 (presenting), Anna Church1, Anna Harrington1,
Robert Harrington1, Shireesha Dhanireddy1, Mari Kitahata1, 
Heidi Crane1
1 University of Washington, Seattle, WA, USA
Background: To assess the extent to which HIV care providers suc-
cessfully identify intentional non-adherence to HAART.
Methods: A routinely-collected assessment of patient-reported out-
comes (PROs) was administered to patients immediately prior to their
clinic visit over a ~2 year period from March 2011 to Feb 2013.
Patients who indicated missing 2 or more doses in the past 30 days
were asked whether or not they had missed any doses during this
time period “on purpose”. Medical records were reviewed from the
same day of the assessment. Provider notes pertaining to adherence
were extracted and coded for 1) whether adherence was discussed;
2) whether the discussion included patient mention or admission of
non-adherence; and 3) whether reasons for non-adherence were
identified. Notes were also coded for thematic content indicating
rationale for missed doses and/or HAART interruption.
Results: 435 PRO assessments indicated missing 2 or more doses in
the past 30 days. Of these, 68 sessions indicated missing doses “on
purpose”, representing 61 unique patients. In 12 (18%) of visits,
providers documented 100% adherence to HAART. Two-thirds of
these patients were non-Caucasian. 10 (15%) of visits lacked
provider documentation regarding adherence.  Non-adherence was
documented in 46 (68%) of provider notes. Of these, 4 (10%) did not
document a reason for non-adherence; of the 42 that did (91%), 85%
documented a reason for intentional non-adherence, and 15% docu-
mented a single non-intentional reason (i.e., forgetting). Nearly all
visits in which non-adherence was documented described a single
reason; most commonly avoidance of side effects (20%), and reasons
related to substance use (15%).
Conclusions: PROs are known to catalyze discussions of adherence.
However, there is room for improvement. Provider training and iden-
tification of feedback delivery needs may enhance utilization of
patient-reported adherence measures.
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190 Understanding Patient and ProviderPriorities for Measuring Patient-
Reported Outcomes Such as Adherence in
Routine Clinical Care Settings
Rob Fredericksen1 (presenting), Todd Edwards1, Anne Skalicky1,
Edgar Paez2, Lydia Dant3, David Batey4, Niko Lazarakis1, 
Nelly Ayala1, Anna Church1, Bill Lober1, Michael Saag4, 
Paul Crane1, Donald Patrick1, Heidi Crane1
1 University of Washington, Seattle, WA, USA
2 University of California, San Diego, San Diego, CA, USA
3 The Fenway Institute, Boston, MA, USA
4 University of Alabama at Birmingham, Birmingham, AL, USA
Background: As part of the NIH-based Patient Reported Outcome
Management Information System (PROMIS) initiative we sought to
understand how HIV-infected patients and their providers prioritize
patient-reported domains for inclusion in clinical care.
Methods: Patients living with HIV participated in focus groups and
completed ranking exercises with lists of PRO domains.  We con-
ducted individual interviews with ~20-25% of patients surveyed to
assess rationale for rank order choices. Using modified Delphi tech-
niques, HIV providers from 8 clinical CFAR Network of Integrated
Clinical Systems (CNICS) sites across the US ranked PRO domains
for clinical care and research.  List 1 included anger, anxiety, depres-
sion, fatigue, physical function, pain, and sleep disturbance. List 2
included alcohol abuse, cognitive function, HIV stigma, HIV and
treatment symptoms, medication adherence, positive effect, sexual
risk behavior, sexual function, social roles, spirituality/meaning of
life, and substance abuse. Interviews were transcribed and coded
for domain-specific and thematic content.
Results: 74 providers and 66 patients participated; 15 of the 66 patients
were interviewed. In list 1, concordance was high between patients
and providers; both patients and providers ranked depression as most
important to address in clinical care. In list 2, both ranked adherence
highly (#1 for providers, #2 for patients). However, patients ranked
substance abuse and alcohol abuse considerably lower than
providers as important to address in care (#7 and #8 vs. #3 and #4,
respectively). Substance use, but not alcohol, ranked even lower
among Black patients (#10). HIV-related stigma ranked third most
important to patients, and seventh for providers. Among women,
Latinos, and those diagnosed with HIV <5 years, stigma ranked first.
Conclusions: Both patients and providers ranked adherence and
depression as key PRO priorities for clinical care. In contrast,
providers considered some of the key adherence barriers such as
alcohol and substance use as much higher priorities for clinical care
than patients.
191Qualitative Exploration ofExperiences with Receipt of HIV
Diagnosis and Engagement in HIV Care
among MSM Living with HIV in Beijing,
China
K. Rivet Amico1, Yu Liu2, Jane M. Simoni3 (presenting), Yuhua
Ruan4, Han-Zhu Qian2, Yiming Shao4, Sten Vermund2
1 University of Connecticut, Storrs, CT, USA
2 Vanderbilt, Nashville, TN, USA
3 University of Washington, Seattle, WA, USA
4 National Center for AIDS/STD Control and Prevention, Beijing,
CHINA
Background: Despite the availability of HIV care at minimal or no cost
in Beijing, timely linkage into and subsequent retention in HIV-care
remains problematic for a number of HIV positive men with have sex
with men (HIV+MSM). However, the extent to which stigma, structur-
al barriers and affective struggles factor into personal narratives
about one’s experience with being diagnosed positive and linking to
care is not well understood. We sought the insights of HIV+MSM to
address this gap.
Methods: Three focus groups with HIV+MSM in Beijing. Guides
included questions about experiences of testing positive and with
HIV-care. Groups were recorded, transcribed, and translated into
English, and reviewed by 3 coders (2 fluent in Mandarin and 1 English
only). Themes were identified using framework analysis focused on
extracting guidance for the study team in developing a linkage inter-
vention for this community.
Results: Focus group participants (n=40) ranged in experiences of
diagnosis receipt, from highly stigmatizing to supportive. Examples of
interactions with providers included being called “a carrier” or lec-
tured on HIV resulting from their ‘careless’ or ‘incorrect’ behaviors.
Stigma was noted as a major barrier across most stages of the HIV
continuum of care, both emanating apparently from testing and care
sites and from the community. Recommendations included normaliz-
ing testing and treatment, mobilizing existing social support struc-
tures specifically for MSM, addressing crisis, and improving nega-
tive attitudes encountered in medical care. Structural improvements
desired included extending hours of care clinics, decreasing wait
times at clinic and increasing clarity in treatment plan.
Conclusions: Experiences with discrimination and stigma were reflect-
ed in focus group discourse. HIV diagnosis was reflected on as a time
of crisis for most participants, exacerbated by the isolation of stigma.
Concrete recommendations provided by the groups will be utilized in
creating a peer based intervention to support HIV+MSM in Beijing.
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192Measuring Antiretroviral TherapyAdherence in a Clinical Care
Setting in the Recent IDU-Driven HIV
Epidemic in Estonia
Kaja-Triin Laisaar1 (presenting), Mait Raag1, Anneli Uusküla1
1 Department of Public Health, University of Tartu, Tartu, ESTONIA
Background: Poor health outcomes (e.g. virologic failure) of patients
on antiretroviral therapy (ART) and recent rapid increase in HIV drug-
resistance in Estonia have been suggested to stem predominantly
from poor adherence. A reliable adherence measure is vital for mon-
itoring adherence and delineating adherence related barriers and
facilitators. Thus two indirect methods for measuring adherence
(patient self-report, pharmacy refill) were compared in a clinical care
setting.
Methods: We report data from a prospective study comparing patient
self-reported (3-day recall) and pharmacy refill based adherence
measures to viral load from 125 patients receiving outpatient HIV
care (a convenience sample).
High adherence rate for the self-reported measure was defined as
90% of pills taken as prescribed, and for pharmacy refill as 90% of
days covered with medication during past 1 month.
Results: Participants were 54% male, mean age 34 years, infected
with HIV for average 5.4 years (62% of through intravenous drug use),
and on ART for an average 1.8 years.
Majority (97%) of respondents reported high adherence based on
self-report and less than half (46%) were highly adherent according
to pharmacy refill data (p<0.001).
At the end of the reporting period, viral load was undetectable for
61% (95% CI 51…70%) among  those highly adherent by self-report
and for 67% (95% CI 53…79%) highly adherent by pharmacy refill
data. Neither the self-reported nor the pharmacy refill based adher-
ence was associated with viral load (Fisher’s exact test p-values
0.648 and 0.184, respectively). Receiver operator characteristics
analysis indicated that both the adherence measures had similar
predictive values for indicating detectableness of viral load (areas
under the curve 0.507 and 0.569, respectively, p=0.231).
Conclusions: Measuring ART adherence remains complex. Rigorous
but user-friendly measures of adherence fitting into busy clinic rou-
tine are needed. Reasons for non-adherence warrant further
research, and enhanced adherence support is vital.
194 Text Messaging ImprovesAntiretroviral Adherence among
Depressed Individuals: Using Ecological
Momentary Assessment to Inform
Interventions
David Moore1 (presenting), Anya Umlauf1, Alexandra Rooney1, 
Ben Gouaux1, Florin Vaida1, J. Hampton Atkinson1
1 University of California, San Diego, San Diego, CA, USA
Background: Antiretroviral (ARV) medication regimens have been
greatly simplified; yet, subgroups, such as HIV+ persons with co-
occurring bipolar disorder (HIV+/BD+), still evidence poor ARV
adherence. Recent evidence suggests that texting interventions
improve ARV adherence. Depression has been long-linked to poor
adherence, and ability to assess mood and adherence via ecological
momentary assessment (EMA) may provide critical information for
adherence interventions.
Methods: 50 HIV+/BD+ persons were randomized to either “individu-
alized Texting for Adherence Building” (iTAB; n=25), which provides
personalized text adherence reminders at participant-selected
times, or an active comparison intervention (CTRL; n=25).  Both
groups received daily text message evaluating mood.  A sentinel ARV
was tracked daily using an electronic monitoring system for approx-
imately 30 days.  Participants who took at least one dose per day
were classified as “adherent” for the day.  We used mixed effects
regression models to assess the influence of time, mood, and inter-
vention on daily medication adherence.  Time effect was measured
by odds ratio per 5-day increase.
Results: ARV adherence decreased over time in both the iTAB and
CTRL groups (OR=0.9, p=0.01). Overall responsiveness to the mood
messages dropped significantly over time among those classified as
“Depressed” (i.e., reporting depressed mood on greater than half of
the days followed; n=6, OR=0.71, p=0.002), while the overall response
rates of those who reported no mood problems on most days (n=41)
were stable (OR=1.03, p=0.46). Interestingly, a significant 3-way inter-
action emerged suggesting that “Depressed” participants assigned
to iTAB were less likely to show time-related ARV adherence
declines compared to CTRL (iTAB: OR=0.98, p=0.92; CTRL: OR=0.50,
p=0.006).
Conclusions: Personalized daily text messaging reminders may
reduce ARV nonadherence among depressed individuals. As med-
ication adherence interventions for HIV-infected persons evolve,
real-time interventions using text messaging and EMA should be
considered to possibly enhance and improve long-term adherence
outcomes in persons at risk for nonadherence.  
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196 Impact of Integrating HIV Serviceswith Other Development Programs
in Agriculture, Nutrition and Saving Scheme
to Promote Adherence for Orphans and
PLWHA in Rwanda: Lessons from Ibyiringiro
Project
Gloria Ekpo1 (presenting), Bosco Muhinda2, Melanie Lopez1
1 World Vision, Washington, DC, USA
2 World Vision, Kigali, RWANDA
Introduction: USAID/Ibyiringiro Project is funded through the United
States President’s Emergency Plan for AIDS Relief (PEPFAR), to
improve access to high quality, sustainable and comprehensive serv-
ices, through integrated HIV services with livelihood security and
resiliency for orphans and households affected and afflicted by HIV
and AIDS.
Description: Ibyiringiro Project was implemented by World Vision in
partnership with ARDA and FHI in six out of 30 districts in Rwanda.
The project integrated HIV prevention care and treatment services
with nutrition education, counseling, assessment and monitoring of
body mass index (BMI); promoting vegetables and fruits gardens,
Framers Field Schools through the use of energy saving Bio-
Intensive Agricultural Techniques (BIAT), household budgeting,
financial management and access to low interest savings and lend-
ing scheme (SILC), and created linkages to complementary package
to clinical services for PLWHA.
Lessons Learned: Among the 6972 total beneficiaries, 78% (3655
females, and 1765 males) were living with HIV/AIDS; 85% of the chil-
dren had normal BMI, 5% were moderately malnourished while only
1% was severely malnourished. The average  a total of  5832 (4093
females and 1739 males)  beneficiaries monthly participated in
HIV/AIDS awareness programs, positive living, hygiene and sanita-
tion,  adherence to ARTs and PMTCT.
A total of 6640 farmers received vegetable and fortified seeds with
training in BIAT. The BIAT technique  beneficiaries reported  a  3-5
times increased production of vegetables with increased household
access to vegetables and food security, improved household income
generation and resiliency of HIV/AIDS affected families and empow-
ered beneficiaries economically.
Recommendations: Integrating HIV and AIDS comprehensive servic-
es with other development programs in agriculture, nutrition and
economic empowerment interventions improved health outcomes for
orphans and PLWHA and should form the basis of minimum package
for effective HIV interventions for vulnerable populations.
197Examining Relationships betweenNeuro-Cognitive Impairment and
Antiretroviral Treatment Adherence among
HIV-Positive Adults who Abuse Alcohol 
Jennifer Attonito1 (presenting), Robert Malow1, Jessy Devieux1,
Brenda Lerner1, Karina Villalba1, Anshul Saxena1
1 Florida International University - Robert Stempel College of
Public Health and Social Work, North Miami, FL, USA
Background: As a neurotropic virus, HIV may cause a range of
neuro-cognitive impairment (NCI), which is frequently hypothesized
to adversely affect disease management, specifically, adherence to
antiretroviral treatment (ART).  Because adherence has been shown
to reduce viral load to levels where health outcomes improve and
risk of transmission is greatly reduced, it is important to understand
the determining role of NCI, particularly in more compromised alco-
hol-abusing patients. 
Methods: Measures of NCI included Color Trails Test 2 (CTT2); Short
Category Test (SCT); and the Rey Auditory Verbal Learning Test
(AVLT). Alcohol use severity was measured using the Alcohol use
Disorders Identification Test (AUDIT) and adherence was a self-
reported percentage over a seven day period. Data was gathered
from 171 HIV-positive adults in Miami, FL who reported recent alco-
hol use-the majority were male (61%) and of minority race/ethnicity
(85%); mean age was 45.9; 72.5% reported 100% adherence; and
45.6% did not complete high school. NCI data was normed for this
sample on age, gender, and education. Significant (p<0.1) factors
from bivariate linear regression were included in a multivariate linear
regression. 
Results: In this sample a mean AUDIT score of 15.7 indicated haz-
ardous drinking. Means of raw SCT (40.1), AVLT (9.2), and CTT2 (58.2)
exceeded norms and indicated possible impairment.  In bivariate
regression, greater age (p=.003) and lower education level (p=0.49)
significantly predicted ART adherence. In the multivariate model,
both factors remained significant predictors: greater age (p=.002; CI=
.23, .048, ß=0.64) and lower years of education (p=.038; CI=-5.4, -0.16;
ß=-2.8). Neither bivariate nor multivariate analyses indicated a rela-
tionship between NCI and ART adherence. 
Conclusions: While NCI may seriously impact HIV-positive adults
who use alcohol, other factors such as age and education may play
a greater role. Additional research investigating factors that may
affect ART adherence in this population is recommended.
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198 Fluctuations in Depressed Affectamong Men who have Sex with
Men on Antiretroviral Therapy
Gertraud Stadler1 (presenting), Patrick A. Wilson1, 
Melissa R. Boone Brown1, Jill Pac1, Niall Bolger1 
1 Columbia University, New York, NY, USA
Background: Depressed affect has been identified as a risk factor for
suboptimal treatment adherence but is usually studied as a relative-
ly stable variable. The current study examined fluctuations in
depressed affect over the course of seven weeks in men who have
sex with men (MSM) taking antiretroviral medication.
Methods: Participants comprised a convenience sample of 116 HIV-
positive MSM living in New York City taking antiretroviral medication.
Men completed a weekly structured survey and reported their level
of depressed affect in the past week  in Week 1, 3, 5, and 7.  To
describe sources of variance and reliability in depressed affect, we
decomposed the available variance, following Cronbach’s generaliz-
ability theory approach, as described by Shrout and colleagues
(Shrout & Lane, 2011; Cranford, Shrout, Iida, Rafaeli, Yip, & Bolger,
2006).
Results: Individual differences between persons accounted for a
quarter of the total variance in depressed affect over the seven
weeks of the study (depressed affect: 23%). Reliability for these indi-
vidual differences was high (RKF = 0.98). In addition, we found that
another substantial part of variance came from fluctuations in
depressed affect from week to week (11%). Reliability for these with-
in-person fluctuations was high as well (RC = 0.85).
Conclusions: In line with current approaches to studying distress,
depressed affect showed some stability over seven weeks in MSM
taking antiretroviral medication. In addition, we found considerable
fluctuations around the person mean across time, and these can be
reliably measured. Fine-grained longitudinal studies that capture
these fluctuations can help to gain a better understanding of the link
between negative affect and adherence.
199 Informal Caregiver Reports of CareRecipients’ ART Adherence:
Implications for Dyadic Intervention
Amy Knowlton1, Allysha Robinson1 (presenting), Mary Mitchell1,
Trang Nguyen1, Lauren Ropelewski1
1 Johns Hopkins Bloomberg School of Public Health, Baltimore,
MD, USA
Background: Informal HIV care receipt has been found to be predic-
tive of virologic outcomes of antiretroviral therapy (ART) in a popula-
tion vulnerable to treatment failure.  We examined associations
between caregivers’ reports of recipients’ ART adherence and recip-
ients’ viral load, and identified individual and relationship factors
associated with agreement in these data.  The findings will further an
understanding of caregivers’ involvement in a vulnerable popula-
tion’s ART adherence, with implications for adherence intervention.
Methods: Participants were former or current injection drug using
(IDU) persons on ART and their main caregivers (n=256 dyads).
Analysis included multivariate logistic regression.
Results: Care recipients reported a median of 10 years on ART, 23%
impaired physical functioning, 50% current heroin or cocaine use, and
85% African American race/ethnicity; 70% were found to be virally
suppressed. Of caregivers, 46% were recipients’ partners, 29% kin,
and 26% friends; 59% reported someone close had died of AIDS, 74%
reported recipient expressed considerable affection and gratitude,
and 36% reported fear of HIV (re)infection from HIV care giving.
Results indicated 73.4% of caregivers’ adherence reports agreed with
recipients’ viral suppression status.  Adjusting for cohabitation and
recipient drug use, agreement was positively associated with recipi-
ent expressing affection or gratitude, caregiver having had someone
close die of AIDS, and fearing care giving related HIV (re)infection.
Agreement was not associated with role relation.
Conclusions: Our findings provide further evidence of caregivers’
role in this population’s ART adherence.  The results suggest strate-
gies for promoting caregivers’ attentiveness to recipients’ ART
adherence and drug users’ HIV health outcomes.
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201Reasons for Missing Doses andOptimal Adherence to HIV
Medication: A Prospective Study among a
Sample of People Living with HIV in Atlanta
Yiyun Chen1 (presenting), Seth Kalichman1
1 University of Connecticut, Storrs, CT, USA
Background: Curbing HIV sexual transmission by virtue of unde-
tectable viral loads requires sustained high levels of adherence to
antiretroviral therapy (ART) among people living with HIV/AIDS
(PLWHA). This study aims to facilitate design of adherence interven-
tion by exploring reasons for missing doses and their relationships
with ART adherence. 
Methods: 300 PLWHA who self-reported to have missed HIV medica-
tion during past month were followed for five weeks with a baseline
assessment at week one and two follow-ups taken two weeks apart.
We evaluated the frequency at which each of the 15 listed reasons
was selected and their stabilities over time by gender, chart-
abstracted viral-load, and involvement in unprotected discordant sex
in the past four months. Generalized equation modeling was used to
assess relationships between reasons and ART adherence, meas-
ured by unannounced pill counts. 
Results: The top four reasons with 20%-40% of endorsement were “I
was too busy doing other things”, “something unexpected came up”,
“I slept through dose time” and “I did not have the right pill with me
at the time”.  These reasons also had higher stabilities with 66%-73%
of participants who chose the reason to have always chosen the
same reason. The pattern of selected reasons differed slightly by
gender and involvement in unprotected discordant sex, but not viral-
load status. Reasons that predicted optimal adherence (pill counts ³
85%) over the next two-week period were: “I was too busy doing
other things”, “I got confused about what I should take”, “I was too
drunk or high at the time”, “I could not afford my medication”, and “I
have been drinking so I did not take my medication”. 
Conclusions: Adherence interventions may work to improve time
management skills, and reduce alcohol use among PLWHA. Efforts
are also needed to reduce pill burden and costs, and identify chron-
ic difficulties of adherence.
203 Predictors of AntiretroviralAdherence among HIV-Positive
Alcohol Abusing Adults: A Bayesian
Network Model
Anshul Saxena1 (presenting), Jennifer Attonito1, Brenda Lerner1,
Jessy Devieux1, Robert Malow1
1 Florida International University - Robert Stempel College of
Public Health and Social Work, North Miami, FL, USA
Background: Nearly perfect treatment adherence is essential for
yielding positive health outcomes and reducing HIV transmission.
Bayesian network modeling is much underused in examining proba-
bilities of varying antiretroviral treatment (ART) adherence levels for
important variables such as neurocognitive impairment (NCI), alco-
hol abuse, and social contextual factors. 
Methods: Data was gathered from 171 HIV-positive adults in Miami,
FL who report recent alcohol use-the majority were male (61%) and
of minority race/ethnicity (85%); mean age was 45.9; 73% reported
100% adherence; mean years living with HIV was 16.4; and 45.6% did
not complete high school. Adherence was a self-reported percent-
age over a 7-day period. Stress was measured using Life
Experiences Survey and social support was measured using the
Medical Outcomes Test. Measures of NCI included Color Trails Test
2 (CTT2); Short Category Test (SCT); and the Rey Auditory Verbal
Learning Test (AVLT). Alcohol use severity was measured using the
Alcohol use Disorders Identification Test (AUDIT). Means were
imputed into GeNIe software to yield discretized values using a hier-
archical method for the Bayesian analysis in order to examine poten-
tial impact upon mean adherence. 
Results: Several factors were identified as significant in this model:
increased stress, greater HIV/STD knowledge, female gender, lower
CTT2, and lower AVLT were associated with greater mean adherence
and entered into the analysis. The model allows for examination of
probabilities: e.g.–if 100% of the sample indicated high stress scores,
68% of the total would be expected to report perfect treatment
adherence. If 100% of the sample had higher CTT scores, ART adher-
ence drops to 61%. 
Conclusions: Bayesian modeling is a useful, dynamic form of analy-
sis allowing us to consider what changes in a health outcome or
behavior like ART adherence might be expected with changes risk
factors such as NTI and stress.
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206Medication Assistance from Familyor Friends is Protective of Effects of
Current Substance Use on Virologic Control:
Implications for Intervention
Amy Knowlton1, Allysha Robinson1 (presenting), Mary Mitchell1,
Trang Nguyen1, Lauren Ropelewski1
1 Johns Hopkins Bloomberg School of Public Health, Baltimore,
MD, USA
Background: Informal care giving relationships have robust effects
on physical and mental health outcomes of persons with serious
chronic conditions.  Few studies have examined caregiver effects on
care recipients’ medical adherence as a potential pathway to the
health benefits of care giving relationships.  Understanding effects of
caregiver assistance on antiretroviral (ART) adherence among drug
using populations at risk for failed ART will inform interventions to
improve their HIV health outcomes.
Methods: Participants were urban current or former injection drug
using (IDU) persons on ART (n=383).  Measures included self-report-
ed assistance with medications, and various types of medication-
related assistance, in the prior year; and depressive symptoms,
assessed by the CES-D. Analysis included multivariate logistic
regression of independent variables on viral suppression.
Results: Participants reported a median of 10 years on ART, 58%
reported current drug use or alcohol misuse (including 50% current
heroin or cocaine use), 85% African American race/ethnicity, 23%
reported impaired physical functioning and 37% any assistance with
medications in the prior year, and various ways their main caregiver
assisted them with medication taking.  70% were found to be virally
suppressed.  In analysis adjusting for depressive symptoms and
other confounders, a significant interactive effect was found in
regard to associations of medication assistance and current sub-
stance use on viral suppression.  For those who reported no assis-
tance with medications, current substance use was strongly nega-
tively associated with viral suppression; for those who received med-
ication assistance, current substance use was not significantly asso-
ciated with viral suppression.
Conclusions: The findings contribute to growing evidence of the role
of informal HIV caregivers on medical adherence among vulnerable
substance abusing populations.  The study results suggest that pro-
moting informal care giving and caregivers’ resources and skills for
sustained care may be viable approaches to optimizing health out-
comes and addressing HIV health disparities among this vulnerable
population.
207Suicidal Ideation in Patients withHIV Enrolling in Clinical Trial of
Measurement-Based Depression Care
E. BYRD Quinlivan1 (presenting), Julie O’Donnell2, Brian Pence2,
Bradley Gaynes1, Riddhi Modi3, Malaika Edwards1, Amy Heine1,
Kristen Shirey2
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 
2 Duke University Center for Health Policy and Inequalities
Research, Durham, NC, USA
3 University of Alabama at Birmingham, Birmingham, AL, USA 
Background: Depression is a barrier to antiretroviral adherence for
people living with HIV (PLWH). Measurement-Based Care (MBC) is
an effective approach to expand availability, accessibility, and effec-
tiveness of antidepressant therapy in primary care settings.  As part
of a clinical trial to evaluate the use of MBC for PLWH, suicidal
ideation (SI) was assessed.  We hypothesized that a greater burden
of physical illness would be associated with SI in this population.  
Methods: Depression screening was performed with PHQ-9, which
includes questions on emotional (5), and physical (3) symptoms and
SI (1). Depression was confirmed with the Mini-International
Neuropsychiatric Interview (MINI).  Descriptive statistics and preva-
lence ratios were used to assess baseline characteristics, frequen-
cies and predictors of SI.
Results: Depression screening was completed for 1286 patients and
72 (6%) reported SI (38% with PHQ9³10; 1% with PHQ9<10).  The 245
enrolled study subjects were 44 years old (average), male (70%),
infected with HIV for >3 years (85%), had HIV suppression (65%) and
a cd4 count >500 c/mm3 (56%).  All study subjects had PHQ-9 score
>9; 71% reported no SI; 17% reported passive  SI and 12% reported
active SI and a prior history of a suicide attempt was present in 30%.
Presence of any SI was not associated with age, gender, time since
HIV diagnosis, emotional or physical symptoms, depressive severity,
HIV RNA, CD4 count; active (vs. passive) SI declined with age (PR per
10 years=0.60, 95%CI=0.42-0.86).  Prevalence risk of active SI for
those with a diagnosis for HIV <3 years was 2.18-fold compared to
those with HIV >3 years but did not reach statistical significance
(p=0.09). 
Conclusions: SI is a common symptom and plans for depression
screening must include management strategies for providers and
clinic staff who may not have experience evaluating patients with SI.
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208 Initiation of a Retention in Care(RiC) Program in a Semi-Rural
Clinic in the Southeastern United States
Erin Wispelwey1 (presenting), Anthony Bradshaw1, Alisha Gordy1,
Katherine Schafer1, Karen Ingersoll1, Rebecca Dillingham1
1 University of Virginia, Charlottesville, VA, USA
Introduction: People living with HIV (PLWH) who do not regularly see
an HIV provider risk worse personal health outcomes. This abstract
describes initiation of a clinic-level retention in care (RiC) program
that strives to better assess and address barriers to retention in care
in a semi-rural clinic.
Description: The target population was defined as all living, non-relo-
cated patients ever seen at the clinic who had not attended a visit for
>6 months. In the first three months, 105 patients were identified.
Clients were added on a rolling basis. 40(38%) were reached by tele-
phone. 65 (62%) clients have not been located. 25/40 (63%) contact-
ed clients returned to care. 18/65 (28%) not reached returned to care.
Patients reached by telephone were invited to participate in a survey
that queried them about perceived barriers to HIV care. 20/40 partic-
ipated.
Lessons Learned: Clients reached by the RiC coordinator were more
likely to return to care. However, only a minority of the clients have
been located.  Of the survey participants, gender was a predictor of
return to care (RTC). 8/9 (89%) female participants returned; 4/11
(45%) male participants returned. Those who cited scheduling con-
flicts as a significant barrier were more likely to RTC (46 % vs 14%).
Other survey questions assessing demographics and perceived bar-
riers did not identify additional significant predictors of RTC in the
current sample.
Recommendations: Establishment of a RiC program with review of all
clients ever served is feasible in a medium-sized semi-rural clinic
and results in increased RTC, even by patients with multi-year
absences. Attention to maintenance of accurate client contact infor-
mation is critical to RiC. Health system navigation assistance by a RiC
coordinator may be particularly helpful to clients who perceive that
scheduling appointments is a problem. More qualitative information
on barriers to RiC for semi-rural PLWH is needed.
209 Impact of ART AdherenceCounseling and Access to
Comprehensive Prevention with Positive
(PwP) Services for PLHWA: Experience from
STEPS OVC Project in Zambia
Gloria Ekpo1 (presenting), Kaira Wezi2, Nachela Chelwa2, 
Peter Funsani2, Shelby Benson1
1 World Vision, Washington DC, USA
2 World Vision, Lusaka, ZAMBIA
Introduction: USAID funded Sustainability Through Economic
Strengthening, Prevention and Support for Orphans and Vulnerable
Children [STEPS OVC] is a World Vision-led project with overall goal
to strengthen capacity of Zambian communities to provide sustain-
able HIV prevention, care and support services.  Assessing the
impact of adherence counseling on access to full PwP services for
PLWHA is presented in this abstract.
Description: Adherence counseling and assessment were critical
components of STEPS OVC intervention. Adherence counseling were
assesses in six areas (assessment of ART adherence, sexual activi-
ty, sexually transmitted diseases (STIs), HIV status of household
members, family planning (FP) needs and community support needs)
and clients were linked to PwP services. ART adherence also
assessed emerging ART drug resistance, body mass index (BMI),
mid-upper arm circumference (MUAC), self-report of missing doses
and spot check of ART at home.  Observations were monitored and
documented over the life of the project.  
Lessons Learned: STEPS OVC registered 390,995 OVC in partnership
with 388 local CBOs/FBOs of which 80% of the beneficiaries received
at least one care service in FY 2012.  Over same period a total of
93,020 PLHIV on ART [37,866 males, 54,154 females] received adher-
ence counseling and 34% (31,407) of these were children under 18
years. All beneficiaries were assessed for sexual activity and HIV
status of household members; 76% were assessed for STIs, 65% for
FP needs and only 4% received all six PwP package. Identified gaps
in access to full PwP services included training resources focusing
on basic care package, incomplete documentation of all services by
caregivers and mentorship for caregivers as they apply their new
PwP skills.
Recommendations: ART Adherence counseling is an essential link to
PwP services, and appropriate training resources, adequate docu-
mentation and mentorship of community caregivers are necessary in
improving access to full PwP package for beneficiaries.  
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211Development and Feasibility Testingof a Bidirectional Text Messaging
Tool to Promote HIV Treatment Adherence
among Non-Urban Substance Users
Karen Ingersoll1, Rebecca Dillingham1 (presenting), 
Jason Freeman1, George Reynolds2, Sharzad Hosseinbor1, 
Jennifer Hettema1, Chris Winstead-Derlega1, Erin Wispelwey1
1 University of Virginia, Charlottesville, VA, USA
2 Health Decision Technologies, Sheboygan, WI, USA
Background: Adherence interventions among HIV+ substance users
show moderate, temporary effects and come too late to prevent viral
rebound. Bidirectional text messaging could reach nonurban
patients to assess HIV nonadherence and respond in real time to
improve adherence.
Methods: We have developed a combined HIV adherence assess-
ment and intervention text messaging tool for non-urban drug users
with a modified ecological momentary assessment methodology.
The tool has a web interface for study staff to manage participants,
generates a message log of all communications, and sends automat-
ed text messages to participants.  Participants respond to queries
about medication adherence, mood, and substance use.  The sub-
stance use query is coded for privacy. The tool is being tested in a
pilot RCT among non-urban substance-using patients with HIV with
poor medication adherence.  The study will compare the 12-week
text messaging intervention to usual adherence care at 3M and 6M
on objective primary outcomes of Missed Visit Percentage,
Pharmacy Refill Adherence, and Unannounced pill counts by tele-
phone. 
Results: Among the first 9 patients randomized to the text messaging
condition, the system recorded 2941 sent & 1153 received messages.
Participants responded to 76% of adherence, 63% of substance use,
and 58% of mood queries. Participant-initiated messages were rare.
Medication queries resulted in responses that were 59.6% positive
and 8.5% negative, with nonresponse to 32%. Mood responses were
57% positive and 43% negative. Participants reported no
drinking/drug use in the past 24 hours to 40.3% of queries, and report-
ed substance use to 36% of queries.
Conclusions: Non-adherent people living with HIV in non-urban set-
tings responded to medication, mood, and substance use queries,
but initiated few messages. Participants responded to over half of all
queries. Patients will report poor mood and substance use, but just-
in-time reporting of nonadherence is uncommon. Nonresponse may
indicate nonadherence or episodes of drug use.
214 Self-Perceived vs. Calculated HIVRisk as Indicators of Willingness to
Use Pre-Exposure Prophylaxis
Alice Cates1, Irene Kuo1, Gregory Phillips1, Jenevieve Opoku2,
Amanda Castel1 (presenting)
1 George Washington University School of Public Health and
Health Services, Washington, DC, USA
2 District of Columbia Department of Health HAHSTA, Washington,
DC, USA
Background: Washington, DC has a generalized HIV epidemic with a
2.7% prevalence rate and all major risk groups affected by HIV. With
the availability of pre-exposure prophylaxis (PrEP), significant reduc-
tions in HIV incidence may be possible; however, uptake of PrEP by
at-risk individuals will require awareness of one’s HIV risk profile and
interest in using PrEP as an HIV prevention method. The objective of
this analysis was to compare self-perceived to actual HIV risk behav-
iors and to determine how HIV risk might impact PrEP uptake.
Methods: We surveyed clinic-attending populations at three DC loca-
tions and assessed participants’ demographics, behaviors, self-per-
ceived HIV risk, and willingness to use PrEP. Using DC HIV/AIDS case
and behavioral surveillance data for known HIV risk factors, an
objective measure of participant risk was calculated. The median
score was used to dichotomize calculated risk: no-low risk (NLR) ver-
sus moderate-high risk (MHR) categories. Distribution of calculated
risk (CR) was compared to self-perceived risk (SP) and potential dif-
ferences between the two measures were assessed in relation to
potential PrEP use.
Results: 278 participants reported their SP HIV risk; 69.1% reported
NLR and 30.9% reported MHR. On a scale of 7.5-54.2, the median CR
was 30.9 (range: 9.80-49.05). After stratification, 52.4% of participants
were at NLR for HIV and 47.6% were at MHR. There were no statisti-
cally significant differences in CR versus SP risk with regard to
potential PrEP use however there was marginally higher perception
that PrEP would be highly effective among those with a higher CR
(30.4% vs. 44.6%,  p=0.0536).
Conclusions: When asked to assess their own risk for HIV, in com-
parison to local epidemics, persons may underestimate their actual
risk for HIV. However, despite this difference in self-perceived versus
known risks for HIV, willingness to use PrEP does not vary by risk cat-
egory as hypothesized.
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216 Remotely-Delivered CognitiveBehavior Therapy and Contingent
Reinforcement of Real-Time Monitored
Adherence for Substance Using People with
HIV 
Honghu Liu1 (presenting), Brent A. Moore2, Yan Wang3, 
Jason Shen3, Karen M. Ablondi2, Anna Sullivan2, Mario Guerrero4,
Lisa Siqueiros4, Eric Daar3, Marc Rosen2
1 University of California, Los Angeles, School of Dentistry, Los
Angeles, CA, USA
2 Yale University, New Haven, CT, USA
3 University of California, Los Angeles, Los Angeles, CA, USA
4 Los Angeles Biomedical Research Institute, Los Angeles, CA,
USA
Background: Substance using HIV patients are at risk for non-adher-
ence, and most  interventions have had modest effects. Contingency
Management (CM) is a promising intervention but requires face-to-
face visits and its effects have not been maintained after discontinu-
ation. We hypothesized the improvement in adherence from remote-
ly-delivered CM could be maintained if it was combined with
Cognitive Behavior Therapy (CBT), a substance abuse treatment that
has been associated with a sustained and post-treatment benefit.
Methods: The Centralized Off-site AdheRence Enhancement (CARE)
program involved real time transmission of bottle-opening data from
a Wisepill device to a website system which generated instant text
messages to patients’ phones indicating the amount of cash-rein-
forcement earned if medication was taken within a specified time
with monetary reinforcement wired to patients’ debit card. Real time
reinforcement of medication-taking was coupled with twelve ses-
sions of CBT by phone.
Results: Eight were recruited to pre-pilot the system. Patients were
predominately male (75%) and Latino (62.5%), with median age 44.5
years. The intervention was well-received with good participation
and retention (2/8 completed the pre-pilot with 97.6% and 91.6% per-
fect adherence days). Patients were engaged by the CM and tracked
their adherence and payments; however, motivation for substance
abstinence was inconsistent. Issues in remotely-delivered therapy
included having to resolve discrepancies between patient’s reported
adherence and WisePill reports, and logistics of communicating with
people with fluid living arrangements and cell phone plans. Available
pilot data up to June 2013 will be presented at the conference.
Conclusions: The adherence pattern of the substance user popula-
tion improved not only on taking the dose every day but reduce the
dose timing error. CARE appears to be engaging and feasible.  It is
important to define therapist, patient, and site clinician roles prior to
implementation as some logistic issues cannot be negotiated by
phone with this patient population. 
217 A Randomized Controlled TrialProtocol to Evaluate the
Effectiveness of an Integrated Care
Management Approach to Improve
Adherence among HIV-Infected Patients in
Routine Clinical Care
Heidi Crane1 (presenting), Rob Fredericksen1, Paul Ciechanowski1,
Shireesha Dhanireddy1, Robert Harrington1, Jennifer Magnani1, 
Kari Nasby1, Bill Lober1, Justin McReynolds1, Jane M. Simoni1,
Steven A. Safren2, James Tufano1, Donald Patrick1, Mari Kitahata1,
Paul Crane1
1 University of Washington, Seattle, WA, USA 
2 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
Introduction: Many adherence intervention trials exclude psychoso-
cially complicated patients including those with substance use or
depression and therefore do not consider many of the patients with
inadequate adherence encountered in clinical settings. Additionally,
many interventions are time-intensive and not feasible for routine
care. Here we describe the design of an on-going randomized con-
trolled trial (RCT) and the rationale for key methodologic decisions.
Description: We are conducting an RCT to determine the effective-
ness of an integrated care management adherence intervention as
part of HIV care. This study is based on routine integration of patient-
reported outcomes (PROs) and an adaptation for clinical care of a
previously tested care management approach. The intervention
includes healthcare delivery team notification of PRO results (includ-
ing measures of adherence and adherence barriers such as depres-
sion) along with targeted care management using a stepped-care
approach with problem solving therapy (PST) for those with persist-
ent issues. Care management is provided by clinic case managers
enhancing generalizability to other HIV clinical sites.
Lessons Learned: We implemented PROs including adherence meas-
ures as part of routine clinical care which facilitated conducting this
trial in a clinical setting. We use a stepped-care approach allowing
interventions tailored to patient needs. PST and more intensive inter-
ventions are costly and time-consuming. The stepped-care approach
allows us to target these interventions to those with the greatest
needs, thereby enabling the incorporation of these tools into a busy
clinical practice.
Recommendations: There is little data to guide implementation of
adherence interventions into clinical care settings. Focusing on
interventions that are both effective and feasible will help bridge the
gap between research and clinical care, develop practice-informed
science, and improve care.
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219 HIV Elimination Potential via TasPIs Determined by R0 More Than
Early Transmission Fraction
James Koopman1 (presenting), Christopher Henry2, 
Michael Hiyashi2, Marisa Eisenberg1
1 University of Michigan, Ann Arbor, MI, USA
2 Deptartment of Epidemiology, University of Michigan, Ann Arbor,
MI, USA
Background: The debate on potential TasP effects often assumes
there is a direct relationship between the number of transmissions
that can be prevented per individual receiving prevention services
and the total effects in the population. That is not the case, however,
when two realistic aspects of HIV transmission systems are added to
models.  The two model aspects are dynamic partnerships and indi-
vidual changes in casual sex risk behavior across time.  
Methods: A model is presented to illustrate how and why these
aspects of reality change what TasP can do. 
Results: In systems where most transmissions occur within partner-
ships formed between infected and uninfected individuals, as low as
4% of transmissions might occur in early infection. That is because
new partners are usually beyond acute infection and they cannot
transmit back to the partner that infected them. But at these low early
infection transmission fractions, other aspects of the system can
make it TasP sensitive or resistant. When most transmissions occur
during episodes of high risk casual sex behavior, as many as 77% of
transmissions can occur during early infection. That is because high
risk behavior and early infection coincide and because high risk set-
tings get an influx of high risk susceptible individuals. Again, howev-
er, systems with these high rates of early infection can be TasP sen-
sitive or resistant. A new way of formulating R0 and the relationship
between endemic levels of infection and R0 explain TasP sensitivity.
These relationships demonstrate how TasP population level effects
can be high given low fractions of transmission prevented in individ-
uals and vice versa.  
Conclusions: Various implications of this for organizing HIV preven-
tion services will be discussed.  A major implication is that surveil-
lance using genetic sequences and partner services data is needed
to focus control efforts effectively.
221Measurement of Self-ReportedAdherence Behaviors Across
Multiple Chronic Diseases
Heidi Crane1 (presenting), Matt Jackson1, Jane M. Simoni1, 
Susan Yount2, Kenneth Mayer3, Donald Patrick1, Elizabeth Hahn2,
Honghu Liu4, Ira B. Wilson5, Matthew Mimiaga3, Niko Lazarakis1,
Sofia Garcia2, Rob Fredericksen1
1 University of Washington, Seattle, WA, USA
2 Northwestern University, Chicago, IL, USA
3 The Fenway Institute, Boston, MA, USA
4 University of California, Los Angeles, School of Dentistry, Los
Angeles, CA, USA
5 Brown University, Providence, RI, USA
Introduction: Detection of inadequate medication adherence prior to
the development of poor outcomes remains one of the most impor-
tant and elusive goals in the treatment of patients across many
chronic diseases. We need valid, accurate, and effective measures
to collect self-reported adherence information for use both in clinical
research and clinical care. Lack of a practical, systematic and cross-
disease approach to self-reported adherence assessment is a criti-
cal gap in our healthcare delivery system.
Description: To develop a medication adherence behavior item pool
for patient populations across multiple chronic diseases, we
reviewed and assembled adherence instruments and items across
multiple chronic disease conditions (e.g. HIV, diabetes, hypertension,
dyslipidemia, transplant, epilepsy, etc.) with a particular focus on for-
mat, recall period, and self-rating items.
Lessons Learned: In assembling adherence behavior items used
across disease conditions to develop an item pool, we found that a
surprisingly large number and complex array of adherence behavior
dimensions were being asked of patients such as frequency, missing
partial doses, stopping therapy, avoiding medications, taking only if
feeling sick/well, dose adjustments, etc. This increasing complexity
was noted across several chronic diseases in contrast to the
increasing simplicity of some measures used in HIV. There was a
lack of consistency regarding which dimensions were measured
across different diseases as well as varying time-frames and
response task variability. Within specific dimensions, there was little
or no consistency regarding how items were asked even within spe-
cific diseases.
Recommendations: We need valid, accurate, and effective measures
to collect self-reported adherence for use both in clinical research
and clinical care. Facilitating better communication regarding adher-
ence measurement across diseases will facilitate advances made in
one chronic condition leading to improvements in care across other
diseases. Ideally, adherence measurement will be considered more
broadly across chronic diseases, with less isolated development. 
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223 Cultural, Ethnic, andSocioeconomic Issues in Treatment
Initiation and Adherence 
Dattatraya Bant1 (presenting)
1 Karnataka Institution Of Medical Sciences, Hubli, Karnataka,
INDIA
Background: Adherence to ART is a key issue in reduction of ART
failure despite of free supply. The present study  focusing on  cultur-
al, ethnic, and socioeconomic issues  to measure the adherence
rates in PLWHA on  ART treatment and regimen
Methods: 484  PLWHA aged 15 to 49 years on ART excluding serious-
ly ill cases, were studied after their consent in this longitudinal study
from December 2008 to November 2012. The patients were followed
for 6 months for adherence, & factors affecting adherence. The data
was tabulated & analyzed using Microsoft excel & SPSS 14 version.
Statistical analysis: Chi square test, Fischer’s exact test, Logistic
regression
Results: Among the 484 study population, Females (55%) preponder-
ance, illiterates from rural areas (62%), unskilled by occupation (64%)
& being from poor socioeconomic status (85.9%) were common.
31.6% were consistent adherers, & 81.4% had ³ 95% adherence after
6 months of ART. Common reasons for missing doses were forgetful-
ness (44.9%), depression (22.5%), fear of disclosure (21.5%), adverse
effects (17.1%), Loss of interest, loss of hours of job, myths & miscon-
ceptions about ART etc. Patients belonging to BPL families {Adjusted
Odds Ratio (AOR) 3.763}, feeling burden to travel to ART centre (AOR
5.383), & CD4 counts at initiation (AOR 1.007) were negatively associ-
ated with adherence, while CD4 count increase after treatment (AOR
1.007), weight increase after treatment (AOR 1.277), being an earning
member (AOR 2.865) were positively associated with adherence.  
Conclusions: Suboptimal Adherence was noted in 81.4 % of PLWHA.
Economic factors affect non adherence more than psychological &
other health factors.  There needs to be focus on female literacy,
decentralizing ART services, economic incentives to PLWHA
throughout treatment period, adopting DOT strategy as in
Tuberculosis  & on increasing the adherence levels of the patients to
achieve lesser ART failures.
227Accessing and Adhering to MedicalCare after Prison Release: The
Individuals Motivating to Participate in
Adherence, Care, and Treatment (imPACT)
Trial
Carol Golin1 (presenting), Catherine Grodensky2,Jennifer Groves1,
Jessica Carda-Auten1, Becky L. White1, Cathie Fogel1, 
David Rosen1, Lynn Tillery2, Makisa Ruffin2, Madeliene McCrary2,
Kemi Amola2, Steve Bradley-Bull2, Steve Bradley-Bull2, 
Michele Gould3, Kevin Knight3, Patrick Flynn3, David Wohl1
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 University of North Carolina Center for AIDS Research, Chapel
Hill, NC, USA
3 Texas Christian University, Fort Worth, TX, USA
Background: Health benefits of effective HIV care provided in prison
are often lost after release due to poor utilization of medical care. To
address these issues, programs to help HIV-infected released pris-
oners access, utilize, and adhere to medical care are needed.
Methods: We used formative studies and theory to develop imPACT,
a program to help released prisoners access, use, and adhere to HIV
care after prison release. Four main components include: 1) Videos
to prepare for release; 2) Motivational Interviewing (two in-prison in-
person and six post-release phone sessions); 3) Link coordination to
schedule medical appointments within 5 days of release; and 4) med-
ication text reminders. Virally suppressed prisoners on antiretrovirals
from two states were randomized into a controlled trial of imPACT.
Unannounced phone pill counts are used to measure antiretroviral
adherence.
Results: As of February 17, 2013, 118 participants had enrolled. Mean
age was 42 years; 47% had not graduated high school; 74% were
African American, 8% Latino, 21% women. Of the 63 in both arms who
had completed 2 weeks post-release follow-up, 6 (10%) were work-
ing and 26 (41%) seeking work, 12 (19%) had stable housing; 48 (76%)
had attended a medical visit, and 19 (30%) self-reported missing a
dose of antiretrovirals. Of the 26 who had reached 6 weeks post-
release, 42% had stable housing, 15% were working and 35% seek-
ing work. 85% had attended at least one medical visit but 54% report-
ed missing antiretroviral doses in the previous 2 weeks; 35% report-
ed missing 4 or more doses.
Conclusions: Program components to help HIV-infected prisoners
transition and adhere to care outside of prison are being implement-
ed successfully in this trial. Longer term follow-up with the full sam-
ple comparing intervention and control groups will illuminate the
intervention features associated with positive health outcomes,
including viral load.
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228 Adherence and HypertensionControl in Patients with HIV
Infection
Jeffrey Weiss1 (presenting), Melissa Martynenko1, 
Katherine Levin1, Marlene Alcorn2, Grace Mhango1, Daniel Fierer1
1 Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 Boston University School of Medicine, Boston, MA, USA
Background: Hypertension is a common condition in patients with
HIV infection that is often not adequately controlled. The role of med-
ication adherence has not been studied.
Methods: Adult patients on medication for HIV infection and hyper-
tension were recruited from outpatient HIV practices at a NYC aca-
demic medical center. Electronic monitoring (MEMS) was used to
measure medication adherence for one ARV medication and one
anti-hypertensive over ten weeks.
Results: We recruited 115 patients (59% male) with a mean age of
53.5(s.d.=8.5); 57% of patients were black, 32% Hispanic, 10% white.
The mean CD4+ cell count is 603 cells/mL(s.d.=286) and 94% have
well controlled HIV infection(<400 copies/mL). Rates of medication
adherence are high for both ARVs and anti-hypertensives [mean HIV
=91.8%(s.d.=14.3); mean anti-hypertensive =89.2(s.d.=18.5)] and high-
ly correlated (r=0.78; p<0.01). Of those with well-controlled HIV infec-
tion, 38% have poorly controlled hypertension (systolic > 139 or dias-
tolic > 89 mmHg). Subjects self-reported their illness perceptions and
medication beliefs for HIV/ARVs and hypertension/anti-hyperten-
sives. Subjects reported greater perceived need for ARVs (4.0 vs. 3.5,
p<0.01) compared to anti-hypertensives and greater concern about
taking ARVs (2.4 vs. 2.2, p<0.01). Illness perceptions differed on mul-
tiple dimensions (p < 0.01) with HIV being viewed as less controllable
by medication (3.7 vs. 3.9), more understood (4.0 vs. 3.7), more chron-
ic (3.2 vs. 2.7), eliciting more emotions (2.8 vs. 2.3), and having more
consequences (3.3 vs. 2.8) than hypertension. There was no differ-
ence between degree of personal control over HIV and hypertension
(4.0 vs. 4.0; p>0.99).
Conclusions: Rates of adherence to ARVs and anti-hypertensives are
high in this urban sample and highly correlated. Despite this, hyper-
tension is not as well controlled as HIV. Patients view HIV as a more
significant concern than hypertension. Efforts to improve hyperten-
sion control are needed as it is a risk factor for cardiovascular dis-
ease.
231Mobile Phone Ownership andAppointment Attendance among HIV
Care Clients in Swaziland Prior to an SMS
Appointment Reminder Pilot - A Baseline
Charles Azih1 (presenting), Sicelo Zondo2, Idris Bello3, Anne Pao3,
Vera Habedi3; Elizabeth Swanton3, Jacqueline Papo3, 
Velephi Okello2, Alison End3
1 Swaziland National AIDS Program, Ministry of Health -
Swaziland, Mbabane, SWAZILAND
2 Ministry of Health, Mbabane, SWAZILAND
3 Clinton Health Access Initiative, Mbabane, SWAZILAND
Background: To improve appointment attendance among ART and
pre-ART patients in Swaziland, the Automated Patient Appointment
(AP) Reminder pilot was launched in five health facilities and 35 affil-
iated primary healthcare clinics (PHC). The AP Reminder automati-
cally sends SMS messages to clients two days before their appoint-
ments, with prior consent. An analysis was conducted to investigate
mobile phone ownership and appointment attendance before the
pilot - “setting the baseline”.
Methods: Datasets from the existing HIV patient electronic medical
records system were extracted from pilot facilities. Using Excel,
Access and STATA, an analysis was carried out for the 12-month
period preceding the pilot (April 2011-March 2012).
Results: Of the 21,810 HIV patients, females comprised 65%. Among
ART patients, mean time since ART initiation was 33 months. Of the
documented 131,473 client visits, mean number of visits/patient/year
was 6. Mobile phone ownership was 66%, reaching 75% including
treatment supporters when a clients’ number was unavailable.
Phone ownership varied by age (lowest among 2-14 years) and
health facility type (lower in PHCs than secondary/tertiary). Total pro-
portion of patients lost to follow-up (>90 days late, not returned into
care) was 9%, reaching 14% among patients initiated 6 months prior,
and 19% for patients initiated 1 year prior. Among scheduled appoint-
ments kept (n=112,730), 77% attended on exact date, while 88% were
considered on-time (7 days early - 2 days late). Appointment timeli-
ness was similar across gender and mobile phone ownership. For the
12% attending late, mean number of days late was 25.0, and was
greater in PHCs (35.6 days) than secondary/tertiary facilities (18.7
days).
Conclusions: The combination of loss to follow-up, missed appoint-
ments, and mobile phone ownership provides opportunity for the AP
Reminder to be impactful on appointment attendance, and possibly
adherence to care and treatment. This finding provides an important
pre-intervention baseline for the SMS appointment reminder inter-
vention.
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234 Women and Suboptimal ART Adherence in High-Income
Countries
Cathy Puskas1 (presenting), Wendy Zhang2, Benita Yip2, 
Kate Salters2, Angela Kaida1, Cari Miller1, Bob Hogg2, 
Julio Montaner2
1 Simon Fraser University, Burnaby, BC, CANADA
2 BC Centre for Excellence in HIV/AIDS, Vancouver, BC, CANADA
Background: Women have been observed to be more vulnerable to
suboptimal adherence than men in high-income countries.  In British
Columbia (BC), we explored whether this was because women were
disproportionately from sub-populations where barriers to adher-
ence are higher irrespective of gender.  
Methods: Analysis was limited to HIV-positive, antiretroviral naïve
adults 19 years and older in BC who initiated therapy from 1996 on.
Optimal adherence was defined as taking ³95% of prescribed anti-
retrovirals in each 6-month period.  Viral suppression was defined as
<500 copies.  A longitudinal regression confounder model was con-
structed to determine whether gender was a significant predictor of
suboptimal adherence after adjusting for Aboriginal identity, injec-
tion drug use (IDU), and year of first HAART use. An additional con-
founder model explored the relationship between viral suppression
and suboptimal adherence after adjusting for gender, IDU, Aboriginal
identity and year of first HAART use.
Results: A total of 2,443 individuals who initiated antiretroviral thera-
py between July 1996 and September 2010 were included in the
adherence model.  Of these, 486 (20%) were women, 1,241 (50.8%)
were injection drug users, and 581 (23.8%) were of Aboriginal
descent.  Mean proportion adherent was 60.0% among men and
40.0% among women.  Viral load suppression was significantly cor-
related with optimal adherence after adjusting for confounders.
Women were less likely to adhere after adjusting for IDU, Aboriginal
identity, and calendar year (OR: 0.63; CI: 0.52 to 0.75; p-value<0.001).
When sub-populations were compared, we observed that women
were less likely to adhere across all sub-groups, however, only
among non-IDU Aboriginal women was it not significant.   This was
likely due to small numbers, as the OR remained less than one.   
Conclusions: In BC, like other high-income settings, women are less
likely to adhere to therapy than men.  This relationship appears to be
independent of IDU, Aboriginal identity, and calendar year.
235 Impact of a Continued ActiveIntervention Strategy on Adherence
to Antiretroviral Therapy in Children Living
with HIV 
Erica Stankievich1 (presenting), Adriana Malanca1, Irene Foradori1,
Silvina Ivalo1, Marcelo Losso1
1 Hospital General de Agudos “Ramos Mejia”, Buenos Aires,
ARGENTINA
Background: Since antiretroviral therapy (ARV) has been successful-
ly introduced, the infection has become a chronic manageable dis-
ease. Adherence is critical to achieve the benefits of the treatment.
Multiple aspects, including social and psychological issues, as well
as pediatrics formulations, affect adherence.  There is limited evi-
dence of strategies to improve children`s adherence. The aim of this
study is to evaluate the effects of a strategy, active intervention (AI),
to improve ARV adherence in pediatrics.
Methods: A prospective study is being conducted in an HIV clinic.
Patients having ARV with suboptimal adherence (SOA) were identi-
fied. AI strategy consists in individual psychological interviews with
patients and their caregivers, monthly workshops (WS) and tele-
phone calls, during a 2 year period. To assess AI effect, viral loads
were measured prior to initiation AI and after 6 months period. The
results of this ongoing study are presented in this preliminary analy-
sis.  
Results: Thirteen of 38 patients on ARV were identified SOA. Mean
age was 9.38±4.56 years (range 4-16); 10 (76%) were female. Baseline
viral load was >1000 copies/ml in all, 69% were class A of CDC HIV
classification. Five of 8 patients older than 6 years knew their diagno-
sis. Prior to the AI strategy the mean number of clinical visits per year
was 5±3.59. Mean time to access to clinic was 1.40 hours (range: 0.5-
2.5). Twelve were cared by their parents. After 6 months of AI, mean
psychological interviews was 4.53±2.43, mean participation at WS
was 1.53, and a mean of  2.7 telephone calls/patient were done. After
6 months, viral load was <1000 c/ml in 7 patients.
Conclusions: An individual active intervention on children and their
caregivers to improve adherence could positively impact viral load
improving the course of the disease. Longer follow up time is needed
to evaluate the effects of this intervention. 
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236What are the Barriers toAntiretroviral Adherence in People
from UK Black-African and Black-Caribbean
Communities? A Qualitative Study
Elizabeth Poliquin1 (presenting), Rob Horne2
1 University College London, London, UNITED KINGDOM
2 University College of London, School of Pharmacy, London, 
UNITED KINGDOM
Background: In the UK nearly one third of those initiating antiretro-
viral therapy (ART) report suboptimal adherence within 6 months.
Substantial numbers of people of black African (UKBA) and black
Caribbean (UKBC) heritage access HIV care, and identifying barri-
ers to their adherence is a priority.
Methods: A cross-sectional, qualitative interview study explored bar-
riers to adherence in 50 people living with HIV (PLWH) (43 UKBA, 7
UKBC) with a history of incomplete ART adherence. Purposive sam-
pling ensured representation in terms of gender and symptomatic
status.  Interviews were subjected to thematic analysis.
Results: From the poorly adherent patient’s perspective, ART acts as
a barrier to achieving/maintaining a good quality of life in its various
domains. Physical wellbeing. PLWH associated ART, rather than HIV,
with poorer physical health including the experience of side effects
and pain. Psychological wellbeing. ART was a constant reminder of
HIV which had negative connotations on how PLWH viewed them-
selves and how they perceived others saw them. Feelings of shame
associated with ART added to difficulty in committing to treatment.
Social relationships.  The meaning of being on ART and its conse-
quences, including stigma, ostracism, and homelessness, impacted
on adherence over and above the consideration of the specific ben-
efits (e.g lower viral load) and costs (e.g side effects).Independence.
ART was associated with the loss of autonomy, forcing PLWH to rely
on medication and doctors. Spirituality. For some PLWH dependence
on ART attested to not being sufficiently deserving of miraculous
healing.
Conclusions: Along with some culturally unique issues, some of the
factors common to other populations with HIV can act in complex
ways within these cultural settings. Representations of ART, which
from a clinical perspective appeared to be misplaced, had a com-
mon-sense rationale. Interventions to improve ART uptake/adher-
ence are likely to be more effective if they take into account these
representations.
237 Cell Phones to Augment Study VisitRetention for HIV+ Individuals
Recently Released from Prison Participating
in the imPACT Study
Jessica Carda-Auten1 (presenting), Michele Gould2, David Wohl1,
Carol Golin1, Jennifer Groves1, Becky L. White1, Brian Pence3,
Michael J. Mugavero4, Cathie Fogel1, David Rosen1, 
Catherine Grodensky5, Lynn Tillery5, Makisa Ruffin5, 
Madeliene McCrary5, Kemi Amola5, Steve Bradley-Bull5, 
Lisa McKeithan5, Kevin Knight2, Patrick Flynn2
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 Texas Christian University, Dallas-Fort Worth, TX, USA
3 Duke Global Health Institute, Center for Health Policy and
Inequalities Research, Durham, NC, USA
4 University of Alabama, Birmingham, AL, USA
5 University of North Carolina Center for AIDS Research, Chapel
Hill, NC, USA
Background: HIV+ individuals released from prison are a challenging
population to study longitudinally, with relatively high rates of loss to
follow-up expected as participants navigate community re-entry.
Cell phones are a useful method for communication with study par-
ticipants through voice and text messaging.  The imPACT Study is an
RCT of an intervention based on motivational interviewing (MI), link-
age to care, and cell phone text medication reminders, designed to
maintain HIV suppression among HIV+ prison releasees in NC and
TX.  Within 48 hours of release, cell phones are provided to both the
intervention (for phone-based MI, text medication reminders, unan-
nounced pill counts, and study visit reminders) and control arms (for
unannounced pill counts and study visit reminders).  
Methods: We examined retention and study visit adherence among
imPACT participants in NC.  Adherence to study visits (number
attending visit/number eligible for that visit) at weeks 2, 6, 14 and 24
post-release was assessed, as was loss to follow-up.
Results: Of the 60 participants enrolled to date, 45 (23 in intervention
arm) have been released.  Most are men (73%) and African-
American (84%); median age is 45 years.  Study visit adherence is
listed below.
Study Visit Adherence (%)
Week 2 34/38 (89.5%)
Week 6 27/29 (93.1%)
Week 14 18/20 (90%)
Week 24 6/8 (75%)
Two participants have been lost to follow-up including one who did
not receive a cell phone.  Two others have been missing since
release, neither received a phone.  One participant’s phone was
reported as stolen, and he has been missing since. Research staff
report cell phones have been critical to retention in both study arms. 
Conclusions: Providing cell phones to HIV+ former prison inmates is
feasible.  Cell phones facilitate contact with participants, and may be
associated with retention in both the intervention and control arms of
this study. 
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238 The Impact of Behavioral andClinical Factors on Associations
Between Age and Medication Adherence:
Age Moderates the Substance Use-
Adherence Association 
Heidi Crane1 (presenting), Steven A. Safren2, Matthew Mimiaga3,
Rob Fredericksen1, Michael J. Mugavero4, James Willig4, 
Greer Burkholder5, W. Chris Mathews6, Katerina Christopoulos7,
Stephan Boswell3, Mari Kitahata1, Jane M. Simoni1, Michael Saag4,
Kenneth Mayer3
1 University of Washington, Seattle, WA, USA
2 Massachusetts General Hospital/Harvard Medical School,
Boston, MA, USA
3 The Fenway Institute, Boston, MA, USA
4 University of Alabama, Birmingham, AL, USA
5 Division of Infectious Diseases, University of Alabama at
Birmingham, Birmingham, AL, USA
6 University of California, San Diego, San Diego, CA, USA
7 University of California, San Francisco, San Francisco, CA, USA 
Background: Prior research, limited by smaller studies and lack of
psychosocial variables, has often demonstrated higher levels of anti-
retroviral therapy (ART) adherence among older patients. This study
examines differences in rates and predictors of adherence focusing
on older and younger patients in clinical care in the era of an aging
HIV-infected patient population.
Methods: Patients complete a touch-screen-based assessment
including ART adherence (self-rating scale), drug/alcohol/tobacco
use, depression, anxiety, health-related quality-of life (HRQL) and
sexual risk behavior measures as part of care. Data from 5 CNICS
sites (Seattle, Boston, Birmingham, San Diego, San Francisco) were
included. We used separate generalized estimating equations by age
category with robust standard errors adjusting for demographic and
clinical characteristics including all illicit substances, at-risk alcohol
use, and binge drinking. Our primary outcome was ART adherence.
Results: 8,879 assessments were completed by 3,831 patients <40
and ³50 years of age receiving ART. Similar associations were found
with adherence for many clinical characteristics among patients <40
and ³50 years of age in adjusted analyses including clinical charac-
teristics, depression, and HRQL (p values <0.001-0.015). Although
rates of binge alcohol use differed by age category, when present a
similar negative association was found with mean adherence in both
age groups (p values 0.02-0.04). In contrast, the associations of cur-
rent and past substance use with adherence differed by age. For
example, current amphetamine use was associated with poorer
adherence in both age groups (p values <0.001), but among older
patients, current cocaine/crack use was associated with even lower
adherence than amphetamine use. Current marijuana use was asso-
ciated with poorer adherence only among younger patients (p values
0.02 vs. 0.4) 
Conclusions: The impact of substance use and other risk factors that
influence adherence differ across age groups. Understanding these
differences will facilitate directed interventions as HIV-infected
patient populations continue to age. 
239WelTel Retain PreliminaryQualitative Investigation of
Healthcare Provider and Patient Perceptions
Kirsten Smillie1 (presenting), Abigael Lukhwaro2, David Ojakaa2,
Natasha Van Borek1, Mia van der Kop3, Neville Li1, Helen Gakuru2,
Sarah Karanja4, Richard Lester5
1 BC Centre for Disease Control, Vancouver, BC, CANADA
2 African Medical and Research Foundation, Nairobi, KENYA
3 Karolinska Institutet, Sweden, Vancouver, BC, CANADA
4 University of Nairobi, Nairobi, KENYA
5 University of British Columbia/BC Centre for Disease Control,
Vancouver, BC, CANADA
Background: As access to antiretroviral therapy (ART) continues to
expand throughout sub-Saharan Africa, levels of patient retention in
care have become widely recognized as critical to the success of
HIV care and treatment programs. Widespread cell phone use pres-
ents new opportunities to develop strategies to engage patients in
care. As part of a study testing the effectiveness of the WelTel text
messaging intervention to promote pre-ART patient retention in care,
we conducted a qualitative study involving patients and healthcare
providers to inform implementation of the text message intervention.
Methods: Semi-structured interviews were conducted with five
healthcare providers and fifteen patients. Healthcare providers were
eligible to participate if they were employed at the Kibera Community
Health Centre (KCHC), Nairobi, Kenya. Patients were eligible if they
were a KCHC client, ³18 years, and HIV positive. Interviews were
conducted in English, with a translator fluent in Kiswahili and English
present to assist. The interviews were recorded, translated into
English, and transcribed verbatim. Two researchers read the tran-
scripts and coded for important concepts, events, and experiences
using NVivo software. Interview data was analyzed using thematic
analysis.
Results: Patients discussed the importance of being treated with
respect and dignity by healthcare providers when they attended a
clinic, and recalled a number of instances when poor service led
them to seek care elsewhere. Patients and healthcare providers
were excited at the prospect of communicating through text messag-
ing. Healthcare providers anticipate having a better understanding of
patients’ individual concerns if in contact on a more regular basis,
and patients appreciate the potential of having questions answered
without having to travel to the clinic.
Conclusions: Establishing open and regular communication via text
messaging was thought by both groups to be a viable and positive
approach to increasing and maintaining patient engagement in care
in a pre-ART setting.
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241Does Literacy Level Moderate theEffects of Behavioral Interventions
on MEMS-Measured Antiretroviral
Adherence: Combined Results from Two
MACH14 Trials
Carol Golin1 (presenting), Judith Erlen2, Yan Wang3, Lisa Tamres2,
Robert Remien4, Nancy Reynolds5, Marc Rosen5, Jane M. Simoni6,
Honghu Liu7
1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2 University of Pittsburgh, Pittsburgh, PA, USA
3 University of California, Los Angeles, Los Angeles, CA, USA
4 Columbia University, New York, NY, USA
5 Yale University, New Haven, CT, USA
6 University of Washington, Seattle, WA, USA
7 University of California, Los Angeles, School of Dentistry, Los
Angeles, CA, USA
Background: Low health literacy level has been linked to poor health
outcomes in several settings. Interventions that mitigate literacy
have shown mixed results in their effect on health outcomes. We
sought to understand the extent to which health literacy may moder-
ate the effects on adherence of antiretroviral interventions that are
not specifically designed to mitigate low literacy. 
Methods: Data were pooled from the two randomized, controlled
clinical trials of adherence-focused behavioral interventions that
also measured health literacy in the Multi-site Adherence
Collaboration on HIV (MACH14) study.  The primary outcome was the
dichotomous variable “achieving at least 95% electronically-moni-
tored mean ART adherence” (defined as percent of prescribed doses
taken) at twelve weeks following baseline from 429 patients.  In both
studies, health literacy was assessed using the Test of Functional
Health Literacy Assessment short form (TOFHLA-S). We conducted
multivariate regression analysis including an interaction term for
intervention group arm and TOHFHLA score (possible range 0-36),
and control covariates of age, gender, education, ethnicity, income,
and employment status.
Results: Adherence was similar across groups (70% intervention,
72% controls > 95%). Average TOFHLA scores varied widely within
the total sample (Mean 32.8, SD 4.81, range = 2-36), but were similar
across the intervention (Mean 33, range 12-36) and control (M = 32.4;
range 2-36) groups. After controlling for potential covariates and
intervention status, logistic regression revealed that literacy was a
significant predictor of >95% adherence (OR = 0.926; 95% CI = 0.880,
0.974), but the interaction between intervention status and TOFHLA
was not.
Conclusions: Literacy was a significant independent predictor of
medication adherence, but literacy level did not moderate the rela-
tionship between intervention status and adherence. Even high qual-
ity adherence interventions are unable to overcome literacy’s impact
on adherence. Better strategies to overcome literacy’s deleterious
impact are needed.
242 Private Facebook Groups:Leveraging Technology to Increase
Social Connectivity and Maximize Retention
in HIV Care
Jen McMillen Smith1 (presenting), Ann Avery1
1 The MetroHealth System, Cleveland, OH, USA
Introduction: Social networks can positively impact health. People
who are socially integrated live longer (Cohen and Janicki-Deverts,
2009) and have better prognoses for chronic illnesses, conversely,
those who are the most isolated are the most likely to have poorer
health (House, Landis & Umberson, 1988). People living with
HIV/AIDS (PLWHA) are vulnerable to isolation, thus arguably, poorer
health, in part because of the stigma our society still places on HIV.
Description: In 2012, MetroHealth collaborated with Blue Star
Design, who specializes in graphic, web and social media design, to
develop a Facebook group exclusively for PLWHA. Using a private
Facebook (FB) group allows us to accomplish 3 aims: 1) connect with
our patients in the way they connect with each other, 2) provide well-
ness messaging with a focus on retention in care, and 3) market
social-service programs for PLWHA in order to strengthen their
social networks with a group of peers who will be supportive. 
Daily posts are utilized for: reminding participants about support and
education groups, linking to interesting HIV-related articles and/or
websites, providing wellness messaging, and encouraging members.
Members can post and comment, and often use the group to garner
support for HIV-related issues, for example; relationships and disclo-
sure, starting and/or adhering to HIV meds, and sharing happy news
or struggles.
Lessons Learned:
• Utilize FB privacy settings so the group isn’t searchable.
• Use a “pass-through” friend to identify people to invite into the
group.
• Organizations (including ASOs) are not accepted.
• Develop policies for what participants can post and participation
guidelines.
• Use a content schedule to plan posts in advance.
Recommendations: The next step is to evaluate participant satisfac-
tion and impact on self-assessment of health.
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243 Implementation of Routine Collectionof Patient-Reported Data and
Outcomes (PROs) in Clinical Care: Findings
from CNICS (CFAR Network of Integrated
Clinical Sciences) and CHARN (Community
Health Applied Research Network)
Heidi Crane1 (presenting), Rob Fredericksen1, Daniela Lembo2, 
Kari Bichell3, Bill Lober1, James Willig4, Michael J. Mugavero4,
Greer Burkholder5, Justin McReynolds1, Robbie Singal6, 
Mari Kitahata1, Michael Saag4, Kenneth Mayer6
1 University of Washington, Seattle, WA, USA
2 Beaufort-Jasper-Hampton Comprehensive Health Services,
Ridgeland, SC, USA
3 Chase Brexton, Columbia, MD, USA
4 University of Alabama at Birmingham, Birmingham, AL, USA
5 Division of Infectious Diseases, University of Alabama at
Birmingham, Birmingham, AL, USA
6 The Fenway Institute, Boston, MA, USA
Introduction: PROs including adherence enhance patient-provider
communication, improve care, and facilitate research.  However,
there are barriers to collecting PROs in clinic settings.  We previous-
ly described PRO implementation in HIV clinics.  Here we provide an
update on PRO collection, describe the impact on clinical care for
HIV-infected patients, and describe methods and challenges of
expanding routine self-reported PRO collection to several communi-
ty health clinics. 
Description: Patients presenting for routine care use touch-screen
tablet PCs to complete a survey including adherence, depression,
drug/alcohol/tobacco use, and HIV risk behavior. Providers receive
feedback immediately prior to the patient’s visit. We use an open-
source, non-proprietary web-based survey software application.
The system tracks patient eligibility and time since last assessment.
Emphasis is placed on not disrupting clinic workflow. We have pilot-
ed the reporting of PRO data into an electronic health record.
Lessons Learned: We demonstrated the feasibility of collecting PROs
in busy, multi-provider HIV clinics across the US and have recently
expanded to several non-specialty community health clinics.  Over
21,000 PRO assessments have been completed to date providing a
tremendous resource of data for clinical care and research. We
found a high prevalence of poor medication adherence, moderate-
to-severe depression, substance abuse, and high symptom burden.
Features such as real-time, automated pager notification when
patients indicate suicidality are especially valuable.  Among patients
with HIV, PRO feedback improved provider awareness and/or actions
for adherence, depression, alcohol, and substance use but not for
sexual risk behavior. Tailored implementation approaches were
required for community health clinics vs. HIV specialty clinics. 
Recommendations: We have demonstrated the feasibility and value
of incorporating routine PRO collection.  Ongoing efforts focus on
qualitative studies of provider feedback format, direct communica-
tion with multiple clinic’s electronic health records to both read
patient scheduling data and report PRO data, and system-level inter-
ventions on clinical care.
244 A MACH14 Cross ProtocolComparison of Self-Reported and
eElectronic Antiretroviral (ARV) Adherence:
It’s Not Only the Type of Measure used that
Influences Adherence Estimates
Nancy Reynolds1 (presenting), Yan Wang2, Carol Golin3, 
Jane M. Simoni4, Kathy Goggin5, Judith Erlen6, Ira B. Wilson7,
Honghu Liu8
1 Yale University, New Haven, CT, USA
2 University of California, Los Angeles, Los Angeles, CA, USA
3 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
4 University of Washington, Seattle, WA, USA
5 University of Missouri-Kansas City, Kansas City, MO, USA
6 University of Pittsburgh, Pittsburgh, PA, USA
7 Brown University, Providence, RI, USA
8 University of California, Los Angeles, School of Dentistry, Los
Angeles, CA, USA
Background: Studies comparing measures of ARV adherence have
shown inconsistent results.  This could be attributable to differences
in designs that have not been consistently controlled in prior studies.
Methods: In the multi-site MACH14 study, we evaluated the concor-
dance and predictive value of two measures of ARV adherence
[(self-report 3-day recall (SR); electronic (EDM)], controlling for fac-
tors that could influence the relationships.  A series of analyses were
conducted using pooled, individual level longitudinal data from the 11
eligible MACH14 studies with viral load and matching SR and EDM
adherence data collected up to 48 weeks.  Each measurement event
at 12, 24, and 48 weeks with matching 3-day SR and EDM data for a
specific ARV were included in the analyses and mean percentage
adherence was analyzed as a continuous variable.
Results: The study sample (n=1325) was 67.5% male, mean age of
41.6 (range 18-70), 44.9% AA and 75.7% > HS education.   Matched SR
and EDM data were significantly (p<0.05) associated (r=0.33, 0.37,
0.24 at 12, 24, and 48 weeks, respectively), but concordance of the SR
and EDM data varied by ARV and time interval (mean difference
across matched SR/EDM estimates = 0.19, range 0.10-0.27).  In multi-
level models of repeated measures that adjusted for age, gender,
ethnicity, education level, and prior ARV experience, SR and EDM
adherence were consistently associated with viral outcome
(p<000.1), with mean 3-day SR and EDM having greater predictive
value than single day summary measures. 
Conclusions: The findings support the validity and predictive value
of these widely used SR and EDM adherence measures, but highlight
how comparative analyses may be influenced by study design.  The
science of ARV adherence would likely be advanced more readily if
common sources of heterogeneity were routinely taken into account
in the design and reports of ARV adherence studies.
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